{"28686d4fff369be9f00224d213decca01b4d5cd0": [["20-21756The Work Under Consideration for Publication Section 2.20-21756Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?20-21756Are there any relevant conflicts of interest?", [["20-21756", "CHEMICAL", 373, 381], ["Publication Section", "TEST", 41, 60], ["statistical analysis", "TEST", 345, 365]]], ["Yes No \u2714 Relevant financial activities outside the submitted work.Section 3.Are there any relevant conflicts of interest?", [["No", "UNCERTAINTY", 4, 6]]], ["Use one line for each entity; add as many lines as you need by clicking the \"Add +\" box.", [["Add +\" box", "DNA", 77, 87], ["many lines", "TREATMENT", 37, 47]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Relevant financial activities outside the submitted work.Identifying Information Section 1.20-21756The Work Under Consideration for Publication Section 2.20-21756Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?20-21756Are there any relevant conflicts of interest?", [["2.20-21756", "CHEMICAL", 337, 347], ["20-21756", "CHEMICAL", 649, 657], ["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["statistical analysis", "TEST", 621, 641]]], ["Yes No \u2714 Relevant financial activities outside the submitted work.Section 3.Are there any relevant conflicts of interest?", [["No", "UNCERTAINTY", 4, 6]]], ["Use one line for each entity; add as many lines as you need by clicking the \"Add +\" box.", [["Add +\" box", "DNA", 77, 87], ["many lines", "TREATMENT", 37, 47]]], ["Chow has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 29, 39], ["Evaluation", "TEST", 168, 178]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Dufort has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 31, 41], ["Evaluation", "TEST", 170, 180]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your Yes, the following relationships/conditions/circumstances are present (explain below):5.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.5.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199]]], ["Easton has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 31, 41], ["Evaluation", "TEST", 170, 180]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent Entity: government agency, foundation, commercial sponsor, academic institution, etc.20-21756The Work Under Consideration for Publication Section 2.20-21756Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?20-21756Are there any relevant conflicts of interest?", [["Section 2.20-21756", "CHEMICAL", 480, 498], ["20-21756", "CHEMICAL", 800, 808], ["statistical analysis", "TEST", 772, 792], ["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199], ["patent", "OBSERVATION", 335, 341]]], ["Yes No \u2714 Relevant financial activities outside the submitted work.Section 3.Are there any relevant conflicts of interest?", [["No", "UNCERTAINTY", 4, 6]]], ["Use one line for each entity; add as many lines as you need by clicking the \"Add +\" box.", [["Add +\" box", "DNA", 77, 87], ["many lines", "TREATMENT", 37, 47]]], ["Hutton has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 31, 41], ["Evaluation", "TEST", 170, 180]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your Yes, the following relationships/conditions/circumstances are present (explain below):5.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.5.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199]]], ["Koumans has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 32, 42], ["Evaluation", "TEST", 171, 181]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your Yes, the following relationships/conditions/circumstances are present (explain below):5.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.5.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199]]], ["Kumar has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 30, 40], ["Evaluation", "TEST", 169, 179]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Maxted has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 31, 41], ["Evaluation", "TEST", 170, 180]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Definitions.Identifying Information Section 1.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Muse has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 29, 39], ["Evaluation", "TEST", 168, 178]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent Entity: government agency, foundation, commercial sponsor, academic institution, etc.20-21756The Work Under Consideration for Publication Section 2.20-21756Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?20-21756Are there any relevant conflicts of interest?", [["Section 2.20-21756", "CHEMICAL", 480, 498], ["20-21756", "CHEMICAL", 800, 808], ["statistical analysis", "TEST", 772, 792], ["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199], ["patent", "OBSERVATION", 335, 341]]], ["Yes No \u2714 Relevant financial activities outside the submitted work.Section 3.Are there any relevant conflicts of interest?", [["No", "UNCERTAINTY", 4, 6]]], ["Use one line for each entity; add as many lines as you need by clicking the \"Add +\" box.", [["Add +\" box", "DNA", 77, 87], ["many lines", "TREATMENT", 37, 47]]], ["Yes No \u2714 Pulver Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?Section 4.Yes, the following relationships/conditions/circumstances are present (explain below):Section 4.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.Section 4.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["No", "UNCERTAINTY", 4, 6], ["Pulver", "OBSERVATION", 9, 15]]], ["Pulver has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 31, 41], ["Evaluation", "TEST", 170, 180]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Relevant financial activities outside the submitted work.Identifying Information Section 1.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95]]], ["Rosenberg has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 34, 44], ["Evaluation", "TEST", 173, 183]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Relevant financial activities outside the submitted work.Identifying Information Section 1.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95]]], ["Rosenthal has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 34, 44], ["Evaluation", "TEST", 173, 183]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved Rowlands Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?Relevant financial activities outside the submitted work.Yes, the following relationships/conditions/circumstances are present (explain below):Relevant financial activities outside the submitted work.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.Relevant financial activities outside the submitted work.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["a study", "TEST", 46, 53]]], ["Rowlands has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 33, 43], ["Evaluation", "TEST", 172, 182]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Relevant financial activities outside the submitted work.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.Intellectual Property.This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.Relationships not covered above.Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.Relationships not covered above.Definitions.", [["a study", "TEST", 46, 53], ["drugs", "TREATMENT", 90, 95], ["this section", "TREATMENT", 352, 364]]], ["Instructions 1.2.3.5.Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent Entity: government agency, foundation, commercial sponsor, academic institution, etc. Yes, the following relationships/conditions/circumstances are present (explain below):Grant:No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.Grant:At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["patent", "OBSERVATION", 93, 99], ["patent", "OBSERVATION", 142, 148], ["patent", "OBSERVATION", 193, 199], ["patent", "OBSERVATION", 335, 341]]], ["Smith has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.Evaluation and FeedbackThe purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work.", [["Evaluation", "TEST", 30, 40], ["Evaluation", "TEST", 169, 179]]], ["Checking \"No\" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you.", [["any financial support", "TREATMENT", 60, 81]]], ["For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.", [["lung cancer", "ANATOMY", 103, 114], ["cancer", "ANATOMY", 214, 220], ["lung cancer", "ANATOMY", 265, 276], ["lung cancer", "DISEASE", 103, 114], ["cancer", "DISEASE", 214, 220], ["lung cancer", "DISEASE", 265, 276], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 49, 81], ["EGFR", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung cancer", "CANCER", 103, 114], ["cancer", "CANCER", 214, 220], ["EGFR", "GENE_OR_GENE_PRODUCT", 257, 261], ["lung cancer", "CANCER", 265, 276], ["epidermal growth factor receptor", "PROTEIN", 49, 81], ["EGFR", "PROTEIN", 83, 87], ["EGFR", "PROTEIN", 257, 261], ["an epidermal growth factor receptor (EGFR) antagonist in lung cancer", "PROBLEM", 46, 114], ["cancer", "PROBLEM", 214, 220], ["EGFR", "PROBLEM", 257, 261], ["lung cancer", "PROBLEM", 265, 276], ["lung", "ANATOMY", 103, 107], ["cancer", "OBSERVATION", 108, 114], ["cancer", "OBSERVATION", 214, 220], ["EGFR", "OBSERVATION", 257, 261], ["lung", "ANATOMY", 265, 269], ["cancer", "OBSERVATION", 270, 276]]], ["Udo Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?Relevant financial activities outside the submitted work.Yes, the following relationships/conditions/circumstances are present (explain below):Relevant financial activities outside the submitted work.No other relationships/conditions/circumstances that present a potential conflict of interest \u2714 Relationships not covered above Section 5.Relevant financial activities outside the submitted work.At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.", [["Udo", "CHEMICAL", 0, 3], ["Udo", "SPECIES", 0, 3]]], ["Udo has nothing to disclose.Evaluation and FeedbackPlease visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.", [["Evaluation", "TEST", 28, 38]]]], "PMC7342821": [["IntroductionThe lifetime prevalence of major depressive disorder (MDD) is approximately 13% of the general population,1 and it is the most disabling health condition in terms of years lived with disability.2 Antidepressants and psychotherapies are effective in treating MDD.", [["major depressive disorder", "DISEASE", 39, 64], ["MDD", "DISEASE", 66, 69], ["disability", "DISEASE", 195, 205], ["MDD", "DISEASE", 270, 273], ["major depressive disorder", "PROBLEM", 39, 64], ["Antidepressants", "TREATMENT", 208, 223], ["psychotherapies", "TREATMENT", 228, 243], ["MDD", "PROBLEM", 270, 273]]], ["However, at least 33% of patients in specialist care,3 and 22% in general primary care,4 fail to respond to adequate trials of at least two antidepressants.", [["antidepressants", "CHEMICAL", 140, 155], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["two antidepressants", "TREATMENT", 136, 155]]], ["Therefore, it is essential to find alternative treatments for such \u2018treatment-resistant depression\u2019 (TRD).IntroductionNeuromodulation techniques that attempt to directly modulate the function of targeted brain regions, such as electroconvulsive therapy (ECT),5 and repetitive transcranial magnetic stimulation (rTMS),6 can be effective treatments for MDD. rTMS uses powerful magnetic pulses that can be focused usually on the left dorsolateral prefrontal cortex (DLPFC) to produce changes in brain activity if it is given as a course of treatments.", [["brain", "ANATOMY", 204, 209], ["left dorsolateral prefrontal cortex", "ANATOMY", 426, 461], ["DLPFC", "ANATOMY", 463, 468], ["brain", "ANATOMY", 492, 497], ["depression", "DISEASE", 88, 98], ["TRD", "DISEASE", 101, 104], ["MDD", "DISEASE", 351, 354], ["brain", "ORGAN", 204, 209], ["dorsolateral prefrontal cortex", "CANCER", 431, 461], ["DLPFC", "CANCER", 463, 468], ["brain", "ORGAN", 492, 497], ["alternative treatments", "TREATMENT", 35, 57], ["such \u2018treatment", "TREATMENT", 62, 77], ["resistant depression", "PROBLEM", 78, 98], ["IntroductionNeuromodulation techniques", "TREATMENT", 106, 144], ["electroconvulsive therapy (ECT)", "TREATMENT", 227, 258], ["repetitive transcranial magnetic stimulation", "TREATMENT", 265, 309], ["MDD", "PROBLEM", 351, 354], ["rTMS", "TREATMENT", 356, 360], ["powerful magnetic pulses", "TEST", 366, 390], ["changes in brain activity", "PROBLEM", 481, 506], ["treatments", "TREATMENT", 537, 547], ["brain", "ANATOMY", 204, 209], ["left", "ANATOMY_MODIFIER", 426, 430], ["dorsolateral", "ANATOMY_MODIFIER", 431, 443], ["prefrontal cortex", "ANATOMY", 444, 461], ["brain", "ANATOMY", 492, 497]]], ["Unlike ECT, rTMS does not require anaesthesia nor produce potential cognitive deficits, and is cost-effective in TRD compared with current standard care.7", [["cognitive deficits", "DISEASE", 68, 86], ["TRD", "DISEASE", 113, 116], ["rTMS", "PROBLEM", 12, 16], ["anaesthesia", "TREATMENT", 34, 45], ["potential cognitive deficits", "PROBLEM", 58, 86], ["current standard care", "TREATMENT", 131, 152]]]], "871115d995995ff30d2a53bcd537989958a7c5fe": [["Prevalence, Taxonomy and Structural Biology of SARS-CoV-2In December 2019, coronavirus disease 2019 (COVID-19) outbreak commenced in Wuhan, Hubei province, China and spread rapidly to other provinces in China and several countries all over the world (1) .", [["SARS", "DISEASE", 47, 51], ["coronavirus disease", "DISEASE", 75, 94], ["COVID-19", "CHEMICAL", 101, 109], ["SARS-CoV", "ORGANISM", 47, 55], ["SARS-CoV-2In December 2019, coronavirus disease 2019 (COVID-19", "SPECIES", 47, 109], ["coronavirus disease", "PROBLEM", 75, 94], ["COVID", "TEST", 101, 106], ["coronavirus disease", "OBSERVATION", 75, 94]]], ["This infectious disease has been identified by the World Health Organization (WHO) as a global pandemic.", [["infectious disease", "DISEASE", 5, 23], ["This infectious disease", "PROBLEM", 0, 23], ["a global pandemic", "PROBLEM", 86, 103], ["infectious", "OBSERVATION", 5, 15]]], ["Based on the WHO declaration on January 30, 2020, the outbreak of COVID-19 is a global health emergency of international concerns due to its capability of rapid human-to-human transmission (2) .", [["COVID-19", "CHEMICAL", 66, 74], ["human", "ORGANISM", 161, 166], ["human", "ORGANISM", 170, 175], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 170, 175], ["COVID", "TEST", 66, 71]]], ["The mortality rate of COVID-19 is terribly growing worldwide.", [["COVID-19", "CHEMICAL", 22, 30], ["The mortality rate", "TEST", 0, 18], ["COVID", "TEST", 22, 27]]], ["As of April 16, 2020 , this severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected a total of 2,060,927 confirmed cases with 134,354 deaths in more than 200 countries and territories (3) .Prevalence, Taxonomy and Structural Biology of SARS-CoV-2SARS-CoV-2 is a novel \u03b2-coronavirus that belongs to the subfamily Orthocoronavirinae in the family of Coronaviridae, in the order of Nidovirales.", [["acute respiratory syndrome coronavirus", "DISEASE", 35, 73], ["deaths", "DISEASE", 152, 158], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV-2SARS-CoV-2", "ORGANISM", 254, 274], ["\u03b2-coronavirus", "CANCER", 286, 299], ["Orthocoronavirinae", "GENE_OR_GENE_PRODUCT", 330, 348], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 366, 379], ["severe acute respiratory syndrome coronavirus", "SPECIES", 28, 73], ["SARS-CoV-2", "SPECIES", 77, 87], ["this severe acute respiratory syndrome coronavirus", "PROBLEM", 23, 73], ["SARS-CoV", "TEST", 77, 85], ["SARS-CoV-2SARS", "TEST", 254, 268], ["Coronaviridae", "TREATMENT", 366, 379], ["Nidovirales", "TREATMENT", 397, 408], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61]]], ["The SARS-CoV-2 is an enveloped positive-sense single-stranded RNA (+ssRNA) virus with 4 major proteins in its structure, including the spike (S) protein (which mediates attachment to the host receptor and subsequent fusion of the virus and cell membrane), the membrane (M) protein, the envelope (E) protein, and the nucleocapsid (N) protein (4) .", [["cell membrane", "ANATOMY", 240, 253], ["membrane", "ANATOMY", 260, 268], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["cell membrane", "CELLULAR_COMPONENT", 240, 253], ["membrane", "CELLULAR_COMPONENT", 260, 268], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 316, 332], ["SARS-CoV-2", "DNA", 4, 14], ["spike (S) protein", "PROTEIN", 135, 152], ["host receptor", "PROTEIN", 187, 200], ["membrane (M) protein", "PROTEIN", 260, 280], ["envelope (E) protein", "PROTEIN", 286, 306], ["nucleocapsid (N) protein", "PROTEIN", 316, 340], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV", "TEST", 0, 12], ["an enveloped positive-sense single-stranded RNA (+ssRNA) virus", "PROBLEM", 18, 80], ["4 major proteins in its structure", "PROBLEM", 86, 119], ["the spike (S) protein", "PROBLEM", 131, 152], ["the host receptor", "TREATMENT", 183, 200], ["the virus and cell membrane", "TEST", 226, 253], ["the envelope (E) protein", "TEST", 282, 306], ["the nucleocapsid (N) protein", "TEST", 312, 340], ["enveloped", "OBSERVATION_MODIFIER", 21, 30], ["positive", "OBSERVATION", 31, 39], ["cell membrane", "OBSERVATION", 240, 253]]], ["Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are other \u03b2-coronavirus widespread epidemics in 2002 and 2012, respectively (5) .", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["SARS-CoV)", "DISEASE", 47, 56], ["Middle East respiratory syndrome coronavirus", "DISEASE", 61, 105], ["Severe acute respiratory syndrome coronavirus", "ORGANISM", 0, 45], ["SARS-CoV", "ORGANISM", 47, 55], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 61, 105], ["MERS-CoV", "ORGANISM", 107, 115], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV", "SPECIES", 47, 55], ["Middle East respiratory syndrome coronavirus", "SPECIES", 61, 105], ["MERS-CoV", "SPECIES", 107, 115], ["Severe acute respiratory syndrome coronavirus (SARS-CoV)", "PROBLEM", 0, 56], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 61, 105], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45], ["Middle", "ANATOMY_MODIFIER", 61, 67], ["respiratory syndrome", "OBSERVATION", 73, 93], ["widespread", "OBSERVATION_MODIFIER", 141, 151], ["epidemics", "OBSERVATION", 152, 161]]], ["Based on recent pieces of evidence, SARS-CoV-2 has approximately 79-82% similarity to human SARS-CoV genome at the nucleotide sequences.", [["SARS", "DISEASE", 36, 40], ["SARS", "DISEASE", 92, 96], ["nucleotide", "CHEMICAL", 115, 125], ["SARS-CoV-2", "ORGANISM", 36, 46], ["human", "ORGANISM", 86, 91], ["SARS-CoV", "ORGANISM", 92, 100], ["human SARS-CoV genome", "DNA", 86, 107], ["nucleotide sequences", "DNA", 115, 135], ["human", "SPECIES", 86, 91], ["SARS-CoV", "SPECIES", 36, 44], ["human SARS-CoV", "SPECIES", 86, 100], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["human SARS", "TEST", 86, 96], ["the nucleotide sequences", "TEST", 111, 135]]], ["It has been supposed that the SARS-CoV-2 virus, similar to SARS CoV, uses the angiotensin-converting enzyme 2 (ACE2) as the receptor for entering host cells (6).", [["cells", "ANATOMY", 151, 156], ["SARS", "DISEASE", 30, 34], ["SARS", "DISEASE", 59, 63], ["angiotensin", "CHEMICAL", 78, 89], ["SARS-CoV-2 virus", "ORGANISM", 30, 46], ["SARS CoV", "ORGANISM", 59, 67], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 78, 109], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["host cells", "CELL", 146, 156], ["angiotensin-converting enzyme 2", "PROTEIN", 78, 109], ["ACE2", "PROTEIN", 111, 115], ["host cells", "CELL_TYPE", 146, 156], ["CoV-2 virus", "SPECIES", 35, 46], ["SARS-CoV-2 virus", "SPECIES", 30, 46], ["SARS CoV", "SPECIES", 59, 67], ["the SARS-CoV-2 virus", "PROBLEM", 26, 46], ["SARS CoV", "PROBLEM", 59, 67], ["the angiotensin-converting enzyme", "TREATMENT", 74, 107], ["host cells", "OBSERVATION", 146, 156]]], ["ACE2 receptors are expressed in the membrane of various cells in the human body, including type II alveolar epithelial cells of the lung (7).", [["membrane", "ANATOMY", 36, 44], ["cells", "ANATOMY", 56, 61], ["body", "ANATOMY", 75, 79], ["type II alveolar epithelial cells", "ANATOMY", 91, 124], ["lung", "ANATOMY", 132, 136], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["cells", "CELL", 56, 61], ["human", "ORGANISM", 69, 74], ["body", "ORGANISM_SUBDIVISION", 75, 79], ["type II alveolar epithelial cells", "CELL", 91, 124], ["lung", "ORGAN", 132, 136], ["ACE2 receptors", "PROTEIN", 0, 14], ["type II alveolar epithelial cells", "CELL_TYPE", 91, 124], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["ACE2 receptors", "TREATMENT", 0, 14], ["type II alveolar epithelial cells of the lung", "PROBLEM", 91, 136], ["membrane", "ANATOMY_MODIFIER", 36, 44], ["various cells", "OBSERVATION", 48, 61], ["human body", "ANATOMY_MODIFIER", 69, 79], ["type II", "OBSERVATION_MODIFIER", 91, 98], ["alveolar", "ANATOMY_MODIFIER", 99, 107], ["epithelial cells", "OBSERVATION", 108, 124], ["lung", "ANATOMY", 132, 136]]], ["Accordingly, it is expected that the bilateral diffuse alveolar injury with cytodiagnosis of myxoid fibroma exudate is the first pathological finding of COVID-19 (8).", [["alveolar", "ANATOMY", 55, 63], ["myxoid fibroma exudate", "ANATOMY", 93, 115], ["alveolar injury", "DISEASE", 55, 70], ["myxoid fibroma", "DISEASE", 93, 107], ["COVID-19", "CHEMICAL", 153, 161], ["alveolar", "MULTI-TISSUE_STRUCTURE", 55, 63], ["myxoid fibroma exudate", "TISSUE", 93, 115], ["the bilateral diffuse alveolar injury", "PROBLEM", 33, 70], ["myxoid fibroma exudate", "PROBLEM", 93, 115], ["COVID", "TEST", 153, 158], ["bilateral", "OBSERVATION_MODIFIER", 37, 46], ["diffuse", "OBSERVATION_MODIFIER", 47, 54], ["alveolar injury", "OBSERVATION", 55, 70], ["myxoid", "OBSERVATION_MODIFIER", 93, 99], ["fibroma", "OBSERVATION", 100, 107]]], ["Furthermore, kidney, intestine, heart, and blood vessels are the other organs expressing ACE2 receptor, and this may describe why some patients with COVID-19 (~46%) experience renal, gastrointestinal, and cardiovascular problems (9,10).", [["kidney", "ANATOMY", 13, 19], ["intestine", "ANATOMY", 21, 30], ["heart", "ANATOMY", 32, 37], ["blood vessels", "ANATOMY", 43, 56], ["organs", "ANATOMY", 71, 77], ["renal", "ANATOMY", 176, 181], ["gastrointestinal", "ANATOMY", 183, 199], ["cardiovascular", "ANATOMY", 205, 219], ["renal, gastrointestinal, and cardiovascular problems", "DISEASE", 176, 228], ["kidney", "ORGAN", 13, 19], ["intestine", "ORGAN", 21, 30], ["heart", "ORGAN", 32, 37], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 43, 56], ["organs", "ORGAN", 71, 77], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 89, 102], ["patients", "ORGANISM", 135, 143], ["renal", "ORGAN", 176, 181], ["gastrointestinal", "ORGAN", 183, 199], ["ACE2 receptor", "PROTEIN", 89, 102], ["patients", "SPECIES", 135, 143], ["COVID", "TEST", 149, 154], ["renal, gastrointestinal, and cardiovascular problems", "PROBLEM", 176, 228], ["kidney", "ANATOMY", 13, 19], ["intestine", "ANATOMY", 21, 30], ["heart", "ANATOMY", 32, 37], ["blood vessels", "ANATOMY", 43, 56], ["renal", "ANATOMY", 176, 181], ["gastrointestinal", "ANATOMY", 183, 199], ["cardiovascular", "ANATOMY", 205, 219]]], ["The spike glycoprotein (S) mediates virus entry via binding to the host cell's ACE2 receptor and membrane fusion (11).", [["cell", "ANATOMY", 72, 76], ["membrane", "ANATOMY", 97, 105], ["spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 4, 26], ["cell", "CELL", 72, 76], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 79, 92], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["spike glycoprotein (S)", "PROTEIN", 4, 26], ["ACE2 receptor", "PROTEIN", 79, 92], ["The spike glycoprotein (S) mediates virus entry", "TREATMENT", 0, 47], ["the host cell's ACE2 receptor", "TREATMENT", 63, 92], ["membrane fusion", "TREATMENT", 97, 112], ["membrane fusion", "OBSERVATION", 97, 112]]], ["It is supposed that the interaction of the viral particle with specific proteins on the host cell surface and entering of the virus to human cells are the main triggers, which initiate infection and inflammatory cascade through various mechanisms with consequent release of pro-inflammatory cytokines (6,12).", [["cell surface", "ANATOMY", 93, 105], ["cells", "ANATOMY", 141, 146], ["infection", "DISEASE", 185, 194], ["cell surface", "CELLULAR_COMPONENT", 93, 105], ["human", "ORGANISM", 135, 140], ["cells", "CELL", 141, 146], ["human cells", "CELL_TYPE", 135, 146], ["pro-inflammatory cytokines", "PROTEIN", 274, 300], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["the viral particle", "PROBLEM", 39, 57], ["the host cell surface", "TREATMENT", 84, 105], ["the virus to human cells", "PROBLEM", 122, 146], ["infection", "PROBLEM", 185, 194], ["inflammatory cascade", "PROBLEM", 199, 219], ["pro-inflammatory cytokines", "PROBLEM", 274, 300], ["viral particle", "OBSERVATION", 43, 57], ["host cell", "OBSERVATION", 88, 97], ["surface", "OBSERVATION_MODIFIER", 98, 105], ["infection", "OBSERVATION", 185, 194], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211], ["pro-inflammatory cytokines", "OBSERVATION", 274, 300]]], ["To the best of our knowledge the main clinical features of patients with COVID-19 consist of a) high concentration of inflammatory parameters such as C-reactive protein (CRP) andPrevalence, Taxonomy and Structural Biology of SARS-CoV-2pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-\u03b1 (TNF\u03b1), etc.; b) Infiltration of immune cells to the lung lesion mostly monocytes and macrophages; c) Destruction of the immune system owing to atrophy of spleen and lymph nodes; d) Reduction of lymphocytes (lymphopenia) in lymphoid organs; and ultimately; e) Vasculitis, hypercoagulability, and multiple organs damage (13) .Prevalence, Taxonomy and Structural Biology of SARS-CoV-2The term \"cytokine release syndrome\" (CRS) or cytokine storm syndrome (CSS) was defined as a systemic inflammatory response, which can occur by a variety of factors, including infections and certain drugs (14) .", [["immune cells", "ANATOMY", 355, 367], ["lung lesion", "ANATOMY", 375, 386], ["monocytes", "ANATOMY", 394, 403], ["macrophages", "ANATOMY", 408, 419], ["immune system", "ANATOMY", 443, 456], ["spleen", "ANATOMY", 477, 483], ["lymph nodes", "ANATOMY", 488, 499], ["lymphocytes", "ANATOMY", 517, 528], ["lymphoid organs", "ANATOMY", 546, 561], ["organs", "ANATOMY", 627, 633], ["necrosis", "DISEASE", 304, 312], ["atrophy", "DISEASE", 466, 473], ["lymphopenia", "DISEASE", 530, 541], ["Vasculitis", "DISEASE", 582, 592], ["hypercoagulability", "DISEASE", 594, 612], ["multiple organs damage", "DISEASE", 618, 640], ["SARS", "DISEASE", 694, 698], ["CRS", "DISEASE", 742, 745], ["CSS", "DISEASE", 775, 778], ["infections", "DISEASE", 880, 890], ["patients", "ORGANISM", 59, 67], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 150, 168], ["CRP", "GENE_OR_GENE_PRODUCT", 170, 173], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 270, 283], ["IL-1", "GENE_OR_GENE_PRODUCT", 285, 289], ["IL-6", "GENE_OR_GENE_PRODUCT", 292, 296], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 298, 321], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 323, 327], ["immune cells", "CELL", 355, 367], ["lung", "ORGAN", 375, 379], ["monocytes", "CELL", 394, 403], ["macrophages", "CELL", 408, 419], ["spleen", "ORGAN", 477, 483], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 488, 499], ["lymphocytes", "CELL", 517, 528], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 546, 561], ["organs", "ORGAN", 627, 633], ["C-reactive protein", "PROTEIN", 150, 168], ["CRP", "PROTEIN", 170, 173], ["SARS-CoV-2pro-inflammatory cytokines", "PROTEIN", 225, 261], ["interleukin-1 (IL-1", "PROTEIN", 270, 289], ["IL-6", "PROTEIN", 292, 296], ["tumor necrosis factor-\u03b1", "PROTEIN", 298, 321], ["TNF\u03b1", "PROTEIN", 323, 327], ["immune cells", "CELL_TYPE", 355, 367], ["monocytes", "CELL_TYPE", 394, 403], ["macrophages", "CELL_TYPE", 408, 419], ["lymphocytes", "CELL_TYPE", 517, 528], ["cytokine", "PROTEIN", 714, 722], ["cytokine", "PROTEIN", 750, 758], ["patients", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 694, 702], ["COVID", "TEST", 73, 78], ["inflammatory parameters", "PROBLEM", 118, 141], ["C-reactive protein", "PROBLEM", 150, 168], ["CRP", "TEST", 170, 173], ["SARS", "TEST", 225, 229], ["CoV", "TEST", 230, 233], ["inflammatory cytokines", "PROBLEM", 239, 261], ["interleukin", "TEST", 270, 281], ["IL", "TEST", 285, 287], ["IL", "TEST", 292, 294], ["tumor necrosis factor", "PROBLEM", 298, 319], ["immune cells", "PROBLEM", 355, 367], ["the lung lesion", "PROBLEM", 371, 386], ["monocytes", "TEST", 394, 403], ["macrophages", "PROBLEM", 408, 419], ["Destruction of the immune system", "PROBLEM", 424, 456], ["atrophy of spleen", "PROBLEM", 466, 483], ["lymph nodes", "PROBLEM", 488, 499], ["Reduction of lymphocytes (lymphopenia) in lymphoid organs", "PROBLEM", 504, 561], ["Vasculitis", "PROBLEM", 582, 592], ["hypercoagulability", "PROBLEM", 594, 612], ["multiple organs damage", "PROBLEM", 618, 640], ["CoV", "TEST", 699, 702], ["The term \"cytokine release syndrome", "PROBLEM", 704, 739], ["CRS", "PROBLEM", 742, 745], ["cytokine storm syndrome", "PROBLEM", 750, 773], ["a systemic inflammatory response", "PROBLEM", 795, 827], ["infections", "PROBLEM", 880, 890], ["inflammatory", "OBSERVATION", 118, 130], ["inflammatory", "OBSERVATION_MODIFIER", 239, 251], ["tumor", "OBSERVATION_MODIFIER", 298, 303], ["necrosis", "OBSERVATION", 304, 312], ["Infiltration", "OBSERVATION", 339, 351], ["immune cells", "OBSERVATION", 355, 367], ["lung", "ANATOMY", 375, 379], ["lesion", "OBSERVATION", 380, 386], ["macrophages", "OBSERVATION_MODIFIER", 408, 419], ["atrophy", "OBSERVATION", 466, 473], ["spleen", "ANATOMY", 477, 483], ["lymph nodes", "OBSERVATION", 488, 499], ["lymphocytes", "ANATOMY", 517, 528], ["lymphopenia", "OBSERVATION", 530, 541], ["lymphoid organs", "ANATOMY", 546, 561], ["Vasculitis", "OBSERVATION", 582, 592], ["hypercoagulability", "OBSERVATION", 594, 612], ["multiple", "OBSERVATION_MODIFIER", 618, 626], ["organs", "ANATOMY", 627, 633], ["damage", "OBSERVATION", 634, 640], ["systemic", "OBSERVATION_MODIFIER", 797, 805], ["inflammatory", "OBSERVATION", 806, 818]]], ["In this review, we addressed the inflammatory pathways of SARS-CoV-2 and its relationship with the host cytokine storm.", [["SARS", "DISEASE", 58, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["cytokine", "PROTEIN", 104, 112], ["SARS-CoV", "SPECIES", 58, 66], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["cytokine storm", "OBSERVATION", 104, 118]]], ["Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned.", [["hyper-inflammation", "DISEASE", 57, 75], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["reverse hyper-inflammation in infected patients", "PROBLEM", 49, 96], ["infected", "OBSERVATION", 79, 87]]], ["The understanding of molecular mechanisms involved in this viral infection provides new insights into the more appropriate management of COVID-19.Inflammatory Pathways of SARS-CoV-2Inflammation is the immediate body's defense against infection or trauma injury; however, it can be considered a double-edged sword.", [["body", "ANATOMY", 211, 215], ["viral infection", "DISEASE", 59, 74], ["infection", "DISEASE", 234, 243], ["trauma", "DISEASE", 247, 253], ["body", "ORGANISM_SUBDIVISION", 211, 215], ["this viral infection", "PROBLEM", 54, 74], ["COVID", "TEST", 137, 142], ["Inflammatory Pathways", "PROBLEM", 146, 167], ["SARS-CoV", "PROBLEM", 171, 179], ["2Inflammation", "PROBLEM", 180, 193], ["infection", "PROBLEM", 234, 243], ["trauma injury", "PROBLEM", 247, 260], ["infection", "OBSERVATION", 65, 74], ["SARS-CoV", "OBSERVATION", 171, 179], ["infection", "OBSERVATION", 234, 243]]], ["Inflammation with activation of both innate and adaptive immune responses can enhance host immunity against infection, while excessive immune responses following some pathogens such as the influenza virus, trigger life-threatening CSS in the host, which can result in excessive production of pro-inflammatory cytokines and eventually, leads to death (15, 16) .Inflammatory Pathways of SARS-CoV-2Cytokines are a group of secreted proteins that are released by some cells with specific effects on the development, differentiation, and regulation of immune cells (17) .Inflammatory Pathways of SARS-CoV-2According to recent studies, SARS-CoV-2 stimulates innate and adaptive immune systems after binding to type II alveolar epithelial cells of the lung; the over-stimulated response of the immune system may cause more damage to the host cells than the SARS-CoV-2 as a foreign invader (18) .Inflammatory Pathways of SARS-CoV-2Toll-like receptors (TLRs), a subfamily of pattern recognition receptors (PRRs), can recognize \"danger signals\" such as SARS-CoV-2 viruses in the extracellular milieu and endosomes and mediate the inflammatory signaling cascade that leads to the activation and production of inflammatory cytokines (19) .", [["cells", "ANATOMY", 464, 469], ["immune cells", "ANATOMY", 547, 559], ["alveolar epithelial cells", "ANATOMY", 712, 737], ["lung", "ANATOMY", 745, 749], ["immune system", "ANATOMY", 787, 800], ["cells", "ANATOMY", 835, 840], ["extracellular milieu", "ANATOMY", 1069, 1089], ["endosomes", "ANATOMY", 1094, 1103], ["Inflammation", "DISEASE", 0, 12], ["infection", "DISEASE", 108, 117], ["influenza virus", "DISEASE", 189, 204], ["CSS", "DISEASE", 231, 234], ["death", "DISEASE", 344, 349], ["influenza virus", "ORGANISM", 189, 204], ["SARS-CoV-2Cytokines", "GENE_OR_GENE_PRODUCT", 385, 404], ["cells", "CELL", 464, 469], ["immune cells", "CELL", 547, 559], ["SARS-CoV", "ORGANISM", 591, 599], ["SARS-CoV-2", "ORGANISM", 630, 640], ["alveolar epithelial cells", "CELL", 712, 737], ["lung", "ORGAN", 745, 749], ["host cells", "CELL", 830, 840], ["SARS-CoV-2", "ORGANISM", 850, 860], ["SARS-CoV-2Toll-like receptors", "GENE_OR_GENE_PRODUCT", 913, 942], ["TLRs", "GENE_OR_GENE_PRODUCT", 944, 948], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 966, 995], ["PRRs", "GENE_OR_GENE_PRODUCT", 997, 1001], ["SARS-CoV-2 viruses", "ORGANISM", 1043, 1061], ["extracellular milieu", "CELLULAR_COMPONENT", 1069, 1089], ["endosomes", "CELLULAR_COMPONENT", 1094, 1103], ["pro-inflammatory cytokines", "PROTEIN", 292, 318], ["secreted proteins", "PROTEIN", 420, 437], ["immune cells", "CELL_TYPE", 547, 559], ["type II alveolar epithelial cells", "CELL_TYPE", 704, 737], ["host cells", "CELL_TYPE", 830, 840], ["SARS-CoV-2Toll-like receptors", "PROTEIN", 913, 942], ["TLRs", "PROTEIN", 944, 948], ["pattern recognition receptors", "PROTEIN", 966, 995], ["PRRs", "PROTEIN", 997, 1001], ["inflammatory cytokines", "PROTEIN", 1198, 1220], ["influenza virus", "SPECIES", 189, 204], ["influenza virus", "SPECIES", 189, 204], ["SARS-CoV", "SPECIES", 385, 393], ["SARS-CoV-2According", "SPECIES", 591, 610], ["SARS-CoV", "SPECIES", 630, 638], ["Inflammation", "PROBLEM", 0, 12], ["adaptive immune responses", "TREATMENT", 48, 73], ["infection", "PROBLEM", 108, 117], ["excessive immune responses", "PROBLEM", 125, 151], ["some pathogens", "PROBLEM", 162, 176], ["the influenza virus", "PROBLEM", 185, 204], ["excessive production of pro-inflammatory cytokines", "PROBLEM", 268, 318], ["Inflammatory Pathways", "PROBLEM", 360, 381], ["SARS", "PROBLEM", 385, 389], ["2Cytokines", "PROBLEM", 394, 404], ["secreted proteins", "PROBLEM", 420, 437], ["immune cells", "PROBLEM", 547, 559], ["Inflammatory Pathways of SARS", "PROBLEM", 566, 595], ["CoV", "TEST", 596, 599], ["recent studies", "TEST", 614, 628], ["SARS", "TEST", 630, 634], ["CoV", "TEST", 635, 638], ["adaptive immune systems", "TREATMENT", 663, 686], ["type II alveolar epithelial cells of the lung", "PROBLEM", 704, 749], ["damage to the host cells", "PROBLEM", 816, 840], ["the SARS", "TEST", 846, 854], ["CoV", "TEST", 855, 858], ["a foreign invader", "TREATMENT", 864, 881], ["Inflammatory Pathways", "PROBLEM", 888, 909], ["SARS", "PROBLEM", 913, 917], ["CoV", "TEST", 918, 921], ["SARS", "PROBLEM", 1043, 1047], ["the inflammatory signaling cascade", "PROBLEM", 1116, 1150], ["inflammatory cytokines", "PROBLEM", 1198, 1220], ["excessive", "OBSERVATION_MODIFIER", 268, 277], ["pro-inflammatory cytokines", "OBSERVATION", 292, 318], ["SARS", "OBSERVATION", 385, 389], ["immune cells", "OBSERVATION", 547, 559], ["alveolar", "ANATOMY_MODIFIER", 712, 720], ["epithelial cells", "OBSERVATION", 721, 737], ["lung", "ANATOMY", 745, 749], ["inflammatory", "OBSERVATION_MODIFIER", 1120, 1132], ["inflammatory", "OBSERVATION_MODIFIER", 1198, 1210]]], ["Inflammasomes are multi-protein cytosolic molecular platforms comprised of caspase-1, Nod-like receptors (NLRs; i.e., NLRP1, NLRP3, and NLRC4) and apoptosis-associated (26) .", [["cytosolic", "ANATOMY", 32, 41], ["Inflammasomes", "GENE_OR_GENE_PRODUCT", 0, 13], ["caspase-1", "GENE_OR_GENE_PRODUCT", 75, 84], ["Nod-like receptors", "GENE_OR_GENE_PRODUCT", 86, 104], ["NLRs", "GENE_OR_GENE_PRODUCT", 106, 110], ["NLRP1", "GENE_OR_GENE_PRODUCT", 118, 123], ["NLRP3", "GENE_OR_GENE_PRODUCT", 125, 130], ["NLRC4", "GENE_OR_GENE_PRODUCT", 136, 141], ["Inflammasomes", "PROTEIN", 0, 13], ["caspase-1", "PROTEIN", 75, 84], ["Nod-like receptors", "PROTEIN", 86, 104], ["NLRs", "PROTEIN", 106, 110], ["NLRP1", "PROTEIN", 118, 123], ["NLRP3", "PROTEIN", 125, 130], ["NLRC4", "PROTEIN", 136, 141], ["Inflammasomes", "PROBLEM", 0, 13], ["multi-protein cytosolic molecular platforms", "TEST", 18, 61], ["caspase", "TEST", 75, 82], ["Nod-like receptors", "TEST", 86, 104], ["NLRs", "TEST", 106, 110], ["NLRP1", "TEST", 118, 123], ["NLRP3", "TEST", 125, 130], ["NLRC4", "TEST", 136, 141], ["apoptosis", "PROBLEM", 147, 156], ["cytosolic molecular platforms", "OBSERVATION", 32, 61]]], ["Similarly, other reports also established the increased level of IL-6 in patients with confirmed COVID-19 pneumonia and it has been shown that the level of IL-6 has a positive correlation with the severity of the disease (4, 27, 28) .Inflammatory Pathways of SARS-CoV-2In another study, Huang C, et al. (29) reported that the plasmatic concentration of IL-2, IL-7, interferon-gamma (IFN-\u03b3), granulocyte-colony stimulating factor (GCSF), interferon \u03b3-inducedSuggested Therapeutic Options to Reverse Hyper-inflammation in Patients with COVID-19Modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19.", [["pneumonia", "DISEASE", 106, 115], ["inflammation", "DISEASE", 504, 516], ["IL-6", "GENE_OR_GENE_PRODUCT", 65, 69], ["patients", "ORGANISM", 73, 81], ["IL-6", "GENE_OR_GENE_PRODUCT", 156, 160], ["IL-2", "GENE_OR_GENE_PRODUCT", 353, 357], ["IL-7", "GENE_OR_GENE_PRODUCT", 359, 363], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 365, 381], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 383, 388], ["granulocyte-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 391, 428], ["GCSF", "GENE_OR_GENE_PRODUCT", 430, 434], ["Patients", "ORGANISM", 520, 528], ["patients", "ORGANISM", 628, 636], ["IL-6", "PROTEIN", 65, 69], ["IL-6", "PROTEIN", 156, 160], ["IL", "PROTEIN", 353, 355], ["IL-7", "PROTEIN", 359, 363], ["interferon-gamma", "PROTEIN", 365, 381], ["IFN", "PROTEIN", 383, 386], ["\u03b3", "PROTEIN", 387, 388], ["granulocyte-colony stimulating factor", "PROTEIN", 391, 428], ["GCSF", "PROTEIN", 430, 434], ["interferon", "PROTEIN", 437, 447], ["patients", "SPECIES", 73, 81], ["Patients", "SPECIES", 520, 528], ["patients", "SPECIES", 628, 636], ["COVID", "TEST", 97, 102], ["pneumonia", "PROBLEM", 106, 115], ["the disease", "PROBLEM", 209, 220], ["Inflammatory Pathways of SARS", "PROBLEM", 234, 263], ["another study", "TEST", 272, 285], ["the plasmatic concentration", "TEST", 322, 349], ["IL", "TEST", 353, 355], ["IL", "TEST", 359, 361], ["interferon", "TEST", 365, 375], ["IFN", "TEST", 383, 386], ["granulocyte", "TEST", 391, 402], ["GCSF", "TEST", 430, 434], ["interferon \u03b3-induced", "TREATMENT", 437, 457], ["Therapeutic Options", "TREATMENT", 467, 486], ["Reverse Hyper-inflammation", "PROBLEM", 490, 516], ["COVID", "TEST", 534, 539], ["systemic immune responses", "TREATMENT", 556, 581], ["COVID", "TEST", 642, 647], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["pneumonia", "OBSERVATION", 106, 115], ["disease", "OBSERVATION", 213, 220], ["gamma", "ANATOMY", 376, 381], ["granulocyte", "ANATOMY", 391, 402], ["inflammation", "OBSERVATION", 504, 516]]], ["Given the importance of the issue and the lack of a vaccine or proven effective therapy, anti-cytokine therapy such as IL-6, TNF\u03b1 and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation as the main leading cause of severe adult respiratory distress syndrome (ARDS) in patients with COVID-19 (31, 32) .", [["respiratory", "ANATOMY", 255, 266], ["hyper-inflammation", "DISEASE", 194, 212], ["adult respiratory distress syndrome", "DISEASE", 249, 284], ["ARDS", "DISEASE", 286, 290], ["COVID-19", "CHEMICAL", 309, 317], ["anti-cytokine", "SIMPLE_CHEMICAL", 89, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 125, 129], ["IL-1 antagonists", "GENE_OR_GENE_PRODUCT", 134, 150], ["patients", "ORGANISM", 295, 303], ["IL-6", "PROTEIN", 119, 123], ["TNF\u03b1", "PROTEIN", 125, 129], ["patients", "SPECIES", 295, 303], ["a vaccine", "TREATMENT", 50, 59], ["effective therapy", "TREATMENT", 70, 87], ["anti-cytokine therapy", "TREATMENT", 89, 110], ["IL", "TREATMENT", 119, 121], ["TNF", "TREATMENT", 125, 128], ["IL-1 antagonists", "TREATMENT", 134, 150], ["hyper-inflammation", "PROBLEM", 194, 212], ["severe adult respiratory distress syndrome", "PROBLEM", 242, 284], ["ARDS", "PROBLEM", 286, 290], ["COVID", "TEST", 309, 314], ["inflammation", "OBSERVATION", 200, 212], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["respiratory distress", "OBSERVATION", 255, 275]]], ["Importantly, some clinical findings in China have shown that Tocilizumab (a monoclonal anti-IL-6 receptor) can significantly improve oxygenation and may be considered a promising therapeutic option in patients with COVID-19 who are at the risk of cytokine storm (33) .", [["Tocilizumab", "CHEMICAL", 61, 72], ["Tocilizumab", "CHEMICAL", 61, 72], ["Tocilizumab", "SIMPLE_CHEMICAL", 61, 72], ["anti-IL-6 receptor", "GENE_OR_GENE_PRODUCT", 87, 105], ["patients", "ORGANISM", 201, 209], ["monoclonal anti-IL-6 receptor", "PROTEIN", 76, 105], ["cytokine", "PROTEIN", 247, 255], ["patients", "SPECIES", 201, 209], ["Tocilizumab", "TREATMENT", 61, 72], ["a monoclonal anti-IL-6 receptor)", "TREATMENT", 74, 106], ["cytokine storm", "OBSERVATION", 247, 261]]], ["Another small sample clinical trial in China has indicated good efficacy of Tocilizumab treatment in severe COVOD-19 patients (34) .", [["Tocilizumab", "CHEMICAL", 76, 87], ["COVOD", "DISEASE", 108, 113], ["Tocilizumab", "CHEMICAL", 76, 87], ["Tocilizumab", "SIMPLE_CHEMICAL", 76, 87], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["Tocilizumab treatment", "TREATMENT", 76, 97], ["severe COVOD", "PROBLEM", 101, 113], ["small", "OBSERVATION_MODIFIER", 8, 13], ["good", "OBSERVATION_MODIFIER", 59, 63]]], ["A case report from France reported successful treatment of Covid-19-related respiratory failure using Tocilizumab in a patient with cancer (35) .", [["respiratory", "ANATOMY", 76, 87], ["cancer", "ANATOMY", 132, 138], ["Covid-19", "CHEMICAL", 59, 67], ["respiratory failure", "DISEASE", 76, 95], ["Tocilizumab", "CHEMICAL", 102, 113], ["cancer", "DISEASE", 132, 138], ["Tocilizumab", "CHEMICAL", 102, 113], ["Tocilizumab", "SIMPLE_CHEMICAL", 102, 113], ["patient", "ORGANISM", 119, 126], ["cancer", "CANCER", 132, 138], ["patient", "SPECIES", 119, 126], ["successful treatment", "TREATMENT", 35, 55], ["Covid", "TEST", 59, 64], ["respiratory failure", "PROBLEM", 76, 95], ["Tocilizumab", "TREATMENT", 102, 113], ["cancer", "PROBLEM", 132, 138], ["respiratory failure", "OBSERVATION", 76, 95], ["cancer", "OBSERVATION", 132, 138]]], ["According to previous studies, Tocilizumab can reduce the affinity of IL-6R to IL-6 by binding to IL-6R and soluble IL-6R, thereby inhibiting the CSS (18) .", [["Tocilizumab", "CHEMICAL", 31, 42], ["Tocilizumab", "CHEMICAL", 31, 42], ["Tocilizumab", "SIMPLE_CHEMICAL", 31, 42], ["IL-6R", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-6", "GENE_OR_GENE_PRODUCT", 79, 83], ["IL-6R", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-6R", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-6R", "PROTEIN", 70, 75], ["IL-6", "PROTEIN", 79, 83], ["IL-6R", "PROTEIN", 98, 103], ["soluble IL-6R", "PROTEIN", 108, 121], ["previous studies", "TEST", 13, 29], ["Tocilizumab", "TREATMENT", 31, 42], ["IL-6R to IL", "TREATMENT", 70, 81]]], ["Tocilizumab as a recombinant humanized monoclonal antibody has been approved for the treatment of patients with severe CSS (36, 37) .IL-1 blockade properties.", [["Tocilizumab", "CHEMICAL", 0, 11], ["CSS", "DISEASE", 119, 122], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 98, 106], ["IL-1", "GENE_OR_GENE_PRODUCT", 133, 137], ["recombinant humanized monoclonal antibody", "PROTEIN", 17, 58], ["IL", "PROTEIN", 133, 135], ["patients", "SPECIES", 98, 106], ["Tocilizumab", "TREATMENT", 0, 11], ["a recombinant humanized monoclonal antibody", "TREATMENT", 15, 58], ["severe CSS", "PROBLEM", 112, 122], ["IL-1 blockade properties", "TREATMENT", 133, 157], ["severe", "OBSERVATION_MODIFIER", 112, 118]]], ["A group of American researchers suggested that continuous intravenousAnakinra infusions might have significant survival benefits owing to possibly reversing the cytokine storm in patients with COVID-19 (38) .", [["intravenous", "ANATOMY", 58, 69], ["Anakinra", "CHEMICAL", 69, 77], ["COVID-19", "CHEMICAL", 193, 201], ["Anakinra", "CHEMICAL", 69, 77], ["COVID-19", "CHEMICAL", 193, 201], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["Anakinra", "SIMPLE_CHEMICAL", 69, 77], ["patients", "ORGANISM", 179, 187], ["cytokine", "PROTEIN", 161, 169], ["patients", "SPECIES", 179, 187], ["continuous intravenousAnakinra infusions", "TREATMENT", 47, 87], ["the cytokine storm", "TREATMENT", 157, 175], ["COVID", "TEST", 193, 198], ["cytokine storm", "OBSERVATION", 161, 175]]], ["Previously, Shakoory B, et al. (39) claimed that the administration of Anakinra intravenously at a dose of 2.0 mg/kg/h for 72 h could significantly reduce the 28 d mortality in 484 patients with severe sepsis.", [["Anakinra", "CHEMICAL", 71, 79], ["sepsis", "DISEASE", 202, 208], ["Anakinra", "CHEMICAL", 71, 79], ["Anakinra", "SIMPLE_CHEMICAL", 71, 79], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["Anakinra intravenously", "TREATMENT", 71, 93], ["severe sepsis", "PROBLEM", 195, 208], ["severe", "OBSERVATION_MODIFIER", 195, 201], ["sepsis", "OBSERVATION", 202, 208]]], ["Though the exact role of IL-1 in the pathogenesis of CSS is unclear, it seems that IL-1 receptor blockade may aid in better control of the inflammatory process.", [["CSS", "DISEASE", 53, 56], ["IL-1", "GENE_OR_GENE_PRODUCT", 25, 29], ["IL-1 receptor", "GENE_OR_GENE_PRODUCT", 83, 96], ["IL-1", "PROTEIN", 25, 29], ["IL-1 receptor blockade", "TREATMENT", 83, 105], ["the inflammatory process", "PROBLEM", 135, 159], ["inflammatory", "OBSERVATION", 139, 151]]], ["According to the previous reports, Anakinra is a biopharmaceutical drug with a wide therapeutic range, and high safety (40).", [["Anakinra", "CHEMICAL", 35, 43], ["Anakinra", "CHEMICAL", 35, 43], ["Anakinra", "SIMPLE_CHEMICAL", 35, 43], ["Anakinra", "TREATMENT", 35, 43], ["a biopharmaceutical drug", "TREATMENT", 47, 71]]], ["Currently, Anakinra has been approved by the food and drug administration (FDA) for the treatment of a variety of auto-immune diseases, including rheumatoid arthritis as well as neonatal-onset multisystem inflammatory disease (41) .IL-1 blockade properties.", [["Anakinra", "CHEMICAL", 11, 19], ["auto-immune diseases", "DISEASE", 114, 134], ["rheumatoid arthritis", "DISEASE", 146, 166], ["multisystem inflammatory disease", "DISEASE", 193, 225], ["Anakinra", "CHEMICAL", 11, 19], ["Anakinra", "SIMPLE_CHEMICAL", 11, 19], [".IL-1", "GENE_OR_GENE_PRODUCT", 231, 236], ["Anakinra", "TREATMENT", 11, 19], ["the treatment", "TREATMENT", 84, 97], ["auto-immune diseases", "PROBLEM", 114, 134], ["rheumatoid arthritis", "PROBLEM", 146, 166], ["neonatal-onset multisystem inflammatory disease", "PROBLEM", 178, 225], [".IL-1 blockade properties", "TREATMENT", 231, 256], ["Anakinra", "OBSERVATION", 11, 19], ["auto-immune diseases", "OBSERVATION", 114, 134], ["rheumatoid arthritis", "OBSERVATION", 146, 166], ["multisystem", "OBSERVATION_MODIFIER", 193, 204], ["inflammatory disease", "OBSERVATION", 205, 225]]], ["A group of American researchers suggested that continuous intravenousTNF\u03b1 is another main cytokine in many inflammatory diseases.", [["intravenousTNF\u03b1", "CHEMICAL", 58, 73], ["intravenousTNF\u03b1", "CHEMICAL", 58, 73], ["intravenousTNF\u03b1", "GENE_OR_GENE_PRODUCT", 58, 73], ["intravenousTNF\u03b1", "PROTEIN", 58, 73], ["continuous intravenousTNF", "TREATMENT", 47, 72], ["many inflammatory diseases", "PROBLEM", 102, 128], ["many", "OBSERVATION_MODIFIER", 102, 106], ["inflammatory", "OBSERVATION", 107, 119]]], ["The elevated level of TNF\u03b1 in blood and tissues of patients with COVID-19 has been indicated in previous reports (42, 43) .", [["blood", "ANATOMY", 30, 35], ["tissues", "ANATOMY", 40, 47], ["COVID-19", "CHEMICAL", 65, 73], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 22, 26], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["tissues", "TISSUE", 40, 47], ["patients", "ORGANISM", 51, 59], ["TNF\u03b1", "PROTEIN", 22, 26], ["patients", "SPECIES", 51, 59], ["The elevated level of TNF", "PROBLEM", 0, 25], ["COVID", "TEST", 65, 70], ["elevated", "OBSERVATION", 4, 12], ["TNF", "ANATOMY", 22, 25], ["tissues", "ANATOMY", 40, 47]]], ["The potential role of anti-TNF therapy has been considered recently for reducing inflammation in COVID-19.", [["inflammation", "DISEASE", 81, 93], ["anti-TNF", "GENE_OR_GENE_PRODUCT", 22, 30], ["anti-TNF", "PROTEIN", 22, 30], ["anti-TNF therapy", "TREATMENT", 22, 38], ["reducing inflammation", "PROBLEM", 72, 93], ["COVID", "TEST", 97, 102], ["anti-TNF therapy", "OBSERVATION", 22, 38]]]], "PMC3335077": [["IntroductionInfluenza A viruses are enveloped RNA viruses of the family Orthomyxoviridae, and a major cause of morbidity and mortality in both humans and livestock, worldwide [1], [2], [3].", [["Influenza A viruses", "DISEASE", 12, 31], ["Influenza A viruses", "ORGANISM", 12, 31], ["humans", "ORGANISM", 143, 149], ["Influenza A viruses", "SPECIES", 12, 31], ["humans", "SPECIES", 143, 149], ["Influenza A viruses", "SPECIES", 12, 31], ["humans", "SPECIES", 143, 149], ["IntroductionInfluenza A viruses", "PROBLEM", 0, 31], ["morbidity", "PROBLEM", 111, 120], ["morbidity", "OBSERVATION", 111, 120]]], ["Spread may be via direct contact, over short distances on large \u2018cough\u2019 droplets (diameter >10 \u00b5m), over longer distances in aerosols of small droplet nuclei (diameter <10 \u00b5m) and on fomites [4], [5].", [["droplet nuclei", "ANATOMY", 143, 157], ["cough", "DISEASE", 65, 70], ["small droplet nuclei", "PROBLEM", 137, 157], ["small", "OBSERVATION_MODIFIER", 137, 142], ["droplet nuclei", "OBSERVATION", 143, 157]]], ["Meteorological variables such as air temperature, relative humidity, rainfall and wind have been suggested as important drivers of the spread and seasonality of influenza in both human [5], [6], [7], [8] and animal populations [9].", [["influenza", "DISEASE", 161, 170], ["human", "ORGANISM", 179, 184], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["Meteorological variables", "TEST", 0, 24], ["air temperature", "PROBLEM", 33, 48], ["influenza", "PROBLEM", 161, 170]]], ["Recently, Lowen et al. described, under laboratory conditions, how relative humidity and ambient temperature combine to influence the transmission of both seasonal (A/H3N2) and pandemic (A/H1N1) human influenza A [6], [8], [10].", [["pandemic", "DISEASE", 177, 185], ["A/H3N2", "ORGANISM", 165, 171], ["A/H1N1", "ORGANISM", 187, 193], ["human", "ORGANISM", 195, 200], ["human", "SPECIES", 195, 200], ["influenza", "SPECIES", 201, 210], ["A/H3N2", "SPECIES", 165, 171], ["A/H1N1) human influenza A", "SPECIES", 187, 212], ["ambient temperature", "TREATMENT", 89, 108], ["pandemic", "PROBLEM", 177, 185]]], ["The effects of several other environmental variables (soil pH, sunlight and surface permeability) on the survivability of influenza A viruses were established in earlier laboratory-based experimentation [11], [12].", [["surface", "ANATOMY", 76, 83], ["influenza A viruses", "ORGANISM", 122, 141], ["influenza A viruses", "SPECIES", 122, 141], ["soil pH", "TEST", 54, 61], ["surface permeability", "TEST", 76, 96], ["influenza A viruses", "PROBLEM", 122, 141]]], ["Analyses of the contribution of wind to the spread of epidemics of influenza, and indeed other infectious diseases, are more limited.", [["influenza", "DISEASE", 67, 76], ["infectious diseases", "DISEASE", 95, 114], ["epidemics", "PROBLEM", 54, 63], ["influenza", "PROBLEM", 67, 76], ["indeed other infectious diseases", "PROBLEM", 82, 114], ["influenza", "OBSERVATION", 67, 76], ["infectious", "OBSERVATION", 95, 105]]], ["Most studies present either circumstantial evidence that the mean direction of epidemic spread coincides with prevailing wind conditions at the time of an outbreak [13], [14], analyses of data aggregated to a low temporal or spatial resolution [15], [16], or associate spread from a small number of sources with atmospheric dispersal modelling outputs [17].", [["Most studies", "TEST", 0, 12], ["epidemic spread", "PROBLEM", 79, 94], ["small", "OBSERVATION_MODIFIER", 283, 288]]], ["Such research must also overcome the added complexity of movement of individuals within the population at risk.IntroductionIn their animal model of human influenza A transmission, Lowen et.al. have shown that dry cool conditions (low relative humidity and cold ambient temperatures) increase the spread of influenza [6].", [["influenza A transmission", "DISEASE", 154, 178], ["influenza", "DISEASE", 306, 315], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human influenza A", "SPECIES", 148, 165], ["dry cool conditions", "PROBLEM", 209, 228], ["low relative humidity", "PROBLEM", 230, 251], ["cold ambient temperatures", "PROBLEM", 256, 281], ["influenza", "PROBLEM", 306, 315], ["dry", "OBSERVATION_MODIFIER", 209, 212], ["cool", "OBSERVATION", 213, 217]]], ["They suggest that this mechanism is mediated by a complex interaction that affects the survivability of both aerosol droplet nuclei and virus particles.", [["nuclei", "ANATOMY", 125, 131], ["nuclei", "CELLULAR_COMPONENT", 125, 131], ["both aerosol droplet nuclei", "TREATMENT", 104, 131], ["virus particles", "PROBLEM", 136, 151]]], ["A detailed analysis, at high spatial and temporal resolution, comparing actual influenza outbreak data with concurrent meteorological data is required to validate and provide context to their model outside of controlled laboratory environments, thus furthering our understanding of how meteorological factors truly influence influenza spread.", [["influenza", "DISEASE", 325, 334], ["A detailed analysis", "TEST", 0, 19], ["actual influenza outbreak data", "PROBLEM", 72, 102], ["influenza spread", "PROBLEM", 325, 341], ["temporal", "OBSERVATION_MODIFIER", 41, 49], ["resolution", "OBSERVATION_MODIFIER", 50, 60]]], ["Outbreaks of disease in animal populations present a unique opportunity to study such effects, \u2018in the field\u2019.", [["disease", "PROBLEM", 13, 20], ["disease", "OBSERVATION", 13, 20]]], ["Research on detailed animal outbreak datasets has several distinct advantages over comparable research on public health influenza data [15], [18], [19], [20].", [["[19]", "SIMPLE_CHEMICAL", 147, 151]]], ["Firstly, human populations move about on a daily basis (albeit with some regularity).", [["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Implementing a complete human movement standstill (\u2018a 24 hour curfew\u2019) to control and contain an outbreak is considered an extraordinary and perhaps unfeasible social distancing measure, reserved for the most severe of human influenza pandemics [21].", [["influenza pandemics", "DISEASE", 225, 244], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 219, 224], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 219, 224], ["a complete human movement standstill", "TREATMENT", 13, 49], ["human influenza pandemics", "PROBLEM", 219, 244]]], ["Conversely, the movements of farm animal populations (such as horses, cattle and sheep) are mostly confined to within single premises, and in the event of an emergency animal disease outbreak, a complete movement ban is often the first control measure to be implemented [22].", [["horses", "ORGANISM_SUBDIVISION", 62, 68], ["sheep", "ORGANISM_SUBDIVISION", 81, 86], ["cattle", "SPECIES", 70, 76], ["sheep", "SPECIES", 81, 86], ["cattle", "SPECIES", 70, 76], ["sheep", "SPECIES", 81, 86], ["an emergency animal disease outbreak", "PROBLEM", 155, 191]]], ["Furthermore, ethical concerns (namely privacy) may constrain the research of human outbreak data, limiting the amount of detailed information that can be collated on the movement of individual people.", [["human", "ORGANISM", 77, 82], ["people", "ORGANISM", 193, 199], ["human", "SPECIES", 77, 82], ["people", "SPECIES", 193, 199], ["human", "SPECIES", 77, 82]]], ["Given that certain human and animal sub-types of influenza A share generally similar modes and patterns of transmission [5], research that utilises detailed animal outbreak datasets has the potential to inform our understanding of the complex mechanisms that influence human influenza A spread and seasonality.", [["influenza", "DISEASE", 49, 58], ["human", "ORGANISM", 19, 24], ["influenza A", "ORGANISM", 49, 60], ["human", "ORGANISM", 269, 274], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 19, 24], ["human influenza A", "SPECIES", 269, 286], ["influenza", "PROBLEM", 49, 58], ["human influenza A spread", "PROBLEM", 269, 293]]], ["The 2007 outbreak of equine influenza in Australia presented an excellent opportunity to study the effects of meteorology on the spread of an influenza A virus as it infected a mostly immunologically naive population, spatially confined (in paddocks).IntroductionEquine influenza virus (A/H3N8) is a highly contagious cause of low mortality, high morbidity respiratory disease capable of infecting all members of the horse family (Equidae).", [["respiratory", "ANATOMY", 357, 368], ["influenza", "DISEASE", 28, 37], ["influenza A virus", "DISEASE", 142, 159], ["Equine influenza virus", "DISEASE", 263, 285], ["respiratory disease", "DISEASE", 357, 376], ["equine", "ORGANISM", 21, 27], ["influenza A virus", "ORGANISM", 142, 159], ["Equine influenza virus", "ORGANISM", 263, 285], ["A/H3N8", "ORGANISM", 287, 293], ["horse", "ORGANISM", 417, 422], ["equine", "SPECIES", 21, 27], ["influenza A virus", "SPECIES", 142, 159], ["Equine influenza virus", "SPECIES", 263, 285], ["horse", "SPECIES", 417, 422], ["influenza A virus", "SPECIES", 142, 159], ["Equine influenza virus", "SPECIES", 263, 285], ["A/H3N8", "SPECIES", 287, 293], ["equine influenza", "PROBLEM", 21, 37], ["an influenza A virus", "PROBLEM", 139, 159], ["IntroductionEquine influenza virus", "PROBLEM", 251, 285], ["low mortality", "PROBLEM", 327, 340], ["high morbidity respiratory disease", "PROBLEM", 342, 376], ["influenza virus", "OBSERVATION", 270, 285], ["low mortality", "OBSERVATION_MODIFIER", 327, 340]]], ["It is considered endemic to equine populations across most of the world [2].", [["endemic", "OBSERVATION_MODIFIER", 17, 24]]], ["The disease is similar in many clinical and epidemiological respects to seasonal human influenza A, and major outbreaks have occurred when novel strains of equine influenza have gained entry into highly susceptible equine populations [2].", [["influenza A", "DISEASE", 87, 98], ["influenza", "DISEASE", 163, 172], ["human", "ORGANISM", 81, 86], ["equine influenza", "ORGANISM", 156, 172], ["equine", "ORGANISM", 215, 221], ["human", "SPECIES", 81, 86], ["equine influenza", "SPECIES", 156, 172], ["human influenza A", "SPECIES", 81, 98], ["equine", "SPECIES", 156, 162], ["The disease", "PROBLEM", 0, 11], ["seasonal human influenza A", "PROBLEM", 72, 98], ["equine influenza", "PROBLEM", 156, 172], ["disease", "OBSERVATION", 4, 11], ["similar", "OBSERVATION_MODIFIER", 15, 22]]], ["The typical incubation period of equine influenza is 1\u20133 days [23], [24], [25], however delayed onset of clinical signs of up to 5 days has been observed after low dose aerosol exposure [26].", [["influenza", "DISEASE", 40, 49], ["equine", "ORGANISM", 33, 39], ["equine influenza", "PROBLEM", 33, 49], ["clinical signs", "PROBLEM", 105, 119], ["low dose aerosol exposure", "TREATMENT", 160, 185]]], ["In 2007, following a breach in the quarantine of infected imported horses [27], Australia experienced its first ever outbreak of equine influenza.", [["influenza", "DISEASE", 136, 145], ["equine", "ORGANISM", 129, 135], ["equine", "SPECIES", 129, 135], ["equine influenza", "PROBLEM", 129, 145], ["equine influenza", "OBSERVATION", 129, 145]]], ["Less than 900 horses are imported annually into Australia from countries that vaccinate for equine influenza [27], therefore almost the entire horse population was susceptible at the start of this outbreak.", [["influenza", "DISEASE", 99, 108], ["horses", "ORGANISM", 14, 20], ["equine influenza", "ORGANISM", 92, 108], ["horse", "ORGANISM", 143, 148], ["equine influenza", "SPECIES", 92, 108], ["horse", "SPECIES", 143, 148], ["horses", "SPECIES", 14, 20], ["horse", "SPECIES", 143, 148], ["equine influenza", "PROBLEM", 92, 108]]], ["Over the course of 4 months, nearly 70 000 horses were infected, on over 9 000 premises in two Australian States\u2014New South Wales (NSW) and Queensland (QLD) [27].", [["horses", "ORGANISM", 43, 49], ["horses", "SPECIES", 43, 49], ["infected", "OBSERVATION", 55, 63]]], ["Timely and complete implementation of a horse movement ban has been widely credited as the most effective of the control measures that facilitated the rapid eradication of this disease from the Australian horse population [27].", [["horse", "ORGANISM", 40, 45], ["horse", "ORGANISM", 205, 210], ["horse", "SPECIES", 40, 45], ["horse", "SPECIES", 205, 210], ["horse", "SPECIES", 40, 45], ["a horse movement ban", "TREATMENT", 38, 58], ["the control measures", "TREATMENT", 109, 129], ["this disease", "PROBLEM", 172, 184]]], ["Although vaccination was used to eradicate the disease, its implementation only commenced 6 weeks into the outbreak, well after the peak of reported daily infections [28].", [["infections", "DISEASE", 155, 165], ["vaccination", "TREATMENT", 9, 20], ["the disease", "PROBLEM", 43, 54], ["disease", "OBSERVATION", 47, 54]]], ["Vaccination was initially restricted to disease containment zones and the protection of high value horses [28].IntroductionContact-tracing early in the 2007 outbreak revealed that the disease initially spread through a network of equestrian events, linked by the movement of infected horses prior to detection of the outbreak, producing clusters of infected premises in widespread locations [27], [29].", [["Vaccination", "TREATMENT", 0, 11], ["disease containment zones", "TREATMENT", 40, 65], ["the disease", "PROBLEM", 180, 191], ["infected horses", "PROBLEM", 275, 290], ["the outbreak", "PROBLEM", 313, 325], ["disease", "OBSERVATION", 184, 191], ["infected", "OBSERVATION", 275, 283], ["clusters", "OBSERVATION_MODIFIER", 337, 345], ["infected", "OBSERVATION_MODIFIER", 349, 357], ["widespread", "OBSERVATION_MODIFIER", 370, 380]]], ["Epidemiological investigations noted rare instances of presumed windborne spread over short ranges (\u22641.5 km, and rarely up to 5 km) based on failure to identify other potential means of transmission (i.e. close contact or on fomites) [30].", [["Epidemiological investigations", "TEST", 0, 30], ["windborne spread", "PROBLEM", 64, 80], ["windborne", "OBSERVATION_MODIFIER", 64, 73], ["spread", "OBSERVATION_MODIFIER", 74, 80], ["failure", "OBSERVATION", 141, 148]]], ["Previous epidemiological analyses of this outbreak have investigated the spatial and network components of early spread [29], [30], [31], [32], and premises-level risk factors for disease spread such as compliance with advised biosecurity measures [33].", [["this outbreak", "PROBLEM", 37, 50], ["disease spread", "PROBLEM", 180, 194]]], ["Two further analyses have specifically investigated environmental factors that might have influenced the spread of this outbreak [13], [34].", [["Two further analyses", "TEST", 0, 20]]], ["In one cluster of 437 infected premises, a relationship was observed between prevailing wind conditions and the global direction of spread [13].IntroductionIn this paper we present a comprehensive analysis of the influence of meteorological variables on time to infection based on an influenza A virus outbreak dataset.", [["infection", "DISEASE", 262, 271], ["influenza A virus", "ORGANISM", 284, 301], ["influenza A virus", "SPECIES", 284, 301], ["influenza A virus", "SPECIES", 284, 301], ["a comprehensive analysis", "TEST", 181, 205], ["infection", "PROBLEM", 262, 271], ["an influenza A virus outbreak dataset", "PROBLEM", 281, 318], ["infected", "OBSERVATION", 22, 30]]], ["This spatio-temporal analysis aims to identify and quantify the association between four meteorological variables (air temperature, relative humidity, rainfall, wind velocity) and time to infection in the largest cluster of the 2007 equine influenza (A/H3N8) outbreak in Australia.", [["infection", "DISEASE", 188, 197], ["influenza", "DISEASE", 240, 249], ["A/H3N8", "ORGANISM", 251, 257], ["A/H3N8", "SPECIES", 251, 257], ["This spatio-temporal analysis", "TEST", 0, 29], ["air temperature", "PROBLEM", 115, 130], ["relative humidity", "PROBLEM", 132, 149], ["infection", "PROBLEM", 188, 197], ["influenza", "PROBLEM", 240, 249], ["infection", "OBSERVATION", 188, 197], ["largest", "OBSERVATION_MODIFIER", 205, 212]]], ["We are unaware of any previously published analysis that combines such a large and spatio-temporally detailed influenza outbreak dataset with concurrent daily meteorological data, to allow meaningful estimation of the contribution of such factors in the spread of an influenza A outbreak.The equine influenza dataset ::: Materials and MethodsThe state government of New South Wales provided contact-tracing and laboratory testing data on all horses investigated during the 2007 outbreak.", [["equine", "ORGANISM", 292, 298], ["any previously published analysis", "PROBLEM", 18, 51], ["a large and spatio", "PROBLEM", 71, 89], ["such factors", "PROBLEM", 234, 246], ["an influenza A outbreak", "PROBLEM", 264, 287], ["Methods", "TREATMENT", 335, 342], ["laboratory testing data", "TEST", 411, 434], ["large", "OBSERVATION_MODIFIER", 73, 78], ["influenza", "OBSERVATION", 267, 276]]], ["This dataset was collected at the level of individual horses and aggregated to the premises level for analysis.", [["horses", "ORGANISM", 54, 60], ["This dataset", "TEST", 0, 12], ["analysis", "TEST", 102, 110]]], ["Premises attribute records included address, geocoded coordinates (based on premises centroid), number of horses, date of onset of clinical signs in the first horse affected (\u2018onset date\u2019), vaccination status and date of vaccination.", [["horse", "ORGANISM_SUBDIVISION", 159, 164], ["horse", "SPECIES", 159, 164], ["clinical signs", "PROBLEM", 131, 145], ["vaccination", "TREATMENT", 221, 232]]], ["Premises were defined as infected (IP) if they held horses that had been observed with the classical clinical signs of equine influenza (cough, elevated temperature, nasal discharge and lethargy).", [["nasal", "ANATOMY", 166, 171], ["influenza", "DISEASE", 126, 135], ["cough", "DISEASE", 137, 142], ["lethargy", "DISEASE", 186, 194], ["horses", "ORGANISM", 52, 58], ["equine", "ORGANISM", 119, 125], ["nasal", "ORGANISM_SUBDIVISION", 166, 171], ["equine", "SPECIES", 119, 125], ["equine influenza", "PROBLEM", 119, 135], ["cough", "PROBLEM", 137, 142], ["elevated temperature", "PROBLEM", 144, 164], ["nasal discharge", "PROBLEM", 166, 181], ["lethargy", "PROBLEM", 186, 194], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["nasal", "ANATOMY", 166, 171]]], ["This status was confirmed by laboratory testing based on real-time reverse transcription polymerase chain reaction assay [36], however, around the peak of the outbreak not all horses were tested due to resource constraints [30].", [["laboratory testing", "TEST", 29, 47]]], ["Contact-tracing records included the date of the movement, the addresses and unique identifiers for the origin and destination premises between which horses were moved prior to the horse movement ban.Study extent: cluster delineation ::: Materials and MethodsThere was a single \u2018index\u2019 for the 2007 outbreak of equine influenza in Australia: an equestrian event located 160 km north of Sydney, at which transmission was known to have occurred.", [["influenza", "DISEASE", 318, 327], ["horses", "ORGANISM", 150, 156], ["horse", "ORGANISM", 181, 186], ["equine", "SPECIES", 311, 317], ["equine influenza", "PROBLEM", 311, 327]]], ["This analysis focused on local spread within the single largest cluster of the outbreak, centred 60 km northwest of Sydney's city centre (Figure 1).", [["This analysis", "TEST", 0, 13], ["local spread", "PROBLEM", 25, 37], ["largest", "OBSERVATION_MODIFIER", 56, 63]]], ["To maintain a computationally tractable dataset, premises were selected for inclusion in the study (from the equine influenza dataset) if their centroid was within 15 km of nine contact-traced \u2018source\u2019 premises.", [["the study", "TEST", 89, 98], ["the equine influenza dataset", "TREATMENT", 105, 133]]], ["All nine contact-traced premises were identified (based on an earlier likelihood-based analysis [32]) to have been infected in the first week of the outbreak following the movement of infected horses from the \u2018index\u2019.", [["horses", "ORGANISM", 193, 199], ["infected horses", "PROBLEM", 184, 199], ["infected", "OBSERVATION", 115, 123], ["infected", "OBSERVATION", 184, 192]]], ["The 15 km buffer used to delineate the cluster was selected based on a previous analysis in which we identified that 98% of premises infected in the first month of the outbreak were within this distance of a contact-traced \u2018source\u2019 premises [29].", [["The 15 km buffer", "TREATMENT", 0, 16], ["a previous analysis", "TEST", 69, 88]]], ["The \u2018Northwest Sydney\u2019 cluster studied was approximately 65 km in diameter, bounded to the North and West by national parks (where horses are prohibited) and to the South and East by metropolitan Sydney.Exploratory spatial and temporal analyses ::: Materials and MethodsThe dataset was imported into the R statistical package version 2.13.0 [37], and an epidemic curve constructed as the count of infected premises reported per day.", [["horses", "ORGANISM_SUBDIVISION", 131, 137], ["Exploratory spatial and temporal analyses", "TEST", 203, 244], ["Methods", "TREATMENT", 263, 270], ["an epidemic curve", "TEST", 351, 368], ["infected", "OBSERVATION", 397, 405]]], ["Extraction mapping was used to investigate the spatial pattern of risk of infection over time.", [["infection", "DISEASE", 74, 83], ["Extraction mapping", "TEST", 0, 18], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["To identify areas of elevated risk, relative risk surfaces with upper 95% tolerance contours were estimated as the Gaussian-smoothed kernel density surface of infected horse premises divided by the surface of the population of horse premises at risk in 4-week time periods.", [["surface", "ANATOMY", 198, 205], ["horse", "ORGANISM", 168, 173], ["horse", "ORGANISM", 227, 232], ["horse", "SPECIES", 168, 173], ["horse", "SPECIES", 227, 232], ["horse", "SPECIES", 168, 173], ["elevated risk", "PROBLEM", 21, 34], ["relative risk surfaces", "PROBLEM", 36, 58], ["upper 95% tolerance contours", "PROBLEM", 64, 92], ["infected horse premises", "PROBLEM", 159, 182], ["elevated risk", "OBSERVATION", 21, 34], ["risk", "OBSERVATION_MODIFIER", 45, 49], ["surfaces", "OBSERVATION_MODIFIER", 50, 58], ["upper", "ANATOMY_MODIFIER", 64, 69], ["density", "OBSERVATION_MODIFIER", 140, 147], ["surface", "OBSERVATION_MODIFIER", 148, 155], ["infected", "OBSERVATION_MODIFIER", 159, 167], ["horse premises", "OBSERVATION", 168, 182], ["surface", "OBSERVATION_MODIFIER", 198, 205], ["population", "OBSERVATION_MODIFIER", 213, 223], ["horse premises", "OBSERVATION", 227, 241]]], ["A spatially adaptive variable smoothing parameter was used to prepare the relative risk surfaces [38], with edge effect correction, implemented in R with the \u2018sparr\u2019 library [39].", [["A spatially adaptive variable smoothing parameter", "TREATMENT", 0, 49]]], ["The amount of smoothing (bandwidth) applied varied across the study extent in inverse proportion to the population at risk in each time period.", [["smoothing (bandwidth)", "TREATMENT", 14, 35], ["the study", "TEST", 58, 67], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["smoothing", "OBSERVATION_MODIFIER", 14, 23], ["population", "OBSERVATION", 104, 114]]], ["To test for directional spread, the mean geographic centre of the outbreak was estimated by week as the mean of the coordinates of the infected premises with dates of onset in each week of the outbreak [40].Explanatory variables ::: Survival analysis ::: Materials and MethodsExplanatory covariates tested for associations with the time to infection of premises in the Northwest Sydney cluster are listed in Table 1.", [["infection", "DISEASE", 340, 349], ["directional spread", "PROBLEM", 12, 30], ["Survival analysis", "TEST", 233, 250], ["Materials", "TREATMENT", 255, 264], ["infected", "OBSERVATION", 135, 143]]], ["These boundaries were used to generate a continuous variable representing the length of fence that each horse premises shared with any contiguous horse premises in the equine influenza dataset.", [["horse", "ORGANISM", 104, 109], ["horse", "ORGANISM", 146, 151], ["equine", "ORGANISM", 168, 174]]], ["Premises elevation was extracted from a digital elevation model of Australia [45], which is a grid of ground level elevation covering the whole of Australia with a grid spacing of approximately 250 metres, as the mean of all grid cells needed to cover a premises.", [["grid cells", "ANATOMY", 225, 235], ["cells", "CELL", 230, 235], ["grid cells", "CELL_TYPE", 225, 235], ["Premises elevation", "PROBLEM", 0, 18], ["ground level elevation", "PROBLEM", 102, 124], ["a grid spacing", "TREATMENT", 162, 176], ["all grid cells", "TREATMENT", 221, 235], ["elevation", "OBSERVATION_MODIFIER", 9, 18], ["elevation", "OBSERVATION_MODIFIER", 48, 57]]], ["Distance to the nearest main road was calculated from the premises boundary using vector data of road Classes 1\u20133 (freeways, highways, primary and arterial roads) [46].", [["arterial", "ANATOMY", 147, 155], ["arterial", "ANATOMY", 147, 155]]], ["Human population density, within approximately 1 km of the premises centroid, was estimated based on high resolution gridded population data from 2005 [47], adjusted by 3% for population growth between 2005 and 2007 [48].Estimation of meteorological time-varying predictors ::: Survival analysis ::: Materials and MethodsHourly wind velocity data (wind direction and speed) and daily data for five other meteorological variables (rainfall, minimum and maximum daily air temperature, and relative humidity measured at 9 am and 3 pm) were obtained from 132 weather stations.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human population density", "PROBLEM", 0, 24], ["Survival analysis", "TEST", 278, 295], ["MethodsHourly wind velocity data", "TEST", 314, 346], ["daily data", "TEST", 378, 388], ["maximum daily air temperature", "TEST", 452, 481], ["relative humidity", "TEST", 487, 504], ["population", "OBSERVATION_MODIFIER", 6, 16], ["density", "OBSERVATION", 17, 24]]], ["All of these weather stations were operated by the Australian Bureau of Meteorology during the study period, and were located either within the cluster or within 20 km of the cluster boundary.", [["the study", "TEST", 91, 100]]], ["Ordinary kriging [49] was used to interpolate daily values at each individual premises location for the meteorological time-varying predictors: maximum wind speed (km hour\u22121), rainfall (mm), maximum and minimum surface air temperature (\u00b0C), and relative humidity (%, measured at 9 am and 3 pm).", [["surface", "ANATOMY", 211, 218]]], ["Each time-varying meteorological covariate was then time-lagged by 1\u20135 days to encompass the full range of incubation periods observed in experimental infection studies [26].Estimation of meteorological time-varying predictors ::: Survival analysis ::: Materials and MethodsKriging is a geostatistical smoothing technique that involves modelling the underlying spatial dependency (autocorrelation) in spatially continuous data based on a covariance function (Figure 2a) [49].", [["infection", "DISEASE", 151, 160], ["experimental infection studies", "PROBLEM", 138, 168], ["Survival analysis", "TEST", 231, 248], ["a geostatistical smoothing technique", "TREATMENT", 285, 321], ["modelling the underlying spatial dependency", "PROBLEM", 336, 379], ["a covariance function", "TEST", 436, 457], ["infection", "OBSERVATION", 151, 160], ["spatial dependency", "OBSERVATION", 361, 379]]], ["For each observation point (hour or day), for each meteorological variable, a binned isotropic empirical variogram was plotted that represented covariance (as semivariance) up until half of the maximum pairwise distance between any two weather stations contributing data at that time point, with bin widths (h) of approximately 10% of the average distance between weather stations [50].", [["a binned isotropic empirical variogram", "TREATMENT", 76, 114]]], ["A stationary exponential variogram model was then fit to the empirical variogram, using iterative least squares regression, and parameter estimates used to interpolate values at each premises location [49].Generation of wind speed covariates ::: Survival analysis ::: Materials and MethodsHourly wind velocity data were available from sixteen of the weather stations, automatically measured on masts at 10(metres above the earth's surface.", [["surface", "ANATOMY", 431, 438], ["A stationary exponential variogram model", "TEST", 0, 40], ["the empirical variogram", "TEST", 57, 80], ["iterative least squares regression", "TREATMENT", 88, 122], ["parameter estimates", "TEST", 128, 147], ["Survival analysis", "TEST", 246, 263], ["Hourly wind velocity data", "TEST", 289, 314]]], ["These wind data were supplied in a polar coordinate structure, comprising the average direction of origin of the wind (in degrees from true north) and the maximum wind speed (in kilometres hour(1), measured over the 10(minutes leading up to the observation time.", [["These wind data", "TEST", 0, 15], ["polar", "ANATOMY_MODIFIER", 35, 40], ["average", "OBSERVATION_MODIFIER", 78, 85], ["direction", "OBSERVATION_MODIFIER", 86, 95], ["origin", "ANATOMY_MODIFIER", 99, 105], ["wind", "OBSERVATION_MODIFIER", 113, 117], ["maximum", "OBSERVATION_MODIFIER", 155, 162]]], ["To avoid the issue of northerly bearings being split at true north (i.e. true bearings of 1( and 359( seeming distant when they are only 2( apart), prior to variography and kriging, the wind velocity data was converted into a Cartesian coordinate system\u2014defined by two components (Figure 2b,c): \u201cu\" representing the East-to-West component of the wind velocity, and \u201cv\" representing the North-to-South component [51].", [["northerly bearings", "PROBLEM", 22, 40], ["the wind velocity data", "TEST", 182, 204], ["wind velocity", "OBSERVATION", 346, 359]]], ["A negative value for the \u201cu\" component therefore represents a wind from one of the westerly bearings (i.e. NW, W or SW).Generation of wind speed covariates ::: Survival analysis ::: Materials and MethodsKriging was then conducted on the two wind velocity vector components [51].", [["Survival analysis", "TEST", 160, 177], ["MethodsKriging", "TREATMENT", 196, 210], ["negative", "OBSERVATION", 2, 10]]], ["Hourly wind velocity vectors were interpolated for each premises and back-transformed into the original polar coordinates (direction of wind origin and maximum wind speed).Generation of wind speed covariates ::: Survival analysis ::: Materials and MethodsTwo approaches were taken to aggregate the hourly wind velocity vectors for each premises into daily maximum wind speed covariates.", [["Hourly wind velocity vectors", "TREATMENT", 0, 28], ["Survival analysis", "TEST", 212, 229], ["polar", "OBSERVATION_MODIFIER", 104, 109]]], ["First, to test the hypothesis that increased wind speed from any direction was associated with increased hazard of infection we generated \u2018undirected\u2019 maximum daily wind speed covariates (\u2018WIND_SPDundir\u2019) without making any directional assumptions, taking the maximum of all hourly wind speed estimates for each premises on each day.Generation of wind speed covariates ::: Survival analysis ::: Materials and MethodsNext, to explore the directionality of wind exposure risk we generated \u2018directed\u2019 maximum daily wind speed covariates (\u2018WIND_SPDdir\u2019) based only on wind coming from within the direction of the nearest k infected premises (for k = 1,2,3) by selecting wind from within 45\u00b0 arcs centred on the bearing of the nearest k infected premises to each premises on each day.", [["infection", "DISEASE", 115, 124], ["increased hazard of infection", "PROBLEM", 95, 124], ["Survival analysis", "TEST", 373, 390], ["MethodsNext", "TREATMENT", 409, 420], ["k", "TEST", 642, 643], ["infection", "OBSERVATION", 115, 124]]], ["For each premises, on each day of observation, we identified the nearest three infected premises from amongst those infected premises that had a date of onset (of clinical signs in the first horse infected on the premises) within the previous 14 days.", [["horse", "ORGANISM", 191, 196], ["horse", "SPECIES", 191, 196], ["clinical signs", "PROBLEM", 163, 177]]], ["Though it is known that individual unvaccinated horses remain infectious for up to 7 days [2], [52], the duration of infectivity may vary on multi-horse premises because of differences in contact rates between individual horses, and individual variability in susceptibility, latency and virus shedding.", [["horses", "ORGANISM", 48, 54], ["horses", "SPECIES", 48, 54], ["individual unvaccinated horses", "PROBLEM", 24, 54], ["infectious", "PROBLEM", 62, 72], ["infectivity", "PROBLEM", 117, 128], ["individual variability in susceptibility", "PROBLEM", 233, 273], ["latency and virus shedding", "PROBLEM", 275, 301]]], ["To infer which premises were holding infectious horses at each time point we assumed that the period of infectivity was 14 days for all premises based on case reports from horse premises of a range of sizes [53], [54], [55], intra-herd simulation modelling [28] and that almost the entire population was immunologically naive to equine influenza at the start of the outbreak.Generation of wind speed covariates ::: Survival analysis ::: Materials and MethodsFinally, these time-varying predictors were lagged by 1\u20135 days to serve as proxies for wind within the range of incubation periods that have been observed for equine influenza, producing 20 time-lagged explanatory covariates: \u2018WIND_SPDundirt\u22121, t\u22122, \u2026, t\u22125\u2019 and \u2018WIND_SPDdir(k)t\u22121, t\u22122, \u2026, t\u22125\u2019, for k = 1,2,3.Univariable analysis ::: Materials and MethodsInstantaneous hazard curves were constructed for each time-invariant covariate with the \u2018epiR\u2019 library in R [56], categorising continuous variables into quartiles.", [["influenza", "DISEASE", 336, 345], ["influenza", "DISEASE", 624, 633], ["equine", "ORGANISM", 329, 335], ["t\u22122", "PROTEIN", 703, 706], ["WIND", "PROTEIN", 721, 725], ["horse", "SPECIES", 172, 177], ["equine", "SPECIES", 617, 623], ["equine", "SPECIES", 329, 335], ["equine influenza", "SPECIES", 617, 633], ["infectivity", "PROBLEM", 104, 115], ["equine influenza", "PROBLEM", 329, 345], ["Survival analysis", "TEST", 415, 432], ["equine influenza", "PROBLEM", 617, 633], ["WIND", "TEST", 721, 725], ["SPDdir", "TEST", 726, 732], ["k", "TEST", 733, 734], ["t", "TEST", 735, 736], ["\u2212", "TEST", 736, 737], ["t\u2212", "TEST", 740, 742], ["\u2026", "TEST", 745, 746], ["t", "TEST", 748, 749], ["k", "TEST", 758, 759], ["Univariable analysis", "TEST", 768, 788], ["MethodsInstantaneous hazard curves", "TREATMENT", 807, 841]]], ["The instantaneous hazard rate, h(t), is the rate at time t, that a randomly-selected individual from the population yet to experience an event, experiences the event at time t[43], and is mathematically defined as:(2)where T is the time that an event is experienced.", [["The instantaneous hazard rate", "TEST", 0, 29]]], ["In this study, the unit of interest was the horse premises, and events were defined as the infection of horses with equine influenza virus on a previously uninfected premises.Univariable analysis ::: Materials and MethodsUnivariable Cox models were then constructed and the statistical strength of the association between each variable (categorical or continuous) and the outcome assessed using likelihood ratio tests [35].", [["infection", "DISEASE", 91, 100], ["equine influenza virus", "DISEASE", 116, 138], ["horse", "ORGANISM", 44, 49], ["horses", "ORGANISM", 104, 110], ["equine influenza virus", "ORGANISM", 116, 138], ["horse", "SPECIES", 44, 49], ["equine influenza virus", "SPECIES", 116, 138], ["equine influenza virus", "SPECIES", 116, 138], ["this study", "TEST", 3, 13], ["the infection of horses", "PROBLEM", 87, 110], ["equine influenza virus", "PROBLEM", 116, 138], ["Univariable analysis", "TEST", 175, 195], ["MethodsUnivariable Cox models", "TREATMENT", 214, 243], ["likelihood ratio tests", "TEST", 395, 417], ["infection", "OBSERVATION", 91, 100]]], ["The linearity of the relationship between log hazard of infection and each continuous variable was assessed graphically using restricted cubic splines [57] with knots spaced at quintiles in the data.", [["infection", "DISEASE", 56, 65], ["infection", "PROBLEM", 56, 65], ["restricted cubic splines", "TREATMENT", 126, 150], ["linearity", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 56, 65]]], ["To differentiate linear and nonlinear component terms, partial likelihood ratio tests were conducted comparing a model containing all spline terms to a nested model containing only a single linear term [57].", [["partial likelihood ratio tests", "TEST", 55, 85], ["a model containing all spline terms", "TREATMENT", 111, 146], ["a nested model", "TREATMENT", 150, 164], ["linear", "OBSERVATION_MODIFIER", 17, 23], ["nonlinear", "OBSERVATION_MODIFIER", 28, 37], ["component", "OBSERVATION_MODIFIER", 38, 47], ["partial", "OBSERVATION_MODIFIER", 55, 62]]], ["If a highly non-linear relationship was detected, the spline of the continuous variable was retained for multivariable analysis.", [["multivariable analysis", "TEST", 105, 127]]], ["All continuous covariates were tested for collinearity in pairs by calculating Spearman's rank correlation coefficient (\u03c1).", [["All continuous covariates", "TREATMENT", 0, 25], ["collinearity in pairs", "PROBLEM", 42, 63]]], ["Intrinsic temporal autocorrelation was expected amongst certain groups of time-lagged time-varying meteorological predictors, such as: \u2018TEMP_MIN t\u22121\u2019with \u2018TEMP_MIN t\u22122, \u2026, t\u22125\u2019 and \u2018RH_3PM t\u22121\u2019 with \u2018RH_9AM t\u22121, t\u22122, \u2026, t\u22125\u2019.", [["Intrinsic temporal autocorrelation", "PROBLEM", 0, 34], ["TEMP", "TEST", 136, 140], ["TEMP", "TEST", 155, 159], ["RH_3PM", "TEST", 182, 188], ["\u2212", "TEST", 190, 191], ["\u2019", "TEST", 192, 193], ["\u2018", "TEST", 199, 200], ["RH_9AM", "TEST", 200, 206], ["\u2212", "TEST", 208, 209], ["t\u22122", "TEST", 212, 215], ["\u2026", "TEST", 217, 218]]], ["From amongst any pair of highly correlated (\u03c1>|0.70|) time-invariant covariates, and from amongst intrinsically temporally autocorrelated groups of time-varying predictors, only the variable with the strongest statistical association with the outcome was retained for further analysis [58].Multivariable analysis ::: Materials and MethodsAll remaining variables (unconditionally statistically associated with the log hazard of infection at P-value<0.25) were entered into a generalised \u2018counting process\u2019 Cox regression model [41].", [["infection", "DISEASE", 427, 436], ["further analysis", "TEST", 268, 284], ["Multivariable analysis", "TEST", 290, 312], ["infection", "PROBLEM", 427, 436], ["Cox regression model", "TEST", 505, 525], ["infection", "OBSERVATION", 427, 436]]], ["Each eligible candidate variable was then individually tested by excluding it from the maximal model and conducting likelihood ratio tests, eliminating any variables with P-value\u22650.10.", [["P-value", "TEST", 171, 178]]], ["To assess confounding, all eliminated variables were individually added back into the model, retaining any terms that resulted in a >20% change in any regression coefficient.", [["a >20% change", "PROBLEM", 130, 143]]], ["The time-varying predictor representing vaccination status was forced into all multivariable models as it was considered a priori to confound disease spread.", [["vaccination status", "PROBLEM", 40, 58], ["confound disease spread", "PROBLEM", 133, 156]]], ["The linearity of the relationship between the outcome and each continuous variable still included in the model was assessed again, using restricted cubic splines [57].", [["restricted cubic splines", "TREATMENT", 137, 161], ["linearity", "OBSERVATION_MODIFIER", 4, 13]]], ["Finally, tests were conducted for all two-way interactions of terms in the preliminary main effects model.Multivariable analysis ::: Materials and MethodsGoodness of fit of the final model was assessed using \u2018Martingale\u2019 residuals.", [["tests", "TEST", 9, 14], ["Multivariable analysis", "TEST", 106, 128]]], ["The influence of every individual observation was tested by omitting it and observing for change in the regression coefficients [59].", [["every individual observation", "TEST", 17, 45]]], ["To test for spatial dependency (autocorrelation) we examined the spatial structure of the residuals of the final model by mapping normalised martingale residuals (\u2018deviance residuals\u2019) and plotting an empirical semivariogram [60].Exploratory spatial and temporal analysis ::: ResultsThe Northwest Sydney cluster of the 2007 equine influenza outbreak in Australia contained 3624 horse premises, of which 1922 were reported to be infected during the 131 day outbreak (cumulative incidence = 53.0%, 95% CI: 51.4, 54.7%).Exploratory spatial and temporal analysis ::: ResultsSurfaces of spatial relative risk by four week period are included as Figure 3.", [["influenza", "DISEASE", 331, 340], ["horse", "ORGANISM", 378, 383], ["horse", "SPECIES", 378, 383], ["spatial dependency", "PROBLEM", 12, 30], ["plotting an empirical semivariogram", "TEST", 189, 224], ["Exploratory spatial and temporal analysis", "TEST", 230, 271], ["CI", "TEST", 500, 502], ["Exploratory spatial and temporal analysis", "TEST", 517, 558], ["infected", "OBSERVATION", 428, 436]]], ["In the first 4 weeks of the outbreak there were two areas of elevated spatial risk localised around the nine source premises for this cluster.", [["elevated spatial risk", "PROBLEM", 61, 82], ["areas", "OBSERVATION_MODIFIER", 52, 57], ["elevated", "OBSERVATION_MODIFIER", 61, 69], ["spatial risk", "OBSERVATION", 70, 82]]], ["Over the next 4 weeks, the two areas of elevated risk coalesced and expanded.", [["elevated risk", "PROBLEM", 40, 53], ["elevated", "OBSERVATION_MODIFIER", 40, 48], ["risk", "OBSERVATION_MODIFIER", 49, 53], ["coalesced", "OBSERVATION_MODIFIER", 54, 63], ["expanded", "OBSERVATION_MODIFIER", 68, 76]]], ["Between weeks 9 to 12, the areas of spatial risk dissipated into several smaller pockets of infection.", [["infection", "DISEASE", 92, 101], ["infection", "PROBLEM", 92, 101], ["spatial risk", "OBSERVATION", 36, 48], ["several", "OBSERVATION_MODIFIER", 65, 72], ["smaller", "OBSERVATION_MODIFIER", 73, 80], ["pockets", "OBSERVATION_MODIFIER", 81, 88], ["infection", "OBSERVATION", 92, 101]]], ["Over the remainder of the outbreak, the spatial risk faded out in isolated pockets of infection.Exploratory spatial and temporal analysis ::: ResultsThe mean centre of the outbreak did not move predominantly in any single direction over the study period, moving Northwest at 3.0 km week\u22121 in the first 4 weeks, then Southwest at 3.9 km week\u22121 for 4 weeks, before moving back to the East at 4.1 km week\u22121 whilst the epidemic faded out.Survival analysis ::: ResultsThe complete survival dataset included 3153 premises containing 1727 events (infections) during the study period.", [["infection", "DISEASE", 86, 95], ["infections", "DISEASE", 540, 550], ["infection", "PROBLEM", 86, 95], ["Exploratory spatial and temporal analysis", "TEST", 96, 137], ["Survival analysis", "TEST", 434, 451], ["infections", "PROBLEM", 540, 550], ["the study", "TEST", 559, 568], ["pockets", "OBSERVATION_MODIFIER", 75, 82], ["infection", "OBSERVATION", 86, 95], ["mean", "OBSERVATION_MODIFIER", 153, 157]]], ["Data on 57 infected horse premises were excluded because their onset dates occurred in the first 14 days of the outbreak (a period when they could possibly have been infected by the movement of infected horses rather than by local spatial spread).", [["horse", "ORGANISM", 20, 25], ["horse", "SPECIES", 20, 25], ["infected horses", "PROBLEM", 194, 209]]], ["Sixty-seven infected premises were missing a date of onset, and 347 premises (71 infected and 276 uninfected premises) were missing data on their number of horses.", [["horses", "ORGANISM_SUBDIVISION", 156, 162], ["missing data", "PROBLEM", 124, 136]]], ["The median survival time, the point at which half of the premises in this cluster were infected, was day 55 of this outbreak (95% CI : 52, 61).", [["infected", "OBSERVATION", 87, 95]]], ["The instantaneous hazard, the proportion of infections per day in the population surviving uninfected until that day, peaked on day 28 (Figure 4); 92 premises were reported to be infected on this day.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsMost horse premises were relatively close to a weather station, with the mean distance to the nearest weather station reporting wind data being 11.7 km (SD = 5.4 km, maximum = 27.4 km).", [["infections", "DISEASE", 44, 54], ["infection", "DISEASE", 240, 249], ["horse", "ORGANISM", 291, 296], ["horse", "SPECIES", 291, 296], ["infections", "PROBLEM", 44, 54], ["Meteorological covariates", "PROBLEM", 200, 225], ["infection", "PROBLEM", 240, 249], ["Univariable analysis", "TEST", 254, 274], ["wind data", "TEST", 414, 423], ["SD", "TEST", 439, 441], ["maximum", "TEST", 452, 459], ["instantaneous", "OBSERVATION_MODIFIER", 4, 17], ["infections", "OBSERVATION", 44, 54], ["infected", "OBSERVATION", 179, 187], ["infection", "OBSERVATION", 240, 249]]], ["For all meteorological data, there was a paucity of weather stations in the Northwest corner of the study extent (because this region is bordered by a national park).Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsDaily rainfall data were available from 127 weather stations in the study extent.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsOver the study period, the median estimated daily rainfall per premises was 0.1 mm day\u22121 (IQR: 0 to 2.8 mm day\u22121, maximum = 106.5 mm day\u22121).", [["infection", "DISEASE", 206, 215], ["infection", "DISEASE", 373, 382], ["all meteorological data", "TEST", 4, 27], ["infection", "PROBLEM", 206, 215], ["Univariable analysis", "TEST", 220, 240], ["rainfall data", "TEST", 258, 271], ["infection", "PROBLEM", 373, 382], ["Univariable analysis", "TEST", 387, 407], ["IQR", "TEST", 509, 512], ["maximum", "TEST", 533, 540], ["paucity", "OBSERVATION_MODIFIER", 41, 48], ["infection", "OBSERVATION", 206, 215], ["infection", "OBSERVATION", 373, 382]]], ["No statistically significant associations were detected between time-lagged rainfall covariates and hazard of infection (Table 2).", [["infection", "DISEASE", 110, 119], ["infection", "PROBLEM", 110, 119], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["infection", "OBSERVATION", 110, 119]]], ["Moderate temporal correlation (\u03c1\u22480.60) was observed between rainfall data 1 day apart, and between rainfall and relative humidity measurements conducted within 1 day of each other.", [["Moderate temporal correlation", "PROBLEM", 0, 29], ["relative humidity measurements", "TEST", 112, 142]]], ["A detailed correlation matrix of all continuous covariates is provided in Supporting Information S1.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsRelative humidity data measured twice daily (at 9 am and 3 pm) were available from eighteen weather stations (Figure 5a).", [["infection", "DISEASE", 140, 149], ["all continuous covariates", "TREATMENT", 33, 58], ["infection", "PROBLEM", 140, 149], ["Univariable analysis", "TEST", 154, 174], ["ResultsRelative humidity data", "TEST", 179, 208], ["infection", "OBSERVATION", 140, 149]]], ["The mean of the estimated 9 am and 3 pm relative humidity measurements for the horse premises under observation were 70.8% (SD = 17.5%) and 52.9% (SD = 20.3%), respectively.", [["horse", "ORGANISM", 79, 84], ["horse", "SPECIES", 79, 84], ["relative humidity measurements", "TEST", 40, 70], ["SD", "TEST", 124, 126], ["SD", "TEST", 147, 149], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Conditions were drier when measured at the same station at 3 pm compared to 9 am, on any given day, with paired relative humidity measurements 16.0% on average lower in the afternoon (95% CI: 15.3, 16.8%).", [["paired relative humidity measurements", "TEST", 105, 142], ["CI", "TEST", 188, 190]]], ["Moderate to high temporal autocorrelation (\u03c1\u22480.70) was observed between 9 am and 3 pm relative humidity data on the same day and at the same time 1 day apart.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsA negative cubic relationship was observed between relative humidity and hazard of infection (Figure 5b).", [["infection", "DISEASE", 198, 207], ["infection", "DISEASE", 327, 336], ["Moderate to high temporal autocorrelation", "PROBLEM", 0, 41], ["infection", "PROBLEM", 198, 207], ["Univariable analysis", "TEST", 212, 232], ["infection", "PROBLEM", 327, 336], ["high", "OBSERVATION_MODIFIER", 12, 16], ["temporal", "OBSERVATION_MODIFIER", 17, 25], ["infection", "OBSERVATION", 198, 207], ["cubic", "OBSERVATION_MODIFIER", 255, 260], ["infection", "OBSERVATION", 327, 336]]], ["Risk of equine influenza infection was highest in dry conditions (<20% relative humidity), decayed rapidly until increasing at intermediate relative humidity (40\u201360%).", [["influenza infection", "DISEASE", 15, 34], ["equine", "ORGANISM", 8, 14], ["equine", "SPECIES", 8, 14], ["equine influenza infection", "PROBLEM", 8, 34], ["equine", "OBSERVATION_MODIFIER", 8, 14], ["influenza", "OBSERVATION", 15, 24], ["highest", "OBSERVATION_MODIFIER", 39, 46]]], ["Once relative humidity was >80% there was effectively no risk.", [["relative humidity", "TEST", 5, 22]]], ["The strongest statistical association was with the 3 pm measurement time-lagged by 5 days, thus, \u2018RH_3PM t\u22125\u2019 was selected as a proxy for relative humidity, irrespective of diurnal variation or time-lag.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsDaily surface air temperature data were available from 21 weather stations (Figure 5c).", [["surface", "ANATOMY", 295, 302], ["infection", "DISEASE", 243, 252], ["infection", "PROBLEM", 243, 252], ["Univariable analysis", "TEST", 257, 277], ["surface air temperature data", "TEST", 295, 323], ["infection", "OBSERVATION", 243, 252]]], ["The mean of the estimated daily maximum and minimum temperatures at the 3153 horse premises was 24.0\u00b0C (95% CI: 22.4, 25.7), and 12.6\u00b0C (95% CI: 9.1, 16.1\u00b0C), respectively.", [["horse", "SPECIES", 77, 82], ["minimum temperatures", "TEST", 44, 64], ["C", "TEST", 101, 102], ["CI", "TEST", 108, 110], ["C", "TEST", 134, 135], ["CI", "TEST", 141, 143], ["\u00b0C", "TEST", 154, 156], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["There was an increasing trend in temperature across the study period as the season changed from spring to summer, and a low level of correlation (\u03c1\u22480.40) between maximum and minimum temperature measured on the same day.", [["the study", "TEST", 52, 61], ["minimum temperature", "TEST", 174, 193], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["trend", "OBSERVATION_MODIFIER", 24, 29], ["temperature", "OBSERVATION_MODIFIER", 33, 44]]], ["Minimum daily temperature data 1\u20134 days apart were moderately to highly correlated (0.61\u2264\u03c1\u22640.75), less correlation was observed between maximum daily temperatures 1 day apart (\u03c1\u22480.53), and a low cross-correlation (0.30<\u03c1<0.50) was observed between minimum daily temperature, rainfall and 9 am relative humidity data for 1\u20135 days.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsA highly nonlinear relationship was observed between infection and maximum daily air temperature (Figure 5d), with risk of infection greatest toward both extremes of the range of observed maximum temperatures (<16\u00b0C and >28\u00b0C).", [["infection", "DISEASE", 369, 378], ["infection", "DISEASE", 468, 477], ["infection", "DISEASE", 538, 547], ["Minimum daily temperature data", "TEST", 0, 30], ["a low cross-correlation", "TEST", 189, 212], ["infection", "PROBLEM", 369, 378], ["Univariable analysis", "TEST", 383, 403], ["infection", "PROBLEM", 468, 477], ["maximum daily air temperature", "PROBLEM", 482, 511], ["infection", "PROBLEM", 538, 547], ["maximum temperatures", "TEST", 603, 623], ["infection", "OBSERVATION", 369, 378], ["infection", "OBSERVATION", 468, 477], ["infection", "OBSERVATION", 538, 547]]], ["Hazard of infection increased linearly as minimum daily temperatures decreased, and the statistical strength of this association was also greatest when a time-lag of 3 days was applied.", [["infection", "DISEASE", 10, 19], ["infection", "PROBLEM", 10, 19], ["infection", "OBSERVATION", 10, 19], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["linearly", "OBSERVATION_MODIFIER", 30, 38], ["decreased", "OBSERVATION_MODIFIER", 69, 78]]], ["Combining daily maximum and minimum measurements into a midpoint daily temperature resulted in weaker associations (data not shown).Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsHourly wind velocity data were available from sixteen weather stations (Figure 2b).", [["infection", "DISEASE", 172, 181], ["a midpoint daily temperature", "TEST", 54, 82], ["infection", "PROBLEM", 172, 181], ["Univariable analysis", "TEST", 186, 206], ["ResultsHourly wind velocity data", "TEST", 211, 243], ["infection", "OBSERVATION", 172, 181]]], ["Wind conditions varied considerably in time with little temporal autocorrelation observed (see correlation matrix in Supporting Information S1).", [["Wind conditions", "PROBLEM", 0, 15], ["little temporal autocorrelation", "PROBLEM", 49, 80]]], ["There was no clearly discernible predominant wind pattern over the study period.", [["no clearly", "UNCERTAINTY", 10, 20], ["discernible", "OBSERVATION_MODIFIER", 21, 32], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["wind pattern", "OBSERVATION", 45, 57]]], ["The median of the maximum daily reported wind speeds estimated for each premises (from all directions) was 26.6 km hour\u22121 (IQR: 22.3, 33.3 km hour\u22121, maximum = 73.3 km hour\u22121).Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsThe univariate relationship between hazard of infection and wind speed, making no directional assumptions (\u2019undirected\u2019), is presented in Figure 6, by time-lag.", [["infection", "DISEASE", 216, 225], ["infection", "DISEASE", 308, 317], ["maximum", "TEST", 150, 157], ["infection", "PROBLEM", 216, 225], ["Univariable analysis", "TEST", 230, 250], ["infection", "PROBLEM", 308, 317], ["infection", "OBSERVATION", 216, 225], ["infection", "OBSERVATION", 308, 317]]], ["Increased hazard of infection was observed on days when the maximum daily wind speed was >30 km hour\u22121.", [["infection", "DISEASE", 20, 29], ["Increased hazard of infection", "PROBLEM", 0, 29], ["infection", "OBSERVATION", 20, 29]]], ["The univariate relationships between hazard of infection and maximum daily wind speed from the direction of the k nearest neighbours are presented in Table 3, and plots of the restricted cubic splines of these relationships are shown in Figure 7 (only for a time-lag of 3 days).", [["infection", "DISEASE", 47, 56], ["infection", "PROBLEM", 47, 56], ["the restricted cubic splines", "TREATMENT", 172, 200], ["infection", "OBSERVATION", 47, 56], ["restricted", "OBSERVATION_MODIFIER", 176, 186], ["cubic splines", "OBSERVATION", 187, 200]]], ["The strongest statistical association between any wind speed covariate and hazard of infection was identified based on \u2018directed\u2019 wind speed from the direction of the three nearest neighbours, time-lagged by 3 days.Meteorological covariates and hazard of infection ::: Univariable analysis ::: ResultsThe following five candidate meteorological variables were consequently selected for multivariable analysis: linear terms for rainfall and minimum daily air temperature, both time-lagged by 3 days, a restricted cubic spline for relative humidity measured at 3 pm time-lagged by 5 days, and splines of maximum daily air temperature and maximum daily wind speed from the direction of the three nearest infected premises, both time-lagged by 3 days.Horse premises attributes and hazard of infection ::: Univariable analysis ::: ResultsHorse premises in the Northwest Sydney cluster were highly skewed in terms of their land area and the number of horses they held at the time of the outbreak.", [["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 255, 264], ["infection", "DISEASE", 787, 796], ["infection", "PROBLEM", 85, 94], ["infection", "PROBLEM", 255, 264], ["Univariable analysis", "TEST", 269, 289], ["multivariable analysis", "TEST", 386, 408], ["a restricted cubic spline", "TREATMENT", 499, 524], ["relative humidity", "TREATMENT", 529, 546], ["infection", "PROBLEM", 787, 796], ["Univariable analysis", "TEST", 801, 821], ["infection", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 255, 264], ["infection", "OBSERVATION", 787, 796], ["skewed", "OBSERVATION_MODIFIER", 892, 898]]], ["The median premises held 2 horses (IQR: 1, 5 horses; maximum: 139 horses) on 5.1 acres (IQR: 4.8, 15.2 acres; maximum: 2 225 acres).", [["IQR", "TEST", 35, 38], ["IQR", "TEST", 88, 91]]], ["These variables were log transformed for all further analyses, with results back-transformed for presentation.", [["all further analyses", "TEST", 41, 61]]], ["Highly non-linear crude relationships were observed between hazard of infection and premises area and horse density (Table 4 and Figure 8a).", [["infection", "DISEASE", 70, 79], ["horse", "ORGANISM_SUBDIVISION", 102, 107], ["horse", "SPECIES", 102, 107], ["Highly non-linear crude relationships", "PROBLEM", 0, 37], ["infection", "PROBLEM", 70, 79], ["horse density", "PROBLEM", 102, 115], ["infection", "OBSERVATION", 70, 79], ["horse density", "OBSERVATION_MODIFIER", 102, 115]]], ["Medium sized (4.8\u201315.2 acres) and medium density premises (1\u20135 acres per horse) were at increased risk of infection, as were horse premises that shared a fence with another horse premises.", [["infection", "DISEASE", 106, 115], ["horse", "ORGANISM_SUBDIVISION", 73, 78], ["horse", "ORGANISM", 173, 178], ["horse", "SPECIES", 73, 78], ["horse", "SPECIES", 125, 130], ["horse", "SPECIES", 173, 178], ["horse", "SPECIES", 125, 130], ["Medium sized (4.8\u201315.2 acres) and medium density premises", "PROBLEM", 0, 57], ["infection", "PROBLEM", 106, 115], ["sized", "OBSERVATION_MODIFIER", 7, 12], ["medium density", "OBSERVATION_MODIFIER", 34, 48], ["infection", "OBSERVATION", 106, 115]]], ["Hazard also increased with the number of horses held on a premises; this trend was well represented by categorisation based on quartiles.Horse premises attributes and hazard of infection ::: Univariable analysis ::: ResultsA trend existed across the study area in terms of premises elevation and surrounding human population density.", [["infection", "DISEASE", 177, 186], ["human", "ORGANISM", 308, 313], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 308, 313], ["infection", "PROBLEM", 177, 186], ["Univariable analysis", "TEST", 191, 211], ["the study area", "TEST", 246, 260], ["surrounding human population density", "PROBLEM", 296, 332], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["infection", "OBSERVATION", 177, 186], ["elevation", "OBSERVATION", 282, 291], ["human", "OBSERVATION_MODIFIER", 308, 313], ["population", "OBSERVATION_MODIFIER", 314, 324], ["density", "OBSERVATION", 325, 332]]], ["Hazard of infection was higher on horses premises located at lower elevations (<45 m) and >2.2 km from main roads (Table 4).", [["infection", "DISEASE", 10, 19], ["infection", "PROBLEM", 10, 19], ["infection", "OBSERVATION", 10, 19], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["lower", "ANATOMY_MODIFIER", 61, 66]]], ["Risk was also higher on horse premises located in peri-urban areas (human population densities between 1\u2013500 people km\u22122) compared to premises located either away from residential areas (human population density within 1 km = 0) or within urban areas (>500 people km\u22122) (Figure 8b).Horse premises attributes and hazard of infection ::: Univariable analysis ::: ResultsPremises area and premises horse density were the only highly correlated pairing (\u03c1 = \u22120.74), amongst the premises attribute variables.", [["infection", "DISEASE", 322, 331], ["horse", "ORGANISM_SUBDIVISION", 24, 29], ["human", "ORGANISM", 68, 73], ["human", "ORGANISM", 187, 192], ["horse", "ORGANISM_SUBDIVISION", 395, 400], ["horse", "SPECIES", 24, 29], ["human", "SPECIES", 68, 73], ["people", "SPECIES", 109, 115], ["human", "SPECIES", 187, 192], ["people", "SPECIES", 257, 263], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 187, 192], ["infection", "PROBLEM", 322, 331], ["Univariable analysis", "TEST", 336, 356], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["infection", "OBSERVATION", 322, 331], ["horse density", "OBSERVATION", 395, 408]]], ["Of these two covariates, premises area was the more strongly associated with the outcome.", [["two", "OBSERVATION_MODIFIER", 9, 12], ["covariates", "OBSERVATION", 13, 23]]], ["The following premises attribute variables were therefore included in multivariable analysis: splines of premises area and local human population density, number of horses, length of shared fence with other horse premises, premises elevation and distance to the nearest main road.", [["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["horse", "SPECIES", 207, 212], ["human", "SPECIES", 129, 134], ["multivariable analysis", "TEST", 70, 92], ["local", "OBSERVATION_MODIFIER", 123, 128], ["human", "OBSERVATION_MODIFIER", 129, 134], ["population", "OBSERVATION_MODIFIER", 135, 145], ["density", "OBSERVATION", 146, 153]]], ["Vaccination status was retained as it was considered an a priori confounder.Model goodness-of-fit and residual analysis ::: Multivariable analysis ::: ResultsThe final model accounted for a quarter of the variability in the data (Schemper and Stare pseudo-R2 = 25.8%).", [["Multivariable analysis", "TEST", 124, 146], ["the data", "TEST", 220, 228], ["Schemper", "TEST", 230, 238], ["Stare pseudo-R2", "TEST", 243, 258]]], ["No issues were identified based on inspection of martingale and deviance residuals, both overall, and when plotted against each variable included in the final model.", [["issues", "PROBLEM", 3, 9], ["inspection of martingale", "TEST", 35, 59], ["deviance residuals", "PROBLEM", 64, 82]]], ["Residual spatial structure was not evident in the empirical semivariogram of the deviance residuals, suggesting that spatial correlation was not unduly influencing our effect estimates (or their associated standard errors).", [["Residual spatial structure", "PROBLEM", 0, 26], ["the empirical semivariogram", "TEST", 46, 73], ["spatial structure", "OBSERVATION", 9, 26], ["not evident", "UNCERTAINTY", 31, 42]]], ["Influence statistics identified only one important outlying premises, infected 36 days after the vaccination of the 2 horses on the property.", [["the vaccination", "TREATMENT", 93, 108]]], ["These horses did not receive a second vaccination, whilst up to three doses may be required to attain protective immunity.Relative humidity and influenza spread ::: DiscussionOur analysis shows that influenza spread in this cluster was highly dependent on relative humidity.", [["influenza", "DISEASE", 144, 153], ["influenza", "DISEASE", 199, 208], ["horses", "ORGANISM", 6, 12], ["a second vaccination", "TREATMENT", 29, 49], ["influenza spread", "PROBLEM", 144, 160], ["DiscussionOur analysis", "TEST", 165, 187], ["influenza spread", "PROBLEM", 199, 215], ["influenza", "OBSERVATION", 199, 208]]], ["Recent reviews [4], [5], [61] present contradictory results from laboratory trials of influenza A virus survival at intermediate humidities [62], [63], and disagreement concerning the importance of aerosol transmission.", [["influenza A virus", "ORGANISM", 86, 103], ["influenza A virus", "SPECIES", 86, 103], ["influenza", "PROBLEM", 86, 95], ["aerosol transmission", "TREATMENT", 198, 218]]], ["The negative cubic relationship that we observed between hazard of infection and relative humidity provides field validation for some of these laboratory trials.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["field validation", "TEST", 108, 124], ["negative cubic", "OBSERVATION_MODIFIER", 4, 18], ["infection", "OBSERVATION", 67, 76]]], ["The curve in Figure 5b across the whole range of relative humidities observed under natural conditions, exactly complements the results presented by Hemmes et. al. [62] of inactivation of aerosolised influenza A virus under controlled conditions.", [["aerosolised", "ORGANISM", 188, 199], ["influenza A virus", "ORGANISM", 200, 217], ["influenza A virus", "SPECIES", 200, 217], ["influenza A virus", "SPECIES", 200, 217], ["aerosolised influenza A virus", "PROBLEM", 188, 217], ["influenza", "OBSERVATION", 200, 209]]], ["Our findings also support the theory presented by Lowen et al. [6] that the relationship between influenza transmission and relative humidity is mediated by both virion and aerosol droplet nuclei stability.", [["nuclei", "ANATOMY", 189, 195], ["influenza", "DISEASE", 97, 106], ["influenza transmission", "TREATMENT", 97, 119], ["relative humidity", "TREATMENT", 124, 141], ["aerosol droplet nuclei stability", "TREATMENT", 173, 205], ["aerosol droplet", "OBSERVATION", 173, 188], ["nuclei stability", "OBSERVATION", 189, 205]]], ["In cool dry conditions, droplets are desiccated and remain small, which may stabilise influenza aerosols and facilitate longer range transmission, whereas at high relative humidity, the droplets absorb water and settle [61].", [["influenza", "DISEASE", 86, 95], ["droplets", "TREATMENT", 24, 32], ["influenza aerosols", "TREATMENT", 86, 104], ["the droplets absorb water", "TREATMENT", 182, 207], ["small", "OBSERVATION_MODIFIER", 59, 64]]], ["The small rise in hazard of infection at intermediate relative humidities (40\u201360%) is perhaps due to a summation of two effects: as relative humidity increases within this range so too does viral survival [63], whilst droplet nuclei settle more readily.", [["droplet nuclei", "ANATOMY", 218, 232], ["infection", "DISEASE", 28, 37], ["The small rise", "PROBLEM", 0, 14], ["infection", "PROBLEM", 28, 37], ["relative humidity increases", "PROBLEM", 132, 159], ["small", "OBSERVATION_MODIFIER", 4, 9], ["rise", "OBSERVATION_MODIFIER", 10, 14], ["infection", "OBSERVATION", 28, 37]]], ["This rise was most pronounced in the spline of relative humidity time-lagged by 3 days, yet the 5 day time-lagged variable was the predictor in the group with the strongest statistical association with hazard of infection.", [["infection", "DISEASE", 212, 221], ["infection", "PROBLEM", 212, 221], ["most pronounced", "OBSERVATION_MODIFIER", 14, 29], ["humidity", "OBSERVATION_MODIFIER", 56, 64], ["infection", "OBSERVATION", 212, 221]]], ["Amongst all other groupings of autocorrelated meteorological variables, a time-lag of 3 days was the predictor with the strongest statistical association with hazard of infection, corresponding closely with the typical 1\u20133 day incubation period of equine influenza.Relative humidity and influenza spread ::: DiscussionRecent research has suggested that in certain situations absolute humidity may better represent the relationship between air humidity and influenza A virus survival [64] and aerosol transmission [65].", [["infection", "DISEASE", 169, 178], ["influenza", "DISEASE", 255, 264], ["influenza", "DISEASE", 287, 296], ["influenza A virus", "ORGANISM", 456, 473], ["influenza A virus", "SPECIES", 456, 473], ["infection", "PROBLEM", 169, 178], ["equine influenza", "PROBLEM", 248, 264], ["influenza spread", "PROBLEM", 287, 303], ["air humidity", "TREATMENT", 439, 451], ["influenza A virus survival", "TREATMENT", 456, 482], ["infection", "OBSERVATION", 169, 178], ["equine influenza", "OBSERVATION", 248, 264]]], ["However, the dependency is perhaps more complex [8], because the amount of water vapour that air can hold increases with temperature.", [["water", "SIMPLE_CHEMICAL", 75, 80], ["more complex", "OBSERVATION_MODIFIER", 35, 47], ["amount", "OBSERVATION_MODIFIER", 65, 71], ["water vapour", "OBSERVATION", 75, 87]]], ["Absolute and relative humidity are related metrics for the amount of water vapour in moist air.", [["water", "SIMPLE_CHEMICAL", 69, 74], ["humidity", "OBSERVATION_MODIFIER", 22, 30], ["moist air", "OBSERVATION", 85, 94]]], ["Absolute humidity is the mass of water vapour per cubic meter of total moist air, whereas, relative humidity is absolute humidity expressed as a percentage of the amount of water vapour needed for saturation at a specific temperature.", [["water", "SIMPLE_CHEMICAL", 173, 178], ["Absolute humidity", "TREATMENT", 0, 17], ["the mass", "PROBLEM", 21, 29], ["water vapour", "TREATMENT", 173, 185], ["mass", "OBSERVATION", 25, 29], ["total", "OBSERVATION_MODIFIER", 65, 70], ["moist air", "OBSERVATION", 71, 80], ["absolute humidity", "OBSERVATION", 112, 129]]], ["We used relative humidity rather than absolute humidity because: the relative humidity data were more complete over the study period, corresponding 9 am and 3 pm air temperature data were not available for all data points so back-transformation of relative humidity measurements into absolute humidity would have resulted in less complete data, and we wanted to ensure we could directly compare our results with the original research describing the dependency between relative humidity, air temperature and influenza virus transmission and survival [6], [62].Air temperature and influenza spread ::: DiscussionThe shape of the highly nonlinear relationship that we observed between hazard of equine influenza infection and maximum daily air temperature suggests two mechanisms of influenza transmission.", [["influenza infection", "DISEASE", 699, 718], ["influenza transmission", "DISEASE", 780, 802], ["equine", "ORGANISM", 692, 698], ["influenza virus", "SPECIES", 507, 522], ["relative humidity", "TREATMENT", 8, 25], ["absolute humidity", "TREATMENT", 38, 55], ["3 pm air temperature data", "TEST", 157, 182], ["air temperature", "PROBLEM", 487, 502], ["influenza virus transmission", "TREATMENT", 507, 535], ["Air temperature", "TEST", 559, 574], ["equine influenza infection", "PROBLEM", 692, 718], ["maximum daily air temperature", "PROBLEM", 723, 752], ["influenza transmission", "PROBLEM", 780, 802], ["influenza", "OBSERVATION", 579, 588], ["shape", "OBSERVATION_MODIFIER", 614, 619], ["highly nonlinear", "OBSERVATION_MODIFIER", 627, 643], ["equine influenza infection", "OBSERVATION", 692, 718], ["influenza", "OBSERVATION", 780, 789]]], ["Hazard was lowest on days when the maximum air temperature was between 20\u201325\u00b0C, and greatly increased on days with lower and higher maximum temperatures.", [["the maximum air temperature", "TEST", 31, 58], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["Aerosol transmission of influenza A viruses has been shown to be enhanced in cooler conditions [6], and on days when maximum daily temperature was <20\u00b0C the air temperature would be expected to remain in the optimal range for aerosol transmission equine influenza for longer.", [["influenza A viruses", "DISEASE", 24, 43], ["influenza", "DISEASE", 254, 263], ["influenza A viruses", "ORGANISM", 24, 43], ["equine", "ORGANISM", 247, 253], ["influenza A viruses", "SPECIES", 24, 43], ["influenza A viruses", "SPECIES", 24, 43], ["influenza A viruses", "PROBLEM", 24, 43], ["maximum daily temperature", "TEST", 117, 142], ["the air temperature", "PROBLEM", 153, 172], ["aerosol transmission equine influenza", "TREATMENT", 226, 263]]], ["The marked increase in hazard of infection when maximum temperature was >25\u00b0C is also consistent with recent research.", [["infection", "DISEASE", 33, 42], ["C", "GENE_OR_GENE_PRODUCT", 76, 77], ["infection", "PROBLEM", 33, 42], ["maximum temperature", "TEST", 48, 67], ["marked", "OBSERVATION_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 33, 42], ["consistent with", "UNCERTAINTY", 86, 101]]], ["Whilst high temperatures block aerosol transmission of influenza A viruses, the success of animal-to-animal contact transmission increases at high temperatures [10] perhaps explaining the spread of influenza in warm tropical environments.Wind velocity and influenza spread ::: DiscussionThere is some consensus in the literature that airborne transmission of influenza is at least possible; however, there is strong disagreement about its importance [5].", [["influenza A viruses", "DISEASE", 55, 74], ["influenza", "DISEASE", 198, 207], ["influenza", "DISEASE", 359, 368], ["influenza A viruses", "ORGANISM", 55, 74], ["influenza A viruses", "SPECIES", 55, 74], ["high temperatures block", "PROBLEM", 7, 30], ["influenza A viruses", "PROBLEM", 55, 74], ["high temperatures", "PROBLEM", 142, 159], ["influenza", "PROBLEM", 198, 207], ["Wind velocity", "TEST", 238, 251], ["influenza", "PROBLEM", 359, 368], ["influenza", "OBSERVATION", 198, 207], ["velocity", "OBSERVATION_MODIFIER", 243, 251], ["influenza", "OBSERVATION", 256, 265]]], ["In the cluster investigated, we observed an association between hazard of infection and increasing wind speed from the direction of nearby potential sources of equine influenza infection.", [["infection", "DISEASE", 74, 83], ["influenza infection", "DISEASE", 167, 186], ["equine influenza", "ORGANISM", 160, 176], ["infection", "PROBLEM", 74, 83], ["increasing wind speed", "PROBLEM", 88, 109], ["equine influenza infection", "PROBLEM", 160, 186], ["infection", "OBSERVATION", 74, 83], ["equine influenza infection", "OBSERVATION", 160, 186]]], ["A similar association was found when wind speed covariates were generated without making any directional assumptions, in effect testing the general hypothesis that hazard of infection was increased on days with increased wind speed (from any direction).", [["infection", "DISEASE", 174, 183], ["infection", "PROBLEM", 174, 183], ["increased wind speed", "PROBLEM", 211, 231], ["infection", "OBSERVATION", 174, 183]]], ["Irrespective of our approach, wind speeds >30 km hour\u22121, lagged by 3 days, were consistently associated with increased hazard of infection.Wind velocity and influenza spread ::: DiscussionIn developing proxy covariates for the directed formulation of the daily wind speed covariates (\u2018WIND_SPDdir(k)\u2019) certain assumptions were required.", [["infection", "DISEASE", 129, 138], ["increased hazard of infection", "PROBLEM", 109, 138], ["Wind velocity", "TEST", 139, 152], ["the directed formulation", "TREATMENT", 223, 247], ["infection", "OBSERVATION", 129, 138], ["velocity", "OBSERVATION_MODIFIER", 144, 152], ["influenza", "OBSERVATION", 157, 166]]], ["Wind data was only included if it was within a 45\u00b0 arc of the nearest k infected premises to each uninfected premises on each observation day.", [["Wind data", "TEST", 0, 9]]], ["The nearest k infected premises were assumed to be the only windborne source of equine influenza virus for a susceptible premises, and we assumed the duration of infectivity at the premises level was 14 days for all premises.", [["influenza virus", "DISEASE", 87, 102], ["equine influenza virus", "ORGANISM", 80, 102], ["equine influenza virus", "SPECIES", 80, 102], ["equine influenza virus", "SPECIES", 80, 102], ["The nearest k infected premises", "PROBLEM", 0, 31], ["equine influenza virus", "PROBLEM", 80, 102], ["infectivity", "PROBLEM", 162, 173]]], ["The statistical strength of association between hazard of infection and wind speed increased as more nearest neighbours were cumulatively incorporated into the method of wind covariate generation, suggesting that the nearest neighbour was not always the only source of windborne infection.", [["infection", "DISEASE", 58, 67], ["infection", "DISEASE", 279, 288], ["infection", "PROBLEM", 58, 67], ["windborne infection", "PROBLEM", 269, 288], ["infection", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 279, 288]]], ["We can state that incorporating three nearest infected neighbours is better than only one or two, that our findings are relatively robust to the assumptions that we made whilst generating directed wind speed covariates, and that the detected association between hazard of infection and wind speed appears related to the direction of proximate infected premises.Wind velocity and influenza spread ::: DiscussionThe associations that we have detected between increasing wind speed and hazard of infection need to be interpreted in the context of our study design.", [["infection", "DISEASE", 272, 281], ["infection", "DISEASE", 493, 502], ["infection", "PROBLEM", 272, 281], ["Wind velocity", "TEST", 361, 374], ["infection", "PROBLEM", 493, 502], ["our study", "TEST", 544, 553], ["infection", "OBSERVATION", 272, 281], ["infected", "OBSERVATION", 343, 351], ["velocity", "OBSERVATION_MODIFIER", 366, 374], ["influenza", "OBSERVATION", 379, 388], ["infection", "OBSERVATION", 493, 502]]], ["There is potential for ecological fallacy in aggregated data analyses such as this, in which the unit of interest is not an individual animal but a group.", [["potential for", "UNCERTAINTY", 9, 22], ["ecological", "OBSERVATION_MODIFIER", 23, 33], ["fallacy", "OBSERVATION", 34, 41]]], ["Furthermore, it is not possible in such observational epidemiological analyses to definitively identify windborne spread from any other transmission route (direct contact, cough droplet and spread on fomites).", [["cough", "DISEASE", 172, 177], ["windborne spread", "PROBLEM", 104, 120], ["cough droplet", "PROBLEM", 172, 185], ["not possible", "UNCERTAINTY", 19, 31]]], ["Nonetheless, the detected association, presumably representing windborne spread of equine influenza, is biologically plausible, and its increasing strength with increasing wind speed from the direction of nearby infected premises is difficult to explain by spread through other means alone.Wind velocity and influenza spread ::: DiscussionAt wind speeds of >30 km hour\u22121 an aerosol of influenza droplet nuclei would only need to be stable for minutes to be able to infect horses on nearby premises.", [["droplet nuclei", "ANATOMY", 395, 409], ["equine influenza", "DISEASE", 83, 99], ["equine influenza", "ORGANISM", 83, 99], ["equine influenza", "SPECIES", 83, 99], ["equine influenza", "PROBLEM", 83, 99], ["its increasing strength", "PROBLEM", 132, 155], ["Wind velocity", "TEST", 290, 303], ["influenza droplet nuclei", "TREATMENT", 385, 409], ["presumably representing", "UNCERTAINTY", 39, 62], ["windborne", "OBSERVATION_MODIFIER", 63, 72], ["spread", "OBSERVATION_MODIFIER", 73, 79], ["equine influenza", "OBSERVATION", 83, 99], ["increasing", "OBSERVATION_MODIFIER", 136, 146], ["strength", "OBSERVATION_MODIFIER", 147, 155], ["infected", "OBSERVATION", 212, 220], ["velocity", "OBSERVATION_MODIFIER", 295, 303], ["influenza", "OBSERVATION", 308, 317]]], ["Equine influenza viruses have been shown to survive for periods of hours to days in soil and water, even in direct sunlight [12], and infected horses shed large amounts of virus (>103 EID50/ml, 50% egg infective dose per ml of swab extract) throughout the roughly 7 days that they are infectious [66].", [["extract", "ANATOMY", 232, 239], ["influenza viruses", "DISEASE", 7, 24], ["Equine influenza viruses", "ORGANISM", 0, 24], ["horses", "ORGANISM", 143, 149], ["Equine influenza viruses", "SPECIES", 0, 24], ["Equine influenza viruses", "SPECIES", 0, 24], ["Equine influenza viruses", "PROBLEM", 0, 24], ["large amounts of virus", "PROBLEM", 155, 177], ["swab extract", "TREATMENT", 227, 239], ["large", "OBSERVATION_MODIFIER", 155, 160], ["infectious", "OBSERVATION", 285, 295]]], ["Infection is more reliably achieved by inhalation of aerosolised virus that intranasal inoculation [26], with a minimum infective dose of 102 EID50/ml.", [["Infection", "PROBLEM", 0, 9], ["aerosolised virus", "PROBLEM", 53, 70], ["intranasal inoculation", "PROBLEM", 76, 98], ["a minimum infective dose", "TREATMENT", 110, 134]]], ["We therefore consider it plausible that infected horses on one premises could cough or otherwise produce a sufficient quantity of aerosolised equine influenza virus, which after travelling wind-assisted could constitute an infectious dose for a horse on a nearby premises (whether inhaled immediately or after surviving a short period on soil or in drinking water).Wind velocity and influenza spread ::: DiscussionA recent time-series analysis investigated correlation between the frequency of paediatric influenza A hospital admissions and several meteorological variables including wind velocity [15].", [["cough", "DISEASE", 78, 83], ["influenza", "DISEASE", 149, 158], ["influenza", "DISEASE", 505, 514], ["horses", "ORGANISM", 49, 55], ["equine influenza virus", "ORGANISM", 142, 164], ["horse", "ORGANISM", 245, 250], ["equine influenza virus", "SPECIES", 142, 164], ["horse", "SPECIES", 245, 250], ["equine influenza virus", "SPECIES", 142, 164], ["horse", "SPECIES", 245, 250], ["cough", "PROBLEM", 78, 83], ["aerosolised equine influenza virus", "PROBLEM", 130, 164], ["Wind velocity", "TEST", 365, 378], ["series analysis", "TEST", 428, 443], ["wind velocity", "TEST", 584, 597], ["infected", "OBSERVATION", 40, 48], ["influenza virus", "OBSERVATION", 149, 164], ["infectious", "OBSERVATION", 223, 233], ["velocity", "OBSERVATION_MODIFIER", 370, 378], ["influenza", "OBSERVATION", 383, 392]]], ["A statistically significant univariable association was observed between increasing wind velocity and increased influenza A hospital admissions, in data collected from one hospital and one weather station [15].", [["increasing wind velocity", "PROBLEM", 73, 97], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["influenza", "OBSERVATION", 112, 121]]], ["However, in multivariable analyses no association was observed between wind velocity and influenza A hospitalisations, perhaps due to the level of spatial and temporal data aggregation (across the hospital catchment and into 14-day time intervals).", [["influenza A", "SPECIES", 89, 100], ["multivariable analyses", "TEST", 12, 34], ["wind velocity", "TEST", 71, 84], ["influenza", "PROBLEM", 89, 98], ["spatial and temporal data aggregation", "PROBLEM", 147, 184]]], ["Aggregated analyses of the association of meteorological factors with the spread of the severe acute respiratory syndrome (SARS) in Beijing [16], and hand, foot and mouth disease (HFMD) of humans in Hong Kong [67], have found statistically significant associations with increasing wind velocity, albeit at much lower wind velocities.", [["hand", "ANATOMY", 150, 154], ["foot", "ANATOMY", 156, 160], ["mouth", "ANATOMY", 165, 170], ["acute respiratory syndrome", "DISEASE", 95, 121], ["SARS", "DISEASE", 123, 127], ["hand, foot and mouth disease", "DISEASE", 150, 178], ["HFMD", "DISEASE", 180, 184], ["hand", "ORGANISM_SUBDIVISION", 150, 154], ["foot", "ORGANISM_SUBDIVISION", 156, 160], ["mouth", "ORGANISM_SUBDIVISION", 165, 170], ["humans", "ORGANISM", 189, 195], ["meteorological factors", "PROTEIN", 42, 64], ["humans", "SPECIES", 189, 195], ["humans", "SPECIES", 189, 195], ["meteorological factors", "PROBLEM", 42, 64], ["the severe acute respiratory syndrome", "PROBLEM", 84, 121], ["hand, foot and mouth disease", "PROBLEM", 150, 178], ["increasing wind velocity", "PROBLEM", 270, 294], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121], ["hand", "ANATOMY", 150, 154], ["foot", "ANATOMY", 156, 160], ["mouth", "ANATOMY", 165, 170], ["disease", "OBSERVATION", 171, 178], ["increasing", "OBSERVATION_MODIFIER", 270, 280], ["wind velocity", "OBSERVATION", 281, 294], ["velocities", "OBSERVATION_MODIFIER", 322, 332]]], ["Atmospheric dispersal modelling of the picornavirus that causes foot and mouth disease (FMD) in cloven-hoofed ungulates has consistently found that the virus is likely to be dispersed even in calm conditions [17], [68], [69].", [["foot", "ANATOMY", 64, 68], ["mouth", "ANATOMY", 73, 78], ["picornavirus", "DISEASE", 39, 51], ["foot and mouth disease", "DISEASE", 64, 86], ["FMD", "DISEASE", 88, 91], ["picornavirus", "ORGANISM", 39, 51], ["foot", "ORGANISM_SUBDIVISION", 64, 68], ["mouth", "ORGAN", 73, 78], ["FMD", "SPECIES", 88, 91], ["the picornavirus", "PROBLEM", 35, 51], ["foot and mouth disease", "PROBLEM", 64, 86], ["the virus", "PROBLEM", 148, 157], ["picornavirus", "OBSERVATION", 39, 51], ["foot", "ANATOMY", 64, 68], ["mouth", "ANATOMY", 73, 78], ["disease", "OBSERVATION", 79, 86], ["virus", "OBSERVATION", 152, 157], ["likely to be", "UNCERTAINTY", 161, 173]]], ["The dependency of influenza A virus survival on relative humidity [6], [62] is completely different to that of poliovirus [62], HFMD [70] and FMD virus [68] (all much smaller RNA viruses of the family Picornaviridae).", [["HFMD", "DISEASE", 128, 132], ["influenza A virus", "ORGANISM", 18, 35], ["poliovirus [62", "ORGANISM", 111, 125], ["FMD virus", "ORGANISM", 142, 151], ["FMD virus", "SPECIES", 142, 151], ["influenza A virus", "SPECIES", 18, 35], ["FMD virus", "SPECIES", 142, 151], ["influenza", "PROBLEM", 18, 27], ["poliovirus", "TEST", 111, 121], ["HFMD", "PROBLEM", 128, 132], ["FMD virus", "PROBLEM", 142, 151], ["influenza", "OBSERVATION", 18, 27]]], ["Therefore, it is perhaps not unexpected that the survival of aerosols of influenza A viruses and picornaviruses could depend on different wind conditions.Wind velocity and influenza spread ::: DiscussionWhen interpolating meteorological covariates and estimating nearest neighbour distances we used centroids to reduce the complexity of the analytical methods.", [["influenza A viruses", "ORGANISM", 73, 92], ["picornaviruses", "ORGANISM", 97, 111], ["influenza A viruses", "SPECIES", 73, 92], ["influenza A viruses", "PROBLEM", 73, 92], ["picornaviruses", "PROBLEM", 97, 111], ["Wind velocity", "TEST", 154, 167], ["centroids", "TREATMENT", 299, 308], ["perhaps not", "UNCERTAINTY", 17, 28], ["velocity", "OBSERVATION_MODIFIER", 159, 167], ["influenza", "OBSERVATION", 172, 181]]], ["For >99% of the premises in our dataset we estimate that the maximum distance between the centroid and premises boundary was <500 m.", [["centroid", "ANATOMY_MODIFIER", 90, 98]]], ["When the largest 1% of premises (in area) were excluded from the final model, the only regression coefficients to change by >20% were the two highest order spline components for relative humidity and maximum daily temperature, and these changes were not discernible in post-adjustment plots.", [["relative humidity", "TREATMENT", 178, 195], ["maximum daily temperature", "TEST", 200, 225], ["largest", "OBSERVATION_MODIFIER", 9, 16]]], ["We therefore consider our findings to be insensitive to measurement bias introduced by representing premises by their centroids.Wind velocity and influenza spread ::: DiscussionEnvironmental variables capable of influencing airborne disease spread (such as local horse density, tree density or terrain undulation) vary considerably in the different regions and clusters of premises infected during the 2007 equine influenza outbreak in Australia.", [["influenza", "DISEASE", 414, 423], ["horse", "ORGANISM_SUBDIVISION", 263, 268], ["horse", "SPECIES", 263, 268], ["Wind velocity", "TEST", 128, 141], ["influencing airborne disease spread", "PROBLEM", 212, 247], ["local horse density", "PROBLEM", 257, 276], ["tree density or terrain undulation)", "PROBLEM", 278, 313], ["velocity", "OBSERVATION_MODIFIER", 133, 141], ["influenza", "OBSERVATION", 146, 155], ["airborne disease", "OBSERVATION", 224, 240], ["tree", "OBSERVATION_MODIFIER", 278, 282], ["density", "OBSERVATION", 283, 290], ["terrain undulation", "OBSERVATION_MODIFIER", 294, 312], ["clusters", "OBSERVATION_MODIFIER", 361, 369], ["infected", "OBSERVATION_MODIFIER", 382, 390]]], ["A potential limitation of this analysis was that we focussed on only one cluster (the largest and most dense cluster in terms of population at risk) from a very large outbreak.", [["this analysis", "TEST", 26, 39], ["a very large outbreak", "PROBLEM", 154, 175], ["largest", "OBSERVATION_MODIFIER", 86, 93], ["most dense", "OBSERVATION_MODIFIER", 98, 108], ["cluster", "OBSERVATION_MODIFIER", 109, 116], ["very", "OBSERVATION_MODIFIER", 156, 160], ["large", "OBSERVATION_MODIFIER", 161, 166], ["outbreak", "OBSERVATION", 167, 175]]], ["There were two considered reasons for our detailed focus: counting process survival analysis involves analysing a very large dataset (204,909 observations on 3153 premises); and owing to a wide variance in local environmental characteristics and potential for differences in disease transmission dynamics, mixing clusters in the same analysis might dilute any meaningful results.", [["survival analysis", "TEST", 75, 92], ["a wide variance", "PROBLEM", 187, 202], ["differences in disease transmission dynamics", "PROBLEM", 260, 304]]], ["Before generalising our findings to the whole outbreak, or indeed other outbreaks, follow-up research to assess the importance of the risk factors investigated in broadly dissimilar environments, is therefore required.Wind velocity and influenza spread ::: DiscussionA classical geostatistical approach [49] (kriging based on a least squares fit of an empirical variogram) was applied to interpolate premises-level meteorological covariates from weather station data.", [["the risk factors", "PROBLEM", 130, 146], ["Wind velocity", "TEST", 218, 231], ["an empirical variogram)", "TREATMENT", 349, 372], ["velocity", "OBSERVATION_MODIFIER", 223, 231], ["influenza", "OBSERVATION", 236, 245]]], ["A more sophisticated model-based geostatistical approach [71] (maximum-likelihood based model fitting that does not rely on an empirical variogram) may be more appropriate.", [["an empirical variogram", "TEST", 124, 146]]], ["However, we considered that the numerous fine adjustments required to undertake a model-based approach to be impractical for fitting the 5616 separate models (117 days\u00d724 hours\u00d72 wind component vectors) that were required to produce hourly wind vector estimates at each of the 3153 individual premises locations across the entire study period.", [["a model-based approach", "TREATMENT", 80, 102]]], ["It was also not possible to assess the assumptions of stationarity or isotropy for each of the thousands of semivariogram models required to generate all of the daily meteorological covariates for each premises.", [["semivariogram models", "TREATMENT", 108, 128]]], ["Our interpolation approach could have been refined by incorporating elevation (regression kriging), a spatial trend or even anisotropy into the method.", [["Our interpolation approach", "TREATMENT", 0, 26], ["regression kriging", "TEST", 79, 97], ["elevation", "OBSERVATION_MODIFIER", 68, 77]]], ["The study extent covered the Northern half of the Sydney basin, which is relatively flat, and bounded by a plateau of national parks where horses are prohibited.", [["horses", "ORGANISM", 139, 145], ["The study", "TEST", 0, 9], ["relatively", "OBSERVATION_MODIFIER", 73, 83], ["flat", "OBSERVATION_MODIFIER", 84, 88], ["plateau", "OBSERVATION_MODIFIER", 107, 114]]], ["These refinements would be recommended when conducting further similar research of clusters located in more varied terrain.Wind velocity and influenza spread ::: DiscussionIn the cluster of infection investigated, disease did not appear to spread predominantly in any single direction.", [["infection", "DISEASE", 190, 199], ["Wind velocity", "TEST", 123, 136], ["infection", "PROBLEM", 190, 199], ["disease", "PROBLEM", 214, 221], ["more varied", "OBSERVATION_MODIFIER", 103, 114], ["velocity", "OBSERVATION_MODIFIER", 128, 136], ["influenza", "OBSERVATION", 141, 150], ["infection", "OBSERVATION", 190, 199]]], ["We purposefully focussed on this cluster rather than other large clusters in which a single global direction of spread has been noted [13], with the intention of estimating the typical contribution of wind to disease spread rather than circumstantially associating prevailing wind with the global direction of disease spread.", [["disease spread", "PROBLEM", 209, 223], ["disease spread", "PROBLEM", 310, 324], ["large", "OBSERVATION_MODIFIER", 59, 64], ["clusters", "OBSERVATION", 65, 73], ["disease", "OBSERVATION", 310, 317]]], ["In any cluster in which an overall direction of spread is detected, an important further research question remains: What proportion of this anisotropic spread is directly attributable to windborne disease spread?", [["this anisotropic spread", "PROBLEM", 135, 158], ["windborne disease spread", "PROBLEM", 187, 211], ["cluster", "OBSERVATION_MODIFIER", 7, 14], ["spread", "OBSERVATION", 48, 54], ["anisotropic spread", "OBSERVATION", 140, 158]]], ["Our methods provide a means to answer this research question, and to retrospectively investigate the contribution of windborne aerosol spread to local disease spread during outbreaks such as the foot-and-mouth disease outbreak in the United Kingdom in 2001.Wind velocity and influenza spread ::: DiscussionBy restricting this analysis to a study period after the horse movement ban was put in place, we focussed this study on factors influencing the local spread of equine influenza.", [["foot-and-mouth disease", "DISEASE", 195, 217], ["influenza", "DISEASE", 473, 482], ["horse", "ORGANISM", 363, 368], ["equine", "ORGANISM", 466, 472], ["foot-and-mouth", "SPECIES", 195, 209], ["windborne aerosol", "TREATMENT", 117, 134], ["local disease spread", "PROBLEM", 145, 165], ["mouth disease outbreak", "PROBLEM", 204, 226], ["Wind velocity", "TEST", 257, 270], ["this study", "TEST", 412, 422], ["equine influenza", "PROBLEM", 466, 482], ["foot", "ANATOMY", 195, 199], ["mouth", "ANATOMY", 204, 209], ["disease", "OBSERVATION", 210, 217], ["velocity", "OBSERVATION_MODIFIER", 262, 270], ["influenza", "OBSERVATION", 275, 284], ["equine influenza", "OBSERVATION", 466, 482]]], ["We also adjusted for a number of relevant confounders of the meteorological associations we aimed to estimate: vaccination status of horses on the premises, premises size (in terms of area and number of horses), whether premises were adjacent to another premises holding horses, and local human population density.", [["human", "ORGANISM", 289, 294], ["human", "SPECIES", 289, 294], ["human", "SPECIES", 289, 294], ["size", "OBSERVATION_MODIFIER", 166, 170], ["population", "OBSERVATION_MODIFIER", 295, 305], ["density", "OBSERVATION", 306, 313]]], ["A small misclassification bias is known to be present in the equine influenza dataset, due to under-reporting of infected premises by owners either attempting to avoid movement restrictions or who failed to detect infection [72].", [["influenza", "DISEASE", 68, 77], ["infection", "DISEASE", 214, 223], ["A small misclassification bias", "PROBLEM", 0, 30], ["the equine influenza dataset", "PROBLEM", 57, 85], ["infection", "PROBLEM", 214, 223], ["small", "OBSERVATION_MODIFIER", 2, 7], ["misclassification bias", "OBSERVATION", 8, 30], ["known to be", "UNCERTAINTY", 34, 45], ["infected", "OBSERVATION", 113, 121]]], ["A previous analysis found <1% under-reporting occurred in this region, suggesting that <13 infected premises were misclassified as uninfected [72]; we considered this bias negligible.Wind velocity and influenza spread ::: DiscussionIn conclusion, by combining influenza outbreak and concurrent meteorological data, we have shown how relative humidity, air temperature and wind velocity combined to influence the spread of an actual influenza outbreak.", [["influenza", "DISEASE", 432, 441], ["A previous analysis", "TEST", 0, 19], ["this bias negligible", "PROBLEM", 162, 182], ["Wind velocity", "TEST", 183, 196], ["combining influenza outbreak", "PROBLEM", 250, 278], ["air temperature", "TEST", 352, 367], ["wind velocity", "TEST", 372, 385], ["an actual influenza outbreak", "PROBLEM", 422, 450], ["velocity", "OBSERVATION_MODIFIER", 188, 196], ["influenza", "OBSERVATION", 201, 210]]], ["Hazard of equine influenza infection was higher when relative humidity was <60% and lowest on days when daily maximum air temperature was 20\u201325\u00b0C. Wind speeds >30 km hour\u22121 from the direction of nearby infected premises were associated with increased hazard of infection.", [["influenza infection", "DISEASE", 17, 36], ["infection", "DISEASE", 261, 270], ["equine", "ORGANISM", 10, 16], ["equine", "SPECIES", 10, 16], ["equine influenza infection", "PROBLEM", 10, 36], ["relative humidity", "TEST", 53, 70], ["daily maximum air temperature", "TEST", 104, 133], ["increased hazard of infection", "PROBLEM", 241, 270], ["equine influenza infection", "OBSERVATION", 10, 36], ["higher", "OBSERVATION_MODIFIER", 41, 47], ["infected", "OBSERVATION", 202, 210], ["increased", "OBSERVATION_MODIFIER", 241, 250], ["infection", "OBSERVATION", 261, 270]]], ["Our analysis supports, and extends, the findings of studies into influenza A transmission conducted under controlled conditions.", [["influenza A transmission", "DISEASE", 65, 89], ["influenza A", "SPECIES", 65, 76], ["Our analysis", "TEST", 0, 12], ["studies", "TEST", 52, 59], ["influenza", "PROBLEM", 65, 74]]], ["The relationships described are of direct importance for managing disease risk during influenza outbreaks in horses, and more generally, advance our understanding of the transmission of influenza A viruses under natural conditions.", [["influenza", "DISEASE", 86, 95], ["influenza A viruses", "DISEASE", 186, 205], ["influenza A viruses", "ORGANISM", 186, 205], ["horses", "SPECIES", 109, 115], ["influenza A viruses", "SPECIES", 186, 205], ["managing disease risk", "PROBLEM", 57, 78], ["influenza outbreaks", "PROBLEM", 86, 105], ["influenza", "PROBLEM", 186, 195]]]], "c227831cafc2e6bacfd21ab0743e75f543594eb7": [["IntroductionAt the dawn of 2019 the World Health Organization (WHO) was notified by the Chinese authorities on novel coronavirus (2019-nCoV) causing severe respiratory illness emerging from Hubei Providence of China and particularly linked to the seafood market of Wuhan city (1) .", [["respiratory", "ANATOMY", 156, 167], ["2019-nCoV", "CHEMICAL", 130, 139], ["respiratory illness", "DISEASE", 156, 175], ["coronavirus", "ORGANISM", 117, 128], ["2019-nCoV", "ORGANISM", 130, 139], ["severe respiratory illness", "PROBLEM", 149, 175], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["respiratory illness", "OBSERVATION", 156, 175]]], ["The clinical characteristics of the disease are non-specific and comprise fever, cough, fatigue and shortness of breath in the majority of cases (2) .", [["fever", "DISEASE", 74, 79], ["cough", "DISEASE", 81, 86], ["fatigue", "DISEASE", 88, 95], ["shortness of breath", "DISEASE", 100, 119], ["the disease", "PROBLEM", 32, 43], ["fever", "PROBLEM", 74, 79], ["cough", "PROBLEM", 81, 86], ["fatigue", "PROBLEM", 88, 95], ["shortness of breath", "PROBLEM", 100, 119], ["disease", "OBSERVATION", 36, 43]]], ["Other factors that contribute to the lethality and severity of the cases include obesity (3), chronic cardiovascular diseases (4) and smoking habits (5) .", [["cardiovascular", "ANATOMY", 102, 116], ["obesity", "DISEASE", 81, 88], ["chronic cardiovascular diseases", "DISEASE", 94, 125], ["Other factors", "PROBLEM", 0, 13], ["the lethality", "PROBLEM", 33, 46], ["obesity", "PROBLEM", 81, 88], ["chronic cardiovascular diseases", "PROBLEM", 94, 125], ["obesity", "OBSERVATION", 81, 88], ["chronic", "OBSERVATION_MODIFIER", 94, 101], ["cardiovascular", "ANATOMY", 102, 116], ["diseases", "OBSERVATION", 117, 125]]], ["Many attempts for an effective vaccine are currently under development (6) and traditional antiviral antibacterial and anti-inflammatory agents such as zinc (7) has been used to reduce the risk of co-infections.", [["zinc", "CHEMICAL", 152, 156], ["co-infections", "DISEASE", 197, 210], ["zinc", "CHEMICAL", 152, 156], ["zinc (7)", "SIMPLE_CHEMICAL", 152, 160], ["an effective vaccine", "TREATMENT", 18, 38], ["traditional antiviral antibacterial", "TREATMENT", 79, 114], ["anti-inflammatory agents", "TREATMENT", 119, 143], ["zinc", "TREATMENT", 152, 156], ["co-infections", "PROBLEM", 197, 210], ["co-infections", "OBSERVATION", 197, 210]]], ["Imaging investigation, in the context of chest X-rays or computed tomography (CT) has a vital role in disease management.", [["Imaging investigation", "TEST", 0, 21], ["chest X-rays", "TEST", 41, 53], ["computed tomography (CT", "TEST", 57, 80], ["disease management", "TREATMENT", 102, 120], ["chest", "ANATOMY", 41, 46]]], ["Bilateral airspace opacities showing a peripheral and lower-zone predominance represent the most frequent findings on both modalities (1, (8) (9) (10) .", [["airspace opacities", "ANATOMY", 10, 28], ["lower-zone", "ANATOMY", 54, 64], ["airspace opacities", "PATHOLOGICAL_FORMATION", 10, 28], ["Bilateral airspace opacities", "PROBLEM", 0, 28], ["a peripheral and lower-zone predominance", "PROBLEM", 37, 77], ["airspace", "ANATOMY_MODIFIER", 10, 18], ["opacities", "OBSERVATION", 19, 28], ["peripheral", "ANATOMY_MODIFIER", 39, 49], ["lower", "ANATOMY_MODIFIER", 54, 59], ["zone", "ANATOMY_MODIFIER", 60, 64], ["predominance", "OBSERVATION", 65, 77], ["most frequent", "OBSERVATION_MODIFIER", 92, 105]]], ["Additionally, it has been reported that chest X-ray screening for asymptomatic carriers of COVID-19 may serve as a viable substitute for the available reverse transcription-quantitative polymerase chain reaction (RT-qPCR) tests (11, 12) .", [["COVID-19", "CHEMICAL", 91, 99], ["COVID-19", "DNA", 91, 99], ["chest X-ray screening", "TEST", 40, 61], ["COVID", "TEST", 91, 96], ["quantitative polymerase chain reaction", "PROBLEM", 173, 211], ["RT-qPCR", "TEST", 213, 220], ["tests", "TEST", 222, 227], ["chest", "ANATOMY", 40, 45]]], ["The high infection rate of COVID-19 caused, in a short period of time, an unprecedented burden on the healthcare systems, pushing intensive care units (ICU) treating multimorbid or other high-risk patients to the limits.", [["infection", "DISEASE", 9, 18], ["COVID-19", "CHEMICAL", 27, 35], ["COVID-19", "CHEMICAL", 27, 35], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["The high infection rate of COVID", "PROBLEM", 0, 32], ["multimorbid", "PROBLEM", 166, 177], ["high", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 9, 18]]], ["Therefore, as recently reported, given the shortages and delays in PCR tests, chest X-rays have become one of the fastest and most affordable ways for doctors to triage patients (13) .", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["PCR tests", "TEST", 67, 76], ["chest X-rays", "TEST", 78, 90], ["chest", "ANATOMY", 78, 83]]], ["As a result, faced with staff shortages and overwhelming patient loads, a growing number of hospitals are turning to automated tools to support them manage the pandemic.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["overwhelming patient loads", "PROBLEM", 44, 70], ["the pandemic", "PROBLEM", 156, 168]]], ["In such a context artificial intelligence (AI) COVID-19 classification systemsInterpretable artificial intelligence framework for COVID-19 screening on chest X-raysbased on chest X-rays represent a cost-beneficial solution for the early detection/diagnosis of infection and timely risk stratifications of patients.", [["chest", "ANATOMY", 152, 157], ["infection", "DISEASE", 260, 269], ["chest", "ORGANISM_SUBDIVISION", 152, 157], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["COVID", "TEST", 47, 52], ["COVID", "TEST", 130, 135], ["chest X-raysbased on chest X-rays", "TEST", 152, 185], ["a cost-beneficial solution", "TREATMENT", 196, 222], ["infection", "PROBLEM", 260, 269], ["chest", "ANATOMY", 152, 157], ["chest", "ANATOMY", 173, 178], ["infection", "OBSERVATION", 260, 269]]], ["The recent COVID-19 pandemic initiated an abundance of unpublished preprints available on open databases claiming accuracy (ACC) scores up to 99% (14) (15) (16) (17) (18) (19) (20) for COVID-19 screening on chest X-rays.", [["The recent COVID", "TEST", 0, 16], ["open databases", "TEST", 90, 104], ["accuracy", "TEST", 114, 122], ["ACC) scores", "TEST", 124, 135], ["COVID", "TEST", 185, 190], ["screening", "TEST", 194, 203], ["chest X-rays", "TEST", 207, 219], ["chest", "ANATOMY", 207, 212]]], ["These deep learning models incorporate a variety of architectures such as Generative Adversarial Networks (GANs) for data augmentation, capsule networks and transfer learning techniques.", [["capsule networks", "ANATOMY", 136, 152], ["capsule networks", "MULTI-TISSUE_STRUCTURE", 136, 152], ["data augmentation", "TREATMENT", 117, 134], ["capsule networks", "TREATMENT", 136, 152], ["learning techniques", "TREATMENT", 166, 185], ["deep", "ANATOMY_MODIFIER", 6, 10]]], ["Most notably, SqueezeNet was used with Bayesian hyperparameter optimization achieving an ACC of 98.3% (21) .", [["Bayesian hyperparameter optimization", "TREATMENT", 39, 75], ["an ACC", "TEST", 86, 92]]], ["Transfer learning techniques are crucial for deep learning model convergence on limited data, since there is a scarcity of a large and widely available COVID-19 imaging repository.", [["COVID", "TEST", 152, 157], ["imaging repository", "TEST", 161, 179], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["Many transfer learning models have been tested on small X-ray datasets with ACC up to 98.75% for binary (COVID and normal) and among three classes, with pneumonia being the third, up to 93.48% (22) .", [["pneumonia", "DISEASE", 153, 162], ["small X-ray datasets", "PROBLEM", 50, 70], ["ACC", "TEST", 76, 79], ["pneumonia", "PROBLEM", 153, 162], ["normal", "OBSERVATION", 115, 121], ["pneumonia", "OBSERVATION", 153, 162]]], ["Moreover, GANs have been used jointly with transfer learning (23) to further augment the limited COVID X-ray pool improving the prediction performance with an ACC of 99.9%.", [["GANs", "GENE_OR_GENE_PRODUCT", 10, 14], ["GANs", "PROTEIN", 10, 14], ["COVID X", "DNA", 97, 104], ["an ACC", "TEST", 156, 162]]], ["Additionally, CT semantic features related to COVID-19 were similarly observed (9) and a significant detection sensitivity (SEN) of the disease of 88% was reported (10) .Interpretable artificial intelligence framework for COVID-19 screening on chest X-raysA self-supervised encoder deep learning architecture was deployed on raw CT slices achieving an area under the curve (AUC) of 94% (24) .", [["chest", "ANATOMY", 244, 249], ["COVID-19", "DNA", 46, 54], ["COVID-19", "DNA", 222, 230], ["CT semantic features", "TEST", 14, 34], ["COVID", "TEST", 46, 51], ["a significant detection sensitivity", "TEST", 87, 122], ["the disease", "PROBLEM", 132, 143], ["COVID", "TEST", 222, 227], ["screening", "TEST", 231, 240], ["chest X", "TEST", 244, 251], ["CT slices", "TEST", 329, 338], ["the curve", "TEST", 363, 372], ["AUC", "TEST", 374, 377], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["chest", "ANATOMY", 244, 249]]], ["This impressive performance was challenged by the poor results of Grad-CAM attention maps mainly denoting regions with high contrast but irrelevant to the lung parenchyma.", [["lung parenchyma", "ANATOMY", 155, 170], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 155, 170], ["Grad-CAM attention maps", "TREATMENT", 66, 89], ["high contrast", "PROBLEM", 119, 132], ["high contrast", "OBSERVATION", 119, 132], ["lung", "ANATOMY", 155, 159], ["parenchyma", "ANATOMY_MODIFIER", 160, 170]]], ["This effect can be attributed to the lack of a proper preprocessing protocol including image resolution normalization and lung segmentation, as well as limitations in the proposed interpretable framework.", [["lung", "ANATOMY", 122, 126], ["lung", "ORGAN", 122, 126], ["a proper preprocessing protocol", "TEST", 45, 76], ["image resolution normalization", "TEST", 87, 117], ["lung segmentation", "TEST", 122, 139], ["lung", "ANATOMY", 122, 126], ["segmentation", "ANATOMY_MODIFIER", 127, 139]]], ["Zhao et al (25) composed a COVID-19 CT dataset with selected lesion slices achieving an AUC of 82.9%.", [["lesion slices", "ANATOMY", 61, 74], ["lesion slices", "CANCER", 61, 74], ["COVID-19 CT dataset", "DNA", 27, 46], ["a COVID", "TEST", 25, 32], ["CT dataset", "TEST", 36, 46], ["selected lesion slices", "TEST", 52, 74], ["an AUC", "TEST", 85, 91]]], ["On the other hand, deep models trained with similar data but evaluated on external testing sets reported AUC up to 90% (26, 27) .", [["external testing sets", "TEST", 74, 95], ["AUC", "TEST", 105, 108], ["deep", "ANATOMY_MODIFIER", 19, 23]]], ["Current scientific evidence suggests that AI can provide the necessary tools for a fast, accessible and accurate screening process based on imaging data such as X-rays or CT examinations, although a robust interpretability framework, which is also evaluated by clinical experts with years of experience, remains an unmet need.Interpretable artificial intelligence framework for COVID-19 screening on chest X-raysThis study proposes a deep learning-based COVID-19 classification system based on X-rays.", [["AI", "PROBLEM", 42, 44], ["imaging data", "TEST", 140, 152], ["X-rays", "TEST", 161, 167], ["CT examinations", "TEST", 171, 186], ["COVID", "TEST", 378, 383], ["chest X-rays", "TEST", 400, 412], ["This study", "TEST", 412, 422], ["a deep learning", "TREATMENT", 432, 447], ["chest", "ANATOMY", 400, 405]]], ["The main novelty of our proposed model lies in the classification of COVID-19 against common pneumonia cases and not normal (healthy) ones.", [["pneumonia", "DISEASE", 93, 102], ["COVID", "TEST", 69, 74], ["common pneumonia cases", "PROBLEM", 86, 108], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pneumonia", "OBSERVATION", 93, 102], ["not", "UNCERTAINTY", 113, 116], ["normal", "OBSERVATION", 117, 123]]], ["The discrimination between COVID-19 and other, especially those of viral origin, pneumonias is intuitively more complex given the non-specific clinical signs and symptoms (2) .", [["pneumonias", "DISEASE", 81, 91], ["The discrimination", "TEST", 0, 18], ["COVID", "TEST", 27, 32], ["pneumonias", "PROBLEM", 81, 91], ["the non-specific clinical signs and symptoms", "PROBLEM", 126, 170], ["viral origin", "OBSERVATION", 67, 79], ["pneumonias", "OBSERVATION", 81, 91]]], ["Another advantage of our proposed pipeline relies on the evaluation of the attention maps that are created for each prediction, which represents a basic interpretability step aiming to increase trust in the final decision.", [["the evaluation", "TEST", 53, 67], ["the attention maps", "TEST", 71, 89]]], ["The proposed method outperforms the state of the art with respect to the binary and quaternary classification tasks of Pneumonia vs COVID-19, achieving an average AUC=1, ACC=100%, SEN=99%, specificity (SPC)=100% for the binary classification and AUC=93, ACC=76%, SEN=93%, SPC=87% for the quaternary classification, across 5 folds.", [["Pneumonia", "DISEASE", 119, 128], ["Pneumonia", "PROBLEM", 119, 128], ["COVID", "TEST", 132, 137], ["an average AUC", "TEST", 152, 166], ["ACC", "TEST", 170, 173], ["SEN", "TEST", 180, 183], ["specificity", "TEST", 189, 200], ["SPC", "TEST", 202, 205], ["the binary classification", "TEST", 216, 241], ["AUC", "TEST", 246, 249], ["ACC", "TEST", 254, 257], ["SEN", "TEST", 263, 266], ["SPC", "TEST", 272, 275], ["the quaternary classification", "PROBLEM", 284, 313], ["Pneumonia", "OBSERVATION", 119, 128]]], ["The model also performs close to the state of the art with respect to the ternary classification task (i.e., normal, pneumonia, COVID-19).", [["pneumonia", "DISEASE", 117, 126], ["pneumonia", "PROBLEM", 117, 126], ["COVID", "TEST", 128, 133], ["pneumonia", "OBSERVATION", 117, 126]]], ["In this study, we used two fully anonymized chest X-ray datasets of COVID-19 cases.", [["this study", "TEST", 3, 13], ["COVID", "TEST", 68, 73], ["chest", "ANATOMY", 44, 49]]], ["It consists of chest X-ray and CT images of several syndromes, such as acute respiratory distress syndrome (ARDS), COVID-19, Middle East respiratory syndrome (MERS), pneumonia, and severe acute respiratory syndrome (SARS).", [["acute respiratory distress syndrome", "DISEASE", 71, 106], ["ARDS", "DISEASE", 108, 112], ["Middle East respiratory syndrome", "DISEASE", 125, 157], ["MERS", "DISEASE", 159, 163], ["pneumonia", "DISEASE", 166, 175], ["acute respiratory syndrome", "DISEASE", 188, 214], ["SARS", "DISEASE", 216, 220], ["chest X-ray", "TEST", 15, 26], ["CT images", "TEST", 31, 40], ["several syndromes", "PROBLEM", 44, 61], ["acute respiratory distress syndrome", "PROBLEM", 71, 106], ["ARDS", "PROBLEM", 108, 112], ["COVID", "TEST", 115, 120], ["Middle East respiratory syndrome", "PROBLEM", 125, 157], ["pneumonia", "PROBLEM", 166, 175], ["severe acute respiratory syndrome", "PROBLEM", 181, 214], ["chest", "ANATOMY", 15, 20], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory", "OBSERVATION", 77, 88], ["distress syndrome", "OBSERVATION", 89, 106], ["Middle", "ANATOMY_MODIFIER", 125, 131], ["respiratory syndrome", "OBSERVATION", 137, 157], ["pneumonia", "OBSERVATION", 166, 175], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["acute", "OBSERVATION_MODIFIER", 188, 193], ["respiratory syndrome", "OBSERVATION", 194, 214]]], ["The X-ray dataset was accessed on the 11th of April 2020, when it included 216 COVID-19 positive cases.", [["The X-ray dataset", "TEST", 0, 17], ["COVID", "TEST", 79, 84]]], ["For this study, 115 postero-anterior (PA) X-ray views were extracted.", [["anterior", "MULTI-TISSUE_STRUCTURE", 28, 36], ["this study", "TEST", 4, 14], ["115 postero-anterior (PA) X-ray views", "TEST", 16, 53], ["anterior", "ANATOMY_MODIFIER", 28, 36]]], ["We have chosen only the PA view, because as it represents the most commonly used radiological investigation in the emergency department (29) , it is available in the corresponding pneumonia dataset.", [["pneumonia", "DISEASE", 180, 189], ["the PA view", "TEST", 20, 31], ["radiological investigation", "TEST", 81, 107], ["the corresponding pneumonia dataset", "PROBLEM", 162, 197], ["pneumonia", "OBSERVATION", 180, 189]]], ["The second COVID-19 dataset originated from the QUIBIM imagingcovid19 platform database and various public repositories, including RSNA, IEEE, RadioGyan and the British Society of Thorathic Imaging.", [["COVID-19 dataset", "DNA", 11, 27], ["The second COVID", "TEST", 0, 16], ["Thorathic Imaging", "TEST", 180, 197]]], ["All these sources provided data mostly from Italy, Argentina, Mexico, and India, and consist of 22 PA X-ray views of patients with determined COVID-19 pneumonia.", [["pneumonia", "DISEASE", 151, 160], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["COVID", "TEST", 142, 147], ["pneumonia", "PROBLEM", 151, 160], ["pneumonia", "OBSERVATION", 151, 160]]], ["These two datasets were subsequently combined into one set, effectively forming the final COVID-19 dataset of 137 images used in this study.", [["COVID-19 dataset", "DNA", 90, 106], ["this study", "TEST", 129, 139]]], ["In addition, we used a publicly available X-ray dataset of patients with pneumonia (30, 31) , since our ultimate objective was to perform a multiclass classification between normal, COVID-19 and pneumonia subjects utilizing sole X-ray data.", [["pneumonia", "DISEASE", 73, 82], ["pneumonia", "DISEASE", 195, 204], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["pneumonia", "PROBLEM", 73, 82], ["COVID", "TEST", 182, 187], ["pneumonia", "PROBLEM", 195, 204], ["sole X-ray data", "TEST", 224, 239], ["pneumonia", "OBSERVATION", 73, 82], ["normal", "OBSERVATION", 174, 180], ["pneumonia", "OBSERVATION", 195, 204]]], ["The pneumonia dataset consisted of 5,856 X-ray images categorized into 3 classes, i.e., 1,583 normal (healthy) cases, 2,780 and 1,493 pneumonia positive cases caused by bacteria and viruses (other viruses apart from COVID-19), respectively.", [["pneumonia", "DISEASE", 4, 13], ["pneumonia", "DISEASE", 134, 143], ["The pneumonia dataset", "PROBLEM", 0, 21], ["X-ray images", "TEST", 41, 53], ["pneumonia positive cases", "PROBLEM", 134, 158], ["bacteria", "PROBLEM", 169, 177], ["viruses", "PROBLEM", 182, 189], ["other viruses", "PROBLEM", 191, 204], ["COVID", "TEST", 216, 221], ["pneumonia", "OBSERVATION", 4, 13], ["pneumonia", "OBSERVATION", 134, 143], ["bacteria", "OBSERVATION", 169, 177]]], ["In order to ensure balance in sample size across datasets (Table I) , we randomly selected 150 images from each class, for the purposes of our study.Materials and methodsPreprocessing and augmentation.", [["our study", "TEST", 139, 148], ["balance", "OBSERVATION", 19, 26], ["augmentation", "OBSERVATION_MODIFIER", 188, 200]]], ["The images were resized to 512 by 512 pixels, and were sample-wise normalized to zero mean and unit variance.", [["The images", "TEST", 0, 10], ["pixels", "TEST", 38, 44], ["sample", "TEST", 55, 61]]], ["A real-time image augmentation technique was used during training, in order to enhance the size and quality of the training dataset.", [["A real-time image augmentation technique", "TREATMENT", 0, 40], ["the training dataset", "TEST", 111, 131], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["The augmentation options included geometrical distortions such as small rotations, shearing and zooming up to a factor of 20%.Materials and methodsModel architecture.", [["The augmentation options", "TREATMENT", 0, 24], ["geometrical distortions", "PROBLEM", 34, 57], ["small rotations", "PROBLEM", 66, 81], ["augmentation", "OBSERVATION_MODIFIER", 4, 16], ["geometrical distortions", "OBSERVATION", 34, 57], ["small", "OBSERVATION_MODIFIER", 66, 71], ["rotations", "OBSERVATION_MODIFIER", 72, 81], ["architecture", "OBSERVATION_MODIFIER", 153, 165]]], ["Hyperparameter optimization was used to identify the highest performing pretrained model (Inception V3) for differentiating the examined COVID-19 X-rays.", [["COVID", "PROTEIN", 137, 142], ["Hyperparameter optimization", "TEST", 0, 27], ["COVID", "TEST", 137, 142]]], ["The proposed model's pipeline includes two main deep learning components.", [["main", "OBSERVATION_MODIFIER", 43, 47], ["deep", "OBSERVATION_MODIFIER", 48, 52], ["learning components", "OBSERVATION", 53, 72]]], ["The first one is a convolutional neural network (CNN) backbone network without its fully connected layers, namely the Inception-V3 (32).", [["neural network", "MULTI-TISSUE_STRUCTURE", 33, 47], ["layers", "TISSUE", 99, 105], ["a convolutional neural network (CNN) backbone network", "PROBLEM", 17, 70]]], ["The Inception-V3 was trained on the ImageNet database (33) , which consists of approximately 14 million images divided into a thousand classes.", [["V3", "DNA", 14, 16], ["the ImageNet database", "TEST", 32, 53]]], ["It is worth stating that transfer learning has been successfully utilized in numerous medical imaging problems, such as diabetic retinopathy detection from fundus images (34) .", [["fundus", "ANATOMY", 156, 162], ["diabetic retinopathy", "DISEASE", 120, 140], ["fundus", "MULTI-TISSUE_STRUCTURE", 156, 162], ["diabetic retinopathy detection", "PROBLEM", 120, 150], ["fundus images", "TEST", 156, 169]]], ["The second component of the model's pipeline is a standard deep neural network classifier (Fig. 1) .", [["neural network", "MULTI-TISSUE_STRUCTURE", 64, 78], ["second", "OBSERVATION_MODIFIER", 4, 10], ["component", "OBSERVATION_MODIFIER", 11, 20], ["model", "OBSERVATION_MODIFIER", 28, 33], ["'s pipeline", "OBSERVATION", 33, 44], ["deep", "ANATOMY_MODIFIER", 59, 63], ["neural network", "OBSERVATION", 64, 78]]], ["It consists of a global average pooling (GAP) layer, 3 fully-connected layers of 256, 128 and 64 neurons, respectively, each activated by a ReLU function, and followed by a Dropout layer with 25% dropout rate.", [["neurons", "ANATOMY", 97, 104], ["neurons", "CELL", 97, 104], ["GAP", "PROTEIN", 41, 44], ["a global average pooling (GAP) layer", "PROBLEM", 15, 51], ["a Dropout layer", "TREATMENT", 171, 186], ["25% dropout rate", "TREATMENT", 192, 208], ["global", "OBSERVATION_MODIFIER", 17, 23], ["average", "OBSERVATION_MODIFIER", 24, 31], ["pooling", "OBSERVATION", 32, 39], ["layer", "OBSERVATION_MODIFIER", 46, 51]]], ["The GAP layer computes the mean value of each feature map, effectively downscaling and flattening the output of InceptionV3.", [["GAP", "GENE_OR_GENE_PRODUCT", 4, 7], ["GAP", "PROTEIN", 4, 7], ["InceptionV3", "PROTEIN", 112, 123], ["GAP", "OBSERVATION_MODIFIER", 4, 7], ["layer", "OBSERVATION_MODIFIER", 8, 13], ["flattening", "OBSERVATION_MODIFIER", 87, 97], ["output", "OBSERVATION_MODIFIER", 102, 108]]], ["A final n-neuron layer follows, which includes 2-neurons for binary classification, 3-neurons for ternary classification and 4-neurons for quaternary classification, with softmax activation function being applied.Materials and methodsEvaluation of transfer learning methods.", [["n-neuron layer", "ANATOMY", 8, 22], ["2-neurons", "ANATOMY", 47, 56], ["3-neurons", "ANATOMY", 84, 93], ["4-neurons", "ANATOMY", 125, 134], ["neurons", "CELL", 49, 56], ["neurons", "CELL", 86, 93], ["neurons", "CELL", 127, 134], ["ternary classification", "TEST", 98, 120], ["quaternary classification", "TREATMENT", 139, 164], ["softmax activation function", "TREATMENT", 171, 198], ["methodsEvaluation", "TEST", 227, 244], ["learning methods", "TREATMENT", 257, 273]]], ["The metrics used are prediction ACC, SEN, precision (PRE), AUC score for the binary, AUC one versus rest (AUC OvR) and AUC one versus one (AUC OvO) for the multiclass classification: Interpretability.", [["AUC score", "TEST", 59, 68], ["AUC", "TEST", 85, 88], ["rest (AUC OvR", "TEST", 100, 113], ["AUC", "TEST", 119, 122]]], ["GradCAM examines the gradient information flowing from the input layer up to the last convolutional layer, for a given class label, providing a qualitative attention map for assessing the performance of the network.", [["GradCAM", "PROTEIN", 0, 7], ["layer", "OBSERVATION_MODIFIER", 65, 70]]], ["In particular, in order to generate the class-discriminative localization map Grad-CAM computes the gradients of the score for class c before the softmax, y c , with respect to the last set of feature maps of the CNN A k (i.e., the output of the last convolutional block, exactly before the FCN), i.e., \u2202y c / \u2202A k .", [["Grad-CAM", "DNA", 78, 86], ["FCN", "PROTEIN", 291, 294], ["the output", "TEST", 228, 238], ["the last convolutional block", "PROBLEM", 242, 270]]], ["To obtain the weights of the neurons importance, the new gradients are computed by the global average pooling layer over the dimensions of the image a k c .", [["neurons", "ANATOMY", 29, 36], ["neurons", "CELL", 29, 36], ["new", "OBSERVATION_MODIFIER", 53, 56], ["gradients", "OBSERVATION_MODIFIER", 57, 66], ["global", "OBSERVATION_MODIFIER", 87, 93], ["average", "OBSERVATION_MODIFIER", 94, 101], ["pooling", "OBSERVATION_MODIFIER", 102, 109], ["layer", "OBSERVATION_MODIFIER", 110, 115]]], ["Finally, a linear combination of the weights and the feature maps is applied, followed by a ReLU function, to produce the heatmap.", [["the weights", "TREATMENT", 33, 44], ["a ReLU function", "TEST", 90, 105], ["linear", "OBSERVATION_MODIFIER", 11, 17]]], ["It should be noted that these visualizations are based on the output of the convolutional part of the network but not on the classification part.", [["these visualizations", "TEST", 24, 44], ["the output", "TEST", 58, 68]]], ["Thus, the fully connected layers of the classification network may further process these features, effectively applying a selection strategy on them, in order to predict the final outcome.", [["a selection strategy", "TREATMENT", 120, 140]]], ["The attention map is mostly homogeneous across the entire image a 1Materials and methodsThe attention map is focusing on totally irrelevant areas outside the lung b 2Materials and methodsThe attention map is focusing on the lung areas but also on other extrapulmonary structures c 3Materials and methodsThe attention map is focusing mostly on the lung areas d 4Materials and methodsThe attention map is focusing exclusively on the lung areas e a Purple color is dominating the image. b All areas (100%) of blue, green and yellow exist only outside the lungs. c Up to 50% of areas of blue, green and yellow are located within the lungs. d Almost all areas (50-99%) of blue, green and yellow exist within the lungs. e All areas (100%) of blue, green and yellow are located only within the lungs.Materials and methodsIn order to validate the interpretability of the generated attention maps, we asked two experienced radiologists to rate these attention maps, based on how close they are with respect to the actual region of diagnostic interest.", [["lung", "ANATOMY", 158, 162], ["lung areas", "ANATOMY", 224, 234], ["lung", "ANATOMY", 347, 351], ["lung areas", "ANATOMY", 431, 441], ["lungs", "ANATOMY", 552, 557], ["lungs", "ANATOMY", 629, 634], ["lungs", "ANATOMY", 707, 712], ["lungs", "ANATOMY", 787, 792], ["lung", "ORGAN", 224, 228], ["lung", "ORGAN", 347, 351], ["lung", "ORGAN", 431, 435], ["lungs", "ORGAN", 552, 557], ["lungs", "ORGAN", 629, 634], ["lungs", "ORGAN", 707, 712], ["lungs", "ORGAN", 787, 792], ["The attention map", "TEST", 0, 17], ["The attention map", "TREATMENT", 88, 105], ["The attention map", "TREATMENT", 187, 204], ["The attention map", "TREATMENT", 303, 320], ["The attention map", "TREATMENT", 382, 399], ["a Purple color", "TEST", 444, 458], ["blue", "PROBLEM", 506, 510], ["blue", "PROBLEM", 583, 587], ["blue", "PROBLEM", 667, 671], ["blue, green and yellow", "PROBLEM", 736, 758], ["mostly", "OBSERVATION_MODIFIER", 21, 27], ["homogeneous", "OBSERVATION_MODIFIER", 28, 39], ["lung", "ANATOMY", 158, 162], ["lung", "ANATOMY", 224, 228], ["extrapulmonary", "ANATOMY", 253, 267], ["lung", "ANATOMY", 347, 351], ["lung", "ANATOMY", 431, 435], ["Purple color", "OBSERVATION", 446, 458], ["areas", "OBSERVATION_MODIFIER", 490, 495], ["100%", "OBSERVATION_MODIFIER", 497, 501], ["green", "OBSERVATION_MODIFIER", 512, 517], ["yellow", "OBSERVATION", 522, 528], ["lungs", "ANATOMY", 552, 557], ["blue", "OBSERVATION", 583, 587], ["green", "OBSERVATION_MODIFIER", 589, 594], ["yellow", "OBSERVATION", 599, 605], ["lungs", "ANATOMY", 629, 634], ["Almost", "OBSERVATION_MODIFIER", 638, 644], ["all", "OBSERVATION_MODIFIER", 645, 648], ["areas", "OBSERVATION_MODIFIER", 649, 654], ["green", "OBSERVATION", 673, 678], ["yellow", "OBSERVATION", 683, 689], ["lungs", "ANATOMY", 707, 712], ["All", "OBSERVATION_MODIFIER", 716, 719], ["areas", "OBSERVATION_MODIFIER", 720, 725], ["green", "OBSERVATION_MODIFIER", 742, 747], ["yellow", "OBSERVATION", 752, 758], ["lungs", "ANATOMY", 787, 792]]], ["For each image they provided two grades, one for each hemithorax (lung).", [["hemithorax", "ANATOMY", 54, 64], ["lung", "ANATOMY", 66, 70], ["hemithorax", "ORGAN", 54, 64], ["lung", "ORGAN", 66, 70], ["hemithorax", "ANATOMY", 54, 64], ["lung", "ANATOMY", 66, 70]]], ["The grading scale ranged from 0 to 4.", [["The grading scale", "TEST", 0, 17]]], ["Any difference between the grading of each expert was resolved via consensus between both experts.ResultsModel convergence.", [["difference", "OBSERVATION_MODIFIER", 4, 14], ["convergence", "OBSERVATION_MODIFIER", 111, 122]]], ["Our model was trained for 20 epochs, using the categorical cross-entropy loss function (equation 1) and Adam optimizer (36) with a batch size of 8.Resultswhere C is the total number of classes, t i is the one-hot-encoded ground truth and f(s i ) is the prediction probability for a given sample s.ResultsAlso, we used an exponentially decaying learning rate with an initial value of 0.001 and a decay rate of 0.96.", [["a batch size", "TEST", 129, 141], ["a decay rate", "TEST", 393, 405]]], ["The CNN InceptionV3 backbone's layers were 'frozen', so that only our custom classifier would be trained.", [["layers", "TISSUE", 31, 37], ["The CNN InceptionV3 backbone's layers", "TREATMENT", 0, 37]]], ["The model was trained on a stratified 5-fold cross validation schema, utilizing one fold for the independent testing and the rest for training and validation purposes.", [["a stratified 5-fold cross validation schema", "TREATMENT", 25, 68], ["the independent testing", "TEST", 93, 116], ["validation purposes", "TEST", 147, 166]]], ["The k-fold separation schema ensured that we can iteratively test the trained models on the whole dataset providing a clearer insight on its performance, while at the same time the training, validation and testing sets do not overlap amongst themselves on the one hand, and across all folds on the other.", [["the training", "TREATMENT", 177, 189], ["validation and testing sets", "TEST", 191, 218]]], ["The validation set was randomly selected as a 10% subset of the training/validation folds, while 90% was used for training.", [["the training/validation folds", "TREATMENT", 60, 89]]], ["The model was trained on a server with an AMD EPYC 7251 8-core 2.9GHz CPU, RTX 2080Ti 11GB GPU and 64GB RAM, and it was implemented on Tensorflow 2.1, utilizing the Keras module.", [["an AMD EPYC", "TEST", 39, 50], ["RTX", "TEST", 75, 78], ["GB RAM", "TEST", 101, 107], ["the Keras module", "TREATMENT", 161, 177], ["GB RAM", "ANATOMY", 101, 107]]], ["We initially trained the model for detecting pneumonia and COVID-19 cases.", [["pneumonia", "DISEASE", 45, 54], ["pneumonia", "PROBLEM", 45, 54], ["COVID", "TEST", 59, 64], ["pneumonia", "OBSERVATION", 45, 54]]], ["Given that our COVID-19 dataset has a size of 137 and since our pneumonia dataset consisted of 300 cases (150 of each subclass i.e., bacteria and virus), we randomly sampled 75 images from each pneumonia subclass, so that we generated balanced datasets.", [["pneumonia", "DISEASE", 64, 73], ["pneumonia", "DISEASE", 194, 203], ["COVID-19 dataset", "DNA", 15, 31], ["our COVID", "TEST", 11, 20], ["our pneumonia dataset", "PROBLEM", 60, 81], ["bacteria", "PROBLEM", 133, 141], ["virus", "PROBLEM", 146, 151], ["each pneumonia subclass", "PROBLEM", 189, 212], ["size", "OBSERVATION_MODIFIER", 38, 42], ["pneumonia", "OBSERVATION", 64, 73], ["pneumonia", "OBSERVATION", 194, 203]]], ["As a result, the dataset for binary classification consisted of 150 pneumonia (75 of each pneumonia subclass) and 137 COVID-19 X-ray images.", [["pneumonia", "DISEASE", 68, 77], ["pneumonia", "DISEASE", 90, 99], ["binary classification", "TEST", 29, 50], ["150 pneumonia", "PROBLEM", 64, 77], ["each pneumonia subclass", "TEST", 85, 108], ["COVID", "TEST", 118, 123], ["ray images", "TEST", 129, 139], ["pneumonia", "OBSERVATION", 68, 77]]], ["Our method consistently achieves 100% in all metrics for every fold except the third one, in which the model displayed only one false negative and no false positive results, achieving a SEN of 99%, SPC of 100%, PRE of 100%, an ACC of 100% and an AUC of 1.", [["a SEN", "TEST", 184, 189], ["SPC", "TEST", 198, 201], ["PRE", "TEST", 211, 214], ["an ACC", "TEST", 224, 230], ["an AUC", "TEST", 243, 249], ["no", "UNCERTAINTY", 147, 149]]], ["It is evident from these results that the model can successfully distinguish and correctly detect the two classes, i.e., pneumonia versus COVID-19.", [["pneumonia", "DISEASE", 121, 130], ["pneumonia", "PROBLEM", 121, 130], ["COVID", "TEST", 138, 143], ["pneumonia", "OBSERVATION", 121, 130]]], ["Fig. 2 illustrates the average confusion matrix across the 5 folds.", [["confusion", "DISEASE", 31, 40], ["matrix", "CELLULAR_COMPONENT", 41, 47], ["average", "OBSERVATION_MODIFIER", 23, 30]]], ["The confusion matrix of each individual fold can be found in the supplementary (Fig. S1 ).", [["confusion", "DISEASE", 4, 13], ["The confusion matrix of each individual fold", "PROBLEM", 0, 44], ["confusion", "OBSERVATION", 4, 13]]], ["It should be noted that, although the SEN is 99% due to the one false-negative prediction, the ACC and AUC are reported as 100% and 1, respectively, due to the 2nd floating point rounding procedure of the metrics.ResultsTernary classification.", [["AUC", "TEST", 103, 106], ["negative", "OBSERVATION", 70, 78]]], ["Subsequently, we trained the model for detecting normal, pneumonia and COVID-19 cases.", [["pneumonia", "DISEASE", 57, 66], ["COVID", "DISEASE", 71, 76], ["pneumonia", "PROBLEM", 57, 66], ["COVID", "TEST", 71, 76], ["normal", "OBSERVATION", 49, 55], ["pneumonia", "OBSERVATION", 57, 66]]], ["We also utilized the subsampled pneumonia dataset, as previously explained in the Binary classification section.", [["pneumonia", "DISEASE", 32, 41], ["the subsampled pneumonia dataset", "PROBLEM", 17, 49], ["pneumonia", "OBSERVATION", 32, 41]]], ["Fig. 3 illustrates the average confusion matrix across the 5 folds.", [["confusion", "DISEASE", 31, 40], ["matrix", "CELLULAR_COMPONENT", 41, 47], ["average", "OBSERVATION_MODIFIER", 23, 30]]], ["The proposed model performs very well in terms of the AUC metric in the One-vs-Rest testing schema, achieving a mean value of 96% across all testing folds (Table III -Ternary row) .", [["Rest testing schema", "TEST", 79, 98], ["a mean value", "TEST", 110, 122]]], ["However, the mean ACC across all folds and classes is 85%, which is lower than that observed in the Binary classification task.", [["mean", "OBSERVATION_MODIFIER", 13, 17], ["ACC", "OBSERVATION_MODIFIER", 18, 21], ["all", "OBSERVATION_MODIFIER", 29, 32], ["folds", "OBSERVATION", 33, 38], ["classes", "OBSERVATION_MODIFIER", 43, 50], ["85%", "OBSERVATION_MODIFIER", 54, 57], ["lower", "OBSERVATION_MODIFIER", 68, 73]]], ["As seen in the confusion matrices of each fold (Fig. S2) , the COVID-19 false positives for the first fold (a) are 18, which is much higher than the other 4 folds, in which the false positives are 0 (folds 2 and 5) and 5 (folds 3 and 4).", [["confusion", "DISEASE", 15, 24], ["COVID", "PROTEIN", 63, 68], ["the COVID", "TEST", 59, 68], ["the false positives", "TEST", 173, 192], ["folds", "TEST", 200, 205], ["false positives", "OBSERVATION", 72, 87], ["much", "OBSERVATION_MODIFIER", 128, 132], ["higher", "OBSERVATION_MODIFIER", 133, 139], ["false positives", "OBSERVATION", 177, 192]]], ["It is our view that in order to properly verify the model and explain such an inconsistency, a much larger training and testing datasets are needed.ResultsQuaternary classification.", [["a much larger training", "TREATMENT", 93, 115], ["testing datasets", "TEST", 120, 136]]], ["The final experiment regards the quaternary classification between all classes of the dataset, i.e., normal, COVID-19, bacterial pneumonia and viral pneumonia cases.", [["pneumonia", "DISEASE", 129, 138], ["viral pneumonia", "DISEASE", 143, 158], ["COVID", "TEST", 109, 114], ["bacterial pneumonia", "PROBLEM", 119, 138], ["viral pneumonia cases", "PROBLEM", 143, 164], ["normal", "OBSERVATION", 101, 107], ["bacterial", "OBSERVATION_MODIFIER", 119, 128], ["pneumonia", "OBSERVATION", 129, 138], ["viral", "OBSERVATION_MODIFIER", 143, 148], ["pneumonia", "OBSERVATION", 149, 158]]], ["The overall performance of the model for the quaternary classification is worse than any of the previous tasks, with a mean ACC of 76% and an AUC of 93%.", [["a mean ACC", "TEST", 117, 127], ["an AUC", "TEST", 139, 145]]], ["Fig. 4 illustrates the average confusion matrix across the 5 folds.ResultsHowever, as shown in the per-class performance tables (Tables SIV-SVII) , the model performs far better regarding the COVID-19 class with less false positives than the one in the ternary classification task, which leads to higher SPC (99%).", [["confusion", "DISEASE", 31, 40], ["matrix", "CELLULAR_COMPONENT", 41, 47]]], ["In addition, the performance of the model regarding the normal class is approximately the same as the one in the ternary classification.ResultsThe model's performance degrades in the last two classes, i.e., bacterial and viral pneumonia cases.", [["pneumonia", "DISEASE", 227, 236], ["bacterial and viral pneumonia cases", "PROBLEM", 207, 242], ["normal", "OBSERVATION", 56, 62], ["ternary", "OBSERVATION_MODIFIER", 113, 120], ["classification", "OBSERVATION", 121, 135], ["bacterial", "OBSERVATION_MODIFIER", 207, 216], ["viral", "OBSERVATION_MODIFIER", 221, 226], ["pneumonia", "OBSERVATION", 227, 236]]], ["Especially in the viral pneumonia, the SEN of the model is far worse than any other class, reaching a mean value of 44% and a median value of 48%.", [["pneumonia", "DISEASE", 24, 33], ["the viral pneumonia", "PROBLEM", 14, 33], ["a mean value", "TEST", 100, 112], ["a median value", "TEST", 124, 138], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["pneumonia", "OBSERVATION", 24, 33]]], ["By looking at the relevant confusion matrices, Fig. S3 , the viral pneumonia cases are misclassified as either bacteria pneumonia or normal healthy cases.", [["confusion", "DISEASE", 27, 36], ["pneumonia", "DISEASE", 67, 76], ["pneumonia", "DISEASE", 120, 129], ["S3", "GENE_OR_GENE_PRODUCT", 52, 54], ["the viral pneumonia cases", "PROBLEM", 57, 82], ["bacteria pneumonia", "PROBLEM", 111, 129], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["pneumonia", "OBSERVATION", 67, 76], ["bacteria", "OBSERVATION_MODIFIER", 111, 119], ["pneumonia", "OBSERVATION", 120, 129]]], ["In addition, in fold 3 many bacterial pneumonia cases are misclassified as viral pneumonia.", [["pneumonia", "DISEASE", 38, 47], ["viral pneumonia", "DISEASE", 75, 90], ["many bacterial pneumonia cases", "PROBLEM", 23, 53], ["viral pneumonia", "PROBLEM", 75, 90], ["bacterial", "OBSERVATION_MODIFIER", 28, 37], ["pneumonia", "OBSERVATION", 38, 47], ["viral", "OBSERVATION_MODIFIER", 75, 80], ["pneumonia", "OBSERVATION", 81, 90]]], ["Overall, splitting the pneumonia cases in two separate subclasses, i.e., bacterial or viral, has helped the model to better predict the COVID-19 cases against all other, which is the desired task in this preliminary study.ResultsAttention maps.", [["pneumonia", "DISEASE", 23, 32], ["splitting the pneumonia cases", "PROBLEM", 9, 38], ["bacterial or viral", "PROBLEM", 73, 91], ["this preliminary study", "TEST", 199, 221], ["ResultsAttention maps", "TEST", 222, 243], ["pneumonia", "OBSERVATION", 23, 32], ["viral", "OBSERVATION", 86, 91]]], ["In order to accelerate the clinical acceptance of AI classification systems there is an ongoing effort to assess the interpretability potential of the proposed solutions.", [["the proposed solutions", "TREATMENT", 147, 169]]], ["In our case, we hypothesize that 'attention' to diagnostically irrelevant regions in the image is an indication of randomness and reduced generalizability.ResultsThe evaluation of the attention maps from two expert radiologists is presented here.", [["randomness", "PROBLEM", 115, 125], ["reduced generalizability", "PROBLEM", 130, 154], ["The evaluation", "TEST", 162, 176], ["the attention maps", "TEST", 180, 198], ["reduced", "OBSERVATION_MODIFIER", 130, 137], ["generalizability", "OBSERVATION", 138, 154]]], ["Rating was done on two randomly selected testing sets of positively COVID-19 classified images from the binary and the ternary classification tasks.", [["COVID", "DNA", 68, 73], ["COVID", "TEST", 68, 73]]], ["The model had predicted all of the images as COVID-19 correctly for the binary classification and all but 4 for the ternary classification task.", [["COVID-19", "DNA", 45, 53], ["the images", "TEST", 31, 41], ["COVID", "TEST", 45, 50]]], ["Regarding the ternary classification the model had misclassified 2 images as pneumonia and 2 as normal.ResultsThe evaluation results can be found in Tables IV and V, while Tables VI and VII report the disagreements of the experts on the first and second testing set, respectively.", [["pneumonia", "DISEASE", 77, 86], ["VII", "PROTEIN", 186, 189], ["pneumonia", "PROBLEM", 77, 86], ["The evaluation", "TEST", 110, 124], ["pneumonia", "OBSERVATION", 77, 86], ["normal", "OBSERVATION", 96, 102]]], ["Regarding the binary classification testing set, the model focuses on relevant regions mostly inside the lung for half of the samples (grade 3).", [["lung", "ANATOMY", 105, 109], ["samples", "ANATOMY", 126, 133], ["lung", "ORGAN", 105, 109], ["the binary classification testing", "TEST", 10, 43], ["lung", "ANATOMY", 105, 109]]], ["The fact that the model 'looks' at these regions is very promising because they may be relevant to diagnosing COVID-19.", [["COVID-19", "CHEMICAL", 110, 118], ["COVID", "TEST", 110, 115]]], ["The fact that the model also focuses on other regions outside the lungs (grade 2) for the other half of samples indicates that training on a much larger dataset is needed, so that the model exhibits a more robust performance in that respect.ResultsOn the other hand, regarding the second testing set, there are a few cases that the model does not focus on a specific region of the X-ray image for predicting COVID-19 (grade 0 -e.g., patient's left lung, Fig. 7) , while there are also some perfectly focused attention maps (grade 4).", [["lungs", "ANATOMY", 66, 71], ["samples", "ANATOMY", 104, 111], ["left lung", "ANATOMY", 443, 452], ["lungs", "ORGAN", 66, 71], ["patient", "ORGANISM", 433, 440], ["lung", "ORGAN", 448, 452], ["patient", "SPECIES", 433, 440], ["the second testing", "TEST", 277, 295], ["the X-ray image", "TEST", 377, 392], ["predicting COVID", "TEST", 397, 413], ["lungs", "ANATOMY", 66, 71], ["left", "ANATOMY_MODIFIER", 443, 447], ["lung", "ANATOMY", 448, 452]]], ["However, most of the gradings are reported, similarly to those in the binary classification, to be grades 2 and 3, indicating yet again the need for further training.", [["further training", "TREATMENT", 149, 165]]], ["The model misclassified the COVID-19 patients 8 and 15 as 'pneumonia'.", [["pneumonia", "DISEASE", 59, 68], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["the COVID", "TEST", 24, 33], ["'pneumonia'", "PROBLEM", 58, 69], ["pneumonia", "OBSERVATION", 59, 68]]], ["The experts graded the attention map as 3 and 4 for the left and right lung of patient 8 (Fig. 8 ) and 2 and 4 for patient 15 (Fig. 9) , respectively.", [["left", "ANATOMY", 56, 60], ["right lung", "ANATOMY", 65, 75], ["lung", "ORGAN", 71, 75], ["patient", "ORGANISM", 79, 86], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 79, 86], ["patient", "SPECIES", 115, 122], ["the attention map", "TEST", 19, 36], ["left", "ANATOMY_MODIFIER", 56, 60], ["right", "ANATOMY_MODIFIER", 65, 70], ["lung", "ANATOMY", 71, 75]]], ["This in our view is interesting, because although the model focuses correctly at the relevant lung regions (amongst others such as the occlusion due to the heart), it does not manage to take the proper decision and to correctly classify these two images.", [["lung", "ANATOMY", 94, 98], ["heart", "ANATOMY", 156, 161], ["lung regions", "MULTI-TISSUE_STRUCTURE", 94, 106], ["heart", "ORGAN", 156, 161], ["these two images", "TEST", 237, 253], ["lung", "ANATOMY", 94, 98], ["regions", "ANATOMY_MODIFIER", 99, 106], ["occlusion", "OBSERVATION", 135, 144], ["heart", "ANATOMY", 156, 161]]], ["Also, the model misclassified the COVID-19DiscussionThe present study focused on COVID-19 classification from routine X-ray examinations without any segmentation pre-processing step.", [["COVID-19", "DNA", 81, 89], ["COVID", "TEST", 81, 86], ["routine X-ray examinations", "TEST", 110, 136]]], ["The AI framework was evaluated in terms of quantitative metrics but also in a qualitative fashion by expert radiologists, who rated the diagnostic relevance of the attention maps of the model's convolutional part on unseen testing sets.", [["The AI framework", "TEST", 0, 16], ["unseen testing sets", "TEST", 216, 235]]], ["The examined attention maps constitute an important tool in deep learning analysis, highlighting a highly probable region of deep feature extraction.", [["attention maps", "TEST", 13, 27], ["deep learning analysis", "TEST", 60, 82], ["deep feature extraction", "TREATMENT", 125, 148], ["deep feature extraction", "OBSERVATION", 125, 148]]], ["Thus, according to the evaluation (criteria in Table II) by radiologists as presented in Tables IV and V , the proposed architecture mostly focuses in the lung region despite the presence of high intensity extrapulmonary areas across the X-ray images.", [["lung region", "ANATOMY", 155, 166], ["lung", "ORGAN", 155, 159], ["the evaluation", "TEST", 19, 33], ["high intensity extrapulmonary areas", "PROBLEM", 191, 226], ["the X-ray images", "TEST", 234, 250], ["architecture", "OBSERVATION_MODIFIER", 120, 132], ["mostly", "OBSERVATION_MODIFIER", 133, 139], ["focuses", "OBSERVATION", 140, 147], ["lung", "ANATOMY", 155, 159], ["region", "ANATOMY_MODIFIER", 160, 166], ["high", "OBSERVATION_MODIFIER", 191, 195], ["intensity", "OBSERVATION_MODIFIER", 196, 205]]], ["In both binary and ternary classification around half of the cases received grade equal to 2, with the remaining half receiving grades 3-4 (Tables IV and V) .", [["binary", "OBSERVATION_MODIFIER", 8, 14], ["ternary", "OBSERVATION_MODIFIER", 19, 26], ["classification", "OBSERVATION", 27, 41]]], ["No outliers (grade 0 or 1) were found in pneumonia versus COVID but three zero-graded cases were identified in ternary classification, a result that was rather expected due to the slightly lower performance achieved by those models.", [["pneumonia", "DISEASE", 41, 50], ["COVID", "DISEASE", 58, 63], ["outliers (grade 0 or 1)", "PROBLEM", 3, 26], ["pneumonia", "PROBLEM", 41, 50], ["COVID", "PROBLEM", 58, 63], ["the slightly lower performance", "PROBLEM", 176, 206], ["pneumonia", "OBSERVATION", 41, 50]]], ["Despite the limited dataset in this study, the proposed framework has the potential to enhance the decision-making process by providing trustworthy predictions in terms of prediction confidence and visual cues representative of the deep learning analysis.", [["this study", "TEST", 31, 41], ["the deep learning analysis", "TEST", 228, 254]]], ["In particular, the pre-trained Inception-v3 models achieved an AUC performance of 100% in pneumonia versus COVID-19, 96% in normal versus pneumonia versus COVID-19 and 93% for quaternary classification.", [["pneumonia", "DISEASE", 90, 99], ["pneumonia", "DISEASE", 138, 147], ["COVID-19", "SPECIES", 107, 115], ["an AUC performance", "TEST", 60, 78], ["pneumonia", "PROBLEM", 90, 99], ["COVID", "TEST", 107, 112], ["pneumonia", "PROBLEM", 138, 147], ["COVID", "TEST", 155, 160], ["pneumonia", "OBSERVATION", 90, 99], ["pneumonia", "OBSERVATION", 138, 147]]], ["It is worth mentioning that the transfer learning technique provided a strong baseline for the examined lesion, in addition to data augmentation mitigating the limited set of COVID-19 X-rays.", [["lesion", "ANATOMY", 104, 110], ["COVID-19 X", "DNA", 175, 185], ["the examined lesion", "PROBLEM", 91, 110], ["data augmentation", "TEST", 127, 144], ["COVID", "TEST", 175, 180], ["lesion", "OBSERVATION", 104, 110]]], ["The proposed fine-tuning scheme achieved better model adaptation for the neural and classification layers reaching state-of-the-art performance in binary classification (pneumonia versus .", [["neural", "ANATOMY", 73, 79], ["pneumonia", "DISEASE", 170, 179], ["pneumonia", "PROBLEM", 170, 179], ["neural", "ANATOMY", 73, 79], ["pneumonia", "OBSERVATION", 170, 179]]], ["Despite these encouraging results, efforts should be put into building a much larger public database of COVID-19 X-ray images, on which the research community will train and evaluate the performance of their proposed models.DiscussionFollowing this study, an extensive examination of modelling other imaging modalities will be explored, particularly deep learning analysis on available datasets with selected tomographic data (23) and on open databases with no data curation (https://radiopaedia.org/).", [["COVID-19 X", "DNA", 104, 114], ["COVID", "TEST", 104, 109], ["ray images", "TEST", 115, 125], ["this study", "TEST", 244, 254], ["an extensive examination", "TEST", 256, 280], ["modelling other imaging modalities", "TEST", 284, 318], ["selected tomographic data", "TEST", 400, 425], ["open databases", "TEST", 438, 452], ["data curation", "TEST", 461, 474]]], ["For instance, He et al (24) developed a CT decision support system with attention map interpretation.", [["attention map interpretation", "TEST", 72, 100]]], ["The results of the study are similar to ours, at least in terms of classification performance (AUC 94%) but in their Grad-CAM attention maps a qualitative discrepancy was observed as the majority of the presented maps include regions (other high contrast tissue) outside the lung parenchyma.", [["tissue", "ANATOMY", 255, 261], ["lung parenchyma", "ANATOMY", 275, 290], ["tissue", "TISSUE", 255, 261], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 275, 290], ["the study", "TEST", 15, 24], ["AUC", "TEST", 95, 98], ["high", "OBSERVATION_MODIFIER", 241, 245], ["contrast tissue", "OBSERVATION", 246, 261], ["lung", "ANATOMY", 275, 279], ["parenchyma", "ANATOMY_MODIFIER", 280, 290]]], ["This issue is probably due to the lack of lung segmentation or detection prior to training leading the model to learn redundant information unrelated to the lung and COVID-19 infected area.", [["lung", "ANATOMY", 42, 46], ["lung", "ANATOMY", 157, 161], ["area", "ANATOMY", 184, 188], ["lung", "ORGAN", 42, 46], ["lung", "ORGAN", 157, 161], ["training", "TREATMENT", 82, 90], ["the lung and COVID-19 infected area", "PROBLEM", 153, 188], ["probably due to", "UNCERTAINTY", 14, 29], ["lung", "ANATOMY", 42, 46], ["segmentation", "OBSERVATION", 47, 59], ["lung", "ANATOMY", 157, 161], ["infected", "OBSERVATION", 175, 183]]], ["These current limitations call for more advanced and interpretable deep learning and preprocessing techniques applied in large datasets in order to provide AI empowered clinical tools that can significantly contribute in the fight against COVID-19.", [["preprocessing techniques", "TREATMENT", 85, 109], ["COVID", "TEST", 239, 244]]]], "64eb4ce04f6fc3dcf08cc1ad80f7cbd72f262880": [["IntroductionProviding quality end-of-life care for older people is one of our biggest challenges in this new COVID-19 era.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["this new COVID", "TREATMENT", 100, 114]]], ["Advanced age, because of its association with a range of physical comorbidities, is associated with greater mortality with COVID-19.", [["COVID-19", "CHEMICAL", 123, 131], ["COVID", "TEST", 123, 128]]], ["Specifically, case fatality rates in the 70 + age group range from 8.6% to 13.4% compared with 0.0026-0.3% in those under 45 (Ruan, 2020; Zhou et al., 2020) .", [["case fatality rates", "TEST", 14, 33]]], ["Those who are at high risk for COVID-19 are the same patients we take care of in geriatric psychiatry, geriatrics, nursing home, hospice, and palliative care, that is, older, ill, frail, cognitively impaired, at high risk of delirium with mental and physical comorbidities (van den Brink et al., 2017) .", [["cognitively impaired", "DISEASE", 187, 207], ["delirium", "DISEASE", 225, 233], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 31, 36], ["hospice", "TREATMENT", 129, 136], ["cognitively impaired", "PROBLEM", 187, 207], ["delirium", "PROBLEM", 225, 233], ["mental and physical comorbidities", "PROBLEM", 239, 272]]], ["An acute COVID infection may be, as Ballentine (2020) suggested, \"what collapses the house of cards\" for our vulnerable patients.IntroductionIn ensuring optimal end-of-life care for this vulnerable population, the palliative and hospice care philosophy is critical.", [["infection", "DISEASE", 15, 24], ["Ballentine", "CHEMICAL", 36, 46], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["An acute COVID infection", "PROBLEM", 0, 24], ["this vulnerable population", "PROBLEM", 182, 208], ["the palliative", "TREATMENT", 210, 224], ["hospice care philosophy", "TREATMENT", 229, 252], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["COVID", "OBSERVATION_MODIFIER", 9, 14], ["infection", "OBSERVATION", 15, 24]]], ["This philosophy is based on the alleviation of distressing pain and other burdensome symptoms, provision of support for psychosocial and spiritual issues and the optimization of quality of life for patients with life-limiting illnesses and their families or caregivers (Ballentine, 2020) .", [["pain", "DISEASE", 59, 63], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["distressing pain", "PROBLEM", 47, 63], ["other burdensome symptoms", "PROBLEM", 68, 93], ["psychosocial and spiritual issues", "PROBLEM", 120, 153]]], ["Ensuring comfort in dying, managing symptoms, ensuring high-quality medico-ethical decision-making based on wishes and preferences and supporting families and providers is business as usual for palliative care, which has never been more important.IntroductionThis paper will explore the key challenges currently afoot in providing quality end-of-life care to older people in the COVID pandemic from the perspective of clinicians and researchers from five countries.", [["people", "ORGANISM", 365, 371], ["people", "SPECIES", 365, 371], ["managing symptoms", "PROBLEM", 27, 44], ["palliative care", "TREATMENT", 194, 209]]], ["We explore ways to preserve the same level of care our patients already receive and to avoid care disparities at the end of life, concluding with suggestions for clinicians trying to achieve this.Human rights and bioethical principles at stakeIn the pre-COVID-19 era, equitable access to high-quality health, implicitly including end of life , was a human right articulated under Article 25 of the Convention of the Rights of Persons with Disabilities (CRPD) (United Nations Committee on the Rights of Persons With Disabilities, 2020).", [["CRPD", "DISEASE", 453, 457], ["patients", "ORGANISM", 55, 63], ["Human", "ORGANISM", 196, 201], ["human", "ORGANISM", 350, 355], ["patients", "SPECIES", 55, 63], ["Human", "SPECIES", 196, 201], ["human", "SPECIES", 350, 355], ["Persons", "SPECIES", 426, 433], ["Persons", "SPECIES", 502, 509], ["Human", "SPECIES", 196, 201], ["human", "SPECIES", 350, 355], ["Human rights", "TREATMENT", 196, 208], ["bioethical principles", "TREATMENT", 213, 234], ["right", "ANATOMY_MODIFIER", 356, 361]]], ["Similarly, equitable access to palliative care, including pain relief, is a human right owed to all, including those in residential care (Froggatt et al., 2020; Markham et al., 2019; Palliative Care for Older People in Care and Nursing Homes in Europe Project, 2019).", [["pain", "DISEASE", 58, 62], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["People", "SPECIES", 209, 215], ["human", "SPECIES", 76, 81], ["palliative care", "TREATMENT", 31, 46], ["pain relief", "TREATMENT", 58, 69]]], ["The challenge in this COVID-19 era is to providewhere possible given our severely compromised health environments-this equitable access to high-quality death and dying even to the most vulnerable.Human rights and bioethical principles at stakeTo honor ethical principles of beneficence, non-maleficence, preserving autonomy, and truthtelling, clinicians must act in the best interests of their patients in a transparent manner to maximize autonomous decision-making and to do no harm.", [["death", "DISEASE", 152, 157], ["Human", "ORGANISM", 196, 201], ["patients", "ORGANISM", 394, 402], ["Human", "SPECIES", 196, 201], ["patients", "SPECIES", 394, 402], ["Human", "SPECIES", 196, 201], ["The challenge", "TREATMENT", 0, 13], ["this COVID", "TREATMENT", 17, 27], ["our severely compromised health environments", "PROBLEM", 69, 113], ["Human rights", "TREATMENT", 196, 208], ["bioethical principles", "TREATMENT", 213, 234]]], ["For many of us depending on health care settings and resources, this pandemic has forced our hand and limited certain treatment options.", [["hand", "ANATOMY", 93, 97], ["hand", "ORGANISM_SUBDIVISION", 93, 97]]], ["Ballentine stated that maintaining grace, while helping patients and families to understand and decide, is all in palliative care's \"wheelhouse\" (Ballentine, 2020) .Human rights and bioethical principles at stakeThere have been a number of ethical approaches to resource allocation, including \"first come, first served,\" saving most life years or maximizing benefits and prognosis, giving priority to the worst off, or to those able to contribute most such as health workers (Emanuel et al., 2020) .", [["Ballentine", "CHEMICAL", 0, 10], ["Ballentine", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 56, 64], ["Human", "ORGANISM", 165, 170], ["patients", "SPECIES", 56, 64], ["Human", "SPECIES", 165, 170], ["Human", "SPECIES", 165, 170], ["Human rights", "TREATMENT", 165, 177], ["bioethical principles", "TREATMENT", 182, 203]]], ["Age should not be a criterion per se among any of these options but tends to correlate with poorer prognosis, less life years, and less-or no-benefits of invasive treatments.", [["invasive treatments", "TREATMENT", 154, 173]]], ["We know that both frailty and age are associated with worst non-beneficial outcomes in intensive care (Carter et al., 2019; Muscedere et al., 2017) , and frailty scoring has become a cornerstone of COVID-19 ICU resource allocation in many countries, although this remains controversial in some parts of the world (see below).Human rights and bioethical principles at stakeThe primary role of beneficence and nonmaleficence in resource allocation existed pre-COVID.", [["frailty", "DISEASE", 18, 25], ["Human", "ORGANISM", 325, 330], ["Human", "SPECIES", 325, 330], ["Human", "SPECIES", 325, 330], ["Human rights", "TREATMENT", 325, 337], ["bioethical principles", "TREATMENT", 342, 363]]], ["At a National Academies workshop in November 2019 to discuss Crisis Standards of Care principles and processes for non-disaster shortages (Hick et al., 2009; Hick et al., 2020) , strategies for scarce resource situations included \"Reallocate\" (removal of resources such as ventilators and Extra-Corporeal Membrane Oxygenation from one area or patient and allocation to those with higher likelihood of benefit).", [["patient", "ORGANISM", 343, 350], ["patient", "SPECIES", 343, 350], ["removal of resources", "TREATMENT", 244, 264], ["ventilators", "TREATMENT", 273, 284], ["Extra-Corporeal Membrane Oxygenation", "TREATMENT", 289, 325]]], ["Therefore, in the allocation process, the older vulnerable person who is unlikely to benefit from ventilation is most likely to be diverted-but beneficently so-to palliative care.", [["person", "ORGANISM", 59, 65], ["person", "SPECIES", 59, 65], ["ventilation", "TREATMENT", 98, 109], ["palliative care", "TREATMENT", 163, 178]]], ["Understanding that such decision-making is driven by principles of beneficence may protect clinicians from the moral injury and distress Williamson et al., 2020) incurred by resource-based ventilator rationing (Truog et al., 2020) .", [["distress", "PROBLEM", 128, 136], ["ventilator rationing", "TREATMENT", 189, 209]]], ["Moreover, if older people are diverted to palliative care for beneficent reasons, this is the message we wish to convey to patients and families.Human rights and bioethical principles at stakeGiven this reality in the middle of a pandemic, we as providers need to be prepared, and we need to prepare patients and families.", [["people", "ORGANISM", 19, 25], ["patients", "ORGANISM", 123, 131], ["Human", "ORGANISM", 145, 150], ["patients", "ORGANISM", 300, 308], ["people", "SPECIES", 19, 25], ["patients", "SPECIES", 123, 131], ["Human", "SPECIES", 145, 150], ["patients", "SPECIES", 300, 308], ["Human", "SPECIES", 145, 150], ["palliative care", "TREATMENT", 42, 57], ["Human rights", "TREATMENT", 145, 157], ["bioethical principles", "TREATMENT", 162, 183], ["middle", "ANATOMY_MODIFIER", 218, 224]]], ["We need to ensure we are honoring patients' wishes, while also ensuring that they receive the appropriate level of care and treatment they need and desire.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["treatment", "TREATMENT", 124, 133]]], ["There is room despite this pandemic to honor the human right to expression of will and preferences, as articulated in Article 12, CRPD.", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["right", "ANATOMY_MODIFIER", 55, 60]]], ["In having conversations about goals of care, and preferences regarding code status, resuscitation, intubation, avoiding the Emergency Department or ICU, or other aggressive interventions associated with low likelihood of meaningful recovery, it is critical to let patients and proxies know what to expect.Human rights and bioethical principles at stakeTo address these morally loaded and very delicate issues, the Dutch Association of Elderly Care Physicians, General Practitioners, Geriatricians, and Internal Medicine specialists issued on March 27, 2020, a practice guideline for triage decisions regarding admission of frail elderly with COVID-19 infection (or suspected) to hospitals, ICUs, or to offer home treatment.", [["infection", "DISEASE", 651, 660], ["patients", "ORGANISM", 264, 272], ["Human", "ORGANISM", 305, 310], ["patients", "SPECIES", 264, 272], ["Human", "SPECIES", 305, 310], ["Human", "SPECIES", 305, 310], ["resuscitation", "TREATMENT", 84, 97], ["intubation", "TREATMENT", 99, 109], ["aggressive interventions", "TREATMENT", 162, 186], ["Human rights", "TREATMENT", 305, 317], ["bioethical principles", "TREATMENT", 322, 343], ["COVID-19 infection", "PROBLEM", 642, 660], ["home treatment", "TREATMENT", 708, 722], ["infection", "OBSERVATION", 651, 660]]], ["Advantages (e.g. more advanced treatment options including ICU care and medications) and disadvantages (e.g. increased risk of delirium, isolation, and functional decline) of hospitalization are outlined.", [["delirium", "DISEASE", 127, 135], ["advanced treatment options", "TREATMENT", 22, 48], ["ICU care", "TREATMENT", 59, 67], ["medications", "TREATMENT", 72, 83], ["disadvantages", "TREATMENT", 89, 102], ["delirium", "PROBLEM", 127, 135], ["isolation", "TREATMENT", 137, 146]]], ["It is recommended that treating physicians consider the prospects of rehabilitation following often burdensome hospitalization.", [["rehabilitation", "TREATMENT", 69, 83]]], ["It is well known that sarcopenia associated with prolonged hospital and ICU admission and mechanical ventilation results in mobility loss and functional decline often requiring intensive geriatric rehabilitation lasting up to 12 months.", [["sarcopenia", "DISEASE", 22, 32], ["mobility loss", "DISEASE", 124, 137], ["sarcopenia", "PROBLEM", 22, 32], ["mechanical ventilation", "TREATMENT", 90, 112], ["mobility loss", "PROBLEM", 124, 137], ["functional decline", "PROBLEM", 142, 160], ["intensive geriatric rehabilitation", "TREATMENT", 177, 211], ["sarcopenia", "OBSERVATION", 22, 32], ["mechanical ventilation", "OBSERVATION", 90, 112], ["mobility loss", "OBSERVATION", 124, 137]]], ["Negative respiratory effects of mechanical ventilation, provisionally called Corona Obstructive Lung Disease, and potential exacerbation of pre-existing cognitive problems further add to the futility of ICU treatment.", [["respiratory", "ANATOMY", 9, 20], ["Lung", "ANATOMY", 96, 100], ["Corona Obstructive Lung Disease", "DISEASE", 77, 108], ["cognitive problems", "DISEASE", 153, 171], ["Lung", "ORGAN", 96, 100], ["mechanical ventilation", "TREATMENT", 32, 54], ["Corona Obstructive Lung Disease", "PROBLEM", 77, 108], ["pre-existing cognitive problems", "PROBLEM", 140, 171], ["ICU treatment", "TREATMENT", 203, 216], ["respiratory effects", "OBSERVATION", 9, 28], ["mechanical ventilation", "OBSERVATION", 32, 54], ["Corona", "OBSERVATION_MODIFIER", 77, 83], ["Obstructive", "OBSERVATION_MODIFIER", 84, 95], ["Lung", "ANATOMY", 96, 100], ["Disease", "OBSERVATION", 101, 108]]], ["The benefits are unclear in those with CFS 4 or 5.", [["CFS", "DISEASE", 39, 42]]], ["However, shared decision-making is always warranted with respect to personal wishes and preferences of the patient and proxies.Human rights and bioethical principles at stakeA similar process has been developed in the United Kingdom (UK) where the National Institute for Clinical Excellence has released guidance on admission to hospitals and ICU highlighting the importance of the CFS, taking a holistic approach to considering comorbidities and underlying health conditions.", [["CFS", "DISEASE", 382, 385], ["patient", "ORGANISM", 107, 114], ["Human", "ORGANISM", 127, 132], ["patient", "SPECIES", 107, 114], ["Human", "SPECIES", 127, 132], ["Human", "SPECIES", 127, 132], ["Human rights", "TREATMENT", 127, 139], ["bioethical principles", "TREATMENT", 144, 165], ["a holistic approach", "TREATMENT", 394, 413], ["comorbidities", "PROBLEM", 429, 442], ["underlying health conditions", "PROBLEM", 447, 475]]], ["An initial suggestion that a CFS score of 5 be used as part of the decision-making process for ICU admission was met with justified objections from a range of stakeholders including organizations representing people with learning difficulties, dementia, and mental health problems.", [["CFS", "DISEASE", 29, 32], ["learning difficulties", "DISEASE", 221, 242], ["dementia", "DISEASE", 244, 252], ["people", "ORGANISM", 209, 215], ["people", "SPECIES", 209, 215], ["a CFS score", "TEST", 27, 38], ["learning difficulties", "PROBLEM", 221, 242], ["dementia", "PROBLEM", 244, 252], ["mental health problems", "PROBLEM", 258, 280]]], ["This led to the guidance being caveated with the statement \"The 1 Very fit-robust, active, energetic, well motivated, and fit; these people commonly exercise regularly and are in the most fit group for their age 2 Well-without active disease, but less fit than people in category 1 3 Well, with treated comorbid disease-disease symptoms are well controlled compared with those in category 4 4 Apparently vulnerable-although not frankly dependent, these people commonly complain of being \"slowed up\" or have disease symptoms 5 Mildly frail-with limited dependence on others for instrumental activities of daily living 6 Moderately frail-help is needed with both instrumental and non-instrumental activities of daily living 7 Severely frail-completely dependent on others for the activities of daily living or terminally ill CFS should not be used in younger people, people with stable long-term disabilities (e.g. cerebral palsy), learning disabilities, or autism.", [["cerebral", "ANATOMY", 913, 921], ["comorbid disease-disease", "DISEASE", 303, 327], ["CFS", "DISEASE", 823, 826], ["cerebral palsy", "DISEASE", 913, 927], ["learning disabilities", "DISEASE", 930, 951], ["autism", "DISEASE", 956, 962], ["people", "ORGANISM", 133, 139], ["people", "ORGANISM", 261, 267], ["people", "ORGANISM", 453, 459], ["people", "ORGANISM", 857, 863], ["people", "ORGANISM", 865, 871], ["cerebral", "ORGAN", 913, 921], ["people", "SPECIES", 133, 139], ["people", "SPECIES", 261, 267], ["people", "SPECIES", 453, 459], ["people", "SPECIES", 857, 863], ["people", "SPECIES", 865, 871], ["active disease", "PROBLEM", 227, 241], ["treated comorbid disease", "PROBLEM", 295, 319], ["disease symptoms", "PROBLEM", 320, 336], ["frankly dependent", "PROBLEM", 428, 445], ["disease symptoms", "PROBLEM", 507, 523], ["Mildly frail", "PROBLEM", 526, 538], ["limited dependence", "PROBLEM", 544, 562], ["Moderately frail", "PROBLEM", 619, 635], ["Severely frail", "PROBLEM", 724, 738], ["terminally ill CFS", "PROBLEM", 808, 826], ["cerebral palsy", "PROBLEM", 913, 927], ["autism", "PROBLEM", 956, 962], ["without", "UNCERTAINTY", 219, 226], ["active", "OBSERVATION_MODIFIER", 227, 233], ["disease", "OBSERVATION", 234, 241], ["frankly dependent", "OBSERVATION_MODIFIER", 428, 445], ["cerebral palsy", "ANATOMY", 913, 927]]], ["An individualized assessment is recommended in all cases where the CFS is not appropriate.\"", [["CFS", "DISEASE", 67, 70], ["An individualized assessment", "TEST", 0, 28]]], ["All acute hospitals in the UK have now established ethics panels to review individual cases and support staff making these difficult decisions.Human rights and bioethical principles at stakeIn Belgium, a COVID-19 guideline for symptom control and clinical decision-making for nursing homes has been released (latest update March 25, 2020), endorsed by the Belgian Association for Gerontology and Geriatric and Crataegus (the Flemish organization responsible for education of the Coordinating and Advisory Physicians working in nursing homes).", [["Human", "ORGANISM", 143, 148], ["Human", "SPECIES", 143, 148], ["Human", "SPECIES", 143, 148], ["Human rights", "TREATMENT", 143, 155], ["bioethical principles", "TREATMENT", 160, 181], ["a COVID", "TREATMENT", 202, 209], ["symptom control", "TREATMENT", 227, 242], ["acute", "OBSERVATION_MODIFIER", 4, 9]]], ["The document includes guidelines for symptom management specific to COVID-19 and risk-benefit analyses regarding hospitalization of nursing home residents, taking into account current ethical recommendations.", [["symptom management", "TREATMENT", 37, 55], ["COVID", "TEST", 68, 73]]], ["Specifically, residents with CFS scores of 8 or 9 should receive palliative care in the nursing home unless advance care planning (ACP) indicates otherwise.", [["CFS", "DISEASE", 29, 32], ["CFS scores", "TEST", 29, 39], ["palliative care", "TREATMENT", 65, 80]]], ["For those with a score of 7, consultation should occur with the resident and/or family regarding palliative or supportive care in the nursing home, or supportive care in an acute geriatric hospital unit.", [["palliative or supportive care", "TREATMENT", 97, 126]]], ["Those with CFS scores less than 7 and two or more alarming symptoms (e.g. consciousness, respiratory rate, saturation level, and pulse/blood pressure) are recommended for hospital admission, taking into account ACP, wishes, and preferences, in consultation with the Emergency Department.Human rights and bioethical principles at stakeIncluded in this Belgian guidance is ethical advice from the Belgian Society of Intensive Care Medicine concerning proportionality of critical care during the pandemic.", [["respiratory", "ANATOMY", 89, 100], ["blood", "ANATOMY", 135, 140], ["CFS", "DISEASE", 11, 14], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["Human", "ORGANISM", 287, 292], ["Human", "SPECIES", 287, 292], ["Human", "SPECIES", 287, 292], ["CFS scores", "TEST", 11, 21], ["more alarming symptoms", "PROBLEM", 45, 67], ["consciousness", "TEST", 74, 87], ["respiratory rate", "TEST", 89, 105], ["saturation level", "TEST", 107, 123], ["pulse/blood pressure", "TEST", 129, 149], ["Human rights", "TREATMENT", 287, 299], ["bioethical principles", "TREATMENT", 304, 325]]], ["This clearly states that \"intensive care medicine should be reserved for patients in whom a good or at least acceptable outcome can be expected, after hospital discharge.\"", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["intensive care medicine", "TREATMENT", 26, 49]]], ["It highlights the need for triage if there is insufficient ICU capacity, although in Belgium so far this has not been the case, as ICU capacity has more than doubled to ensure sufficient capacity.", [["triage", "TEST", 27, 33], ["insufficient ICU capacity", "PROBLEM", 46, 71], ["ICU capacity", "TEST", 131, 143]]], ["It recommends early initiation of ACP (before ICU admission and before an acute phase) and advises against ICU admission for nursing home residents unless there is a clearly defined realistic therapeutic goal.Human rights and bioethical principles at stakeAdvance care planning ACP is vital in the COVID-19 context because of the unpredictable and rapid deterioration seen in some patients, leaving little time to consult with the patient or family.", [["Human", "ORGANISM", 209, 214], ["patients", "ORGANISM", 381, 389], ["patient", "ORGANISM", 431, 438], ["Human", "SPECIES", 209, 214], ["patients", "SPECIES", 381, 389], ["patient", "SPECIES", 431, 438], ["Human", "SPECIES", 209, 214], ["Human rights", "TREATMENT", 209, 221], ["bioethical principles", "TREATMENT", 226, 247], ["the unpredictable and rapid deterioration", "PROBLEM", 326, 367], ["rapid", "OBSERVATION_MODIFIER", 348, 353], ["deterioration", "OBSERVATION", 354, 367]]], ["ACP is a particularly pressing issue for people with dementia who may lack capacity to make these decisions for themselves.Human rights and bioethical principles at stakeAlthough harder to do in a pandemic, escalation and facilitation of ACP implementation has been the cornerstone of the pandemic response for those countries such as Australia afforded the luxury of some preparation (Advance Care Planning Australia, 2020).", [["dementia", "DISEASE", 53, 61], ["people", "ORGANISM", 41, 47], ["Human", "ORGANISM", 123, 128], ["people", "SPECIES", 41, 47], ["Human", "SPECIES", 123, 128], ["Human", "SPECIES", 123, 128], ["dementia", "PROBLEM", 53, 61], ["Human rights", "TREATMENT", 123, 135], ["bioethical principles", "TREATMENT", 140, 161], ["ACP implementation", "TREATMENT", 238, 256]]], ["For every newly admitted resident, preferences and wishes regarding resuscitation, hospital admission, ICU treatment, and the existence of an ACP are established.", [["resuscitation", "TREATMENT", 68, 81], ["ICU treatment", "TREATMENT", 103, 116]]], ["In the COVID era, these discussions must be adapted since prognosis of hospitalization and ICU treatment are futile in frail elderly.", [["ICU treatment", "TREATMENT", 91, 104]]], ["In the Dutch experience, most older people agree not to be hospitalized and prefer to stay in their home environment.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42]]], ["In Belgium, there has been an increase in ACP over the past few years in nursing homes, but there is still room for much improvement (Gilissen et al., 2018) .Human rights and bioethical principles at stakeTo facilitate ACP, just as some advocate the use of the Surprise Question in dementia (\"Would you be surprised if this patient were to die in the next 6-12 months\") (Empowered Project, 2020; Markham et al., 2019; White et al., 2017) , adjunctive use of the Supportive and Palliative Care Indicators Tool (Highet et al., 2014) has been advocated in the COVID-19 pandemic to promote transparency and truthfulness in advance planning (Greenaway and Arunarthy, 2020) .Human rights and bioethical principles at stakeOne important consideration concerning ACP is that for people who have not had the opportunity to discuss and reflect on their wishes and preferences for end-of-life decisions pre-COVID, ACP might be biased toward the emotions and fears induced by the pandemic.", [["dementia", "DISEASE", 282, 290], ["Human", "ORGANISM", 158, 163], ["patient", "ORGANISM", 324, 331], ["Human", "ORGANISM", 669, 674], ["people", "ORGANISM", 771, 777], ["Human", "SPECIES", 158, 163], ["patient", "SPECIES", 324, 331], ["Human", "SPECIES", 669, 674], ["people", "SPECIES", 771, 777], ["Human", "SPECIES", 158, 163], ["Human", "SPECIES", 669, 674], ["Human rights", "TREATMENT", 158, 170], ["bioethical principles", "TREATMENT", 175, 196], ["dementia", "PROBLEM", 282, 290], ["Human rights", "TREATMENT", 669, 681], ["bioethical principles", "TREATMENT", 686, 707], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["ACP", "OBSERVATION_MODIFIER", 42, 45]]], ["Making advance directives without indepth reflection and opportunities to discuss might be very difficult for people.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116]]], ["Hence, sensitive and compassionate communication seem key, and organizations such as Center to Advance Palliative Care in the USA have been making and distributing communication guidelines that might help with this.", [["Palliative Care", "TREATMENT", 103, 118]]], ["Capacity issues associated with impaired cognition and delirium complicate this further.Commentary 3This pandemic has unfolded a lack of awareness among people about end-of-life decision-making.", [["impaired cognition", "DISEASE", 32, 50], ["delirium", "DISEASE", 55, 63], ["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["Capacity issues", "PROBLEM", 0, 15], ["impaired cognition", "PROBLEM", 32, 50], ["delirium", "PROBLEM", 55, 63]]], ["At least in Belgium, where euthanasia and palliative sedation are the two end-of-life practices that have received most attention in public forums over the past two decades, the lack of clarity around other end-of-life decisions such as non-treatment or withholding treatment (e.g. do not hospitalize or do not intubate) is surprising.", [["euthanasia", "PROBLEM", 27, 37], ["palliative sedation", "TREATMENT", 42, 61], ["treatment", "TREATMENT", 266, 275]]], ["The crisis is an opportunity to discuss these issues more openly and increase death literacy in the population, hopefully culminating in more authentic ACP in the future.Symptom management including palliative sedationIn the Netherlands, the Dutch Association of Elderly Care Physicians issued treatment guidelines regarding the most prevalent symptoms in COVID patients such as dyspnea, pain, cough, delirium, nausea and vomiting, anxiety, and sleepiness.", [["death", "DISEASE", 78, 83], ["COVID", "DISEASE", 356, 361], ["dyspnea", "DISEASE", 379, 386], ["pain", "DISEASE", 388, 392], ["cough", "DISEASE", 394, 399], ["delirium", "DISEASE", 401, 409], ["nausea", "DISEASE", 411, 417], ["vomiting", "DISEASE", 422, 430], ["anxiety", "DISEASE", 432, 439], ["sleepiness", "DISEASE", 445, 455], ["patients", "ORGANISM", 362, 370], ["patients", "SPECIES", 362, 370], ["Symptom management", "TREATMENT", 170, 188], ["palliative sedationIn", "TREATMENT", 199, 220], ["treatment guidelines", "TREATMENT", 294, 314], ["the most prevalent symptoms", "PROBLEM", 325, 352], ["dyspnea", "PROBLEM", 379, 386], ["pain", "PROBLEM", 388, 392], ["cough", "PROBLEM", 394, 399], ["delirium", "PROBLEM", 401, 409], ["nausea", "PROBLEM", 411, 417], ["vomiting", "PROBLEM", 422, 430], ["anxiety", "PROBLEM", 432, 439], ["sleepiness", "PROBLEM", 445, 455], ["crisis", "OBSERVATION", 4, 10]]], ["Similarly, in Belgium, the aforementioned nursing home document provides guidelines for pharmacological and non-pharmacological approaches to symptom management in line with existing guidelines for symptom management in palliative care.", [["pharmacological and non-pharmacological approaches", "TREATMENT", 88, 138], ["symptom management", "TREATMENT", 142, 160], ["existing guidelines", "TREATMENT", 174, 193], ["symptom management", "TREATMENT", 198, 216], ["palliative care", "TREATMENT", 220, 235]]], ["Treatment of dyspnea, especially the so-called silent dyspnea, with a saturation level of 70% without visible signs, is an additional challenge.", [["dyspnea", "DISEASE", 13, 20], ["dyspnea", "DISEASE", 54, 61], ["dyspnea", "PROBLEM", 13, 20], ["the so-called silent dyspnea", "PROBLEM", 33, 61], ["a saturation level", "TEST", 68, 86], ["visible signs", "PROBLEM", 102, 115], ["dyspnea", "OBSERVATION", 13, 20]]], ["In these cases, treatment with oxygen supplemented by morphine is warranted.", [["oxygen", "CHEMICAL", 31, 37], ["morphine", "CHEMICAL", 54, 62], ["oxygen", "CHEMICAL", 31, 37], ["morphine", "CHEMICAL", 54, 62], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["morphine", "SIMPLE_CHEMICAL", 54, 62], ["oxygen", "TREATMENT", 31, 37], ["morphine", "TREATMENT", 54, 62]]], ["However, Dutch and Belgian long-term care facilities face shortages in oxygen supplies, which is a serious threat for optimal symptom management.Symptom management including palliative sedationAdditionally, there is often a need to apply palliative sedation.", [["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["Belgian long-term care", "TREATMENT", 19, 41], ["oxygen supplies", "TREATMENT", 71, 86], ["optimal symptom management", "TREATMENT", 118, 144], ["Symptom management", "TREATMENT", 145, 163], ["palliative sedation", "TREATMENT", 174, 193], ["palliative sedation", "TREATMENT", 238, 257]]], ["Palliative sedation involves the deliberate lowering of the patient's consciousness in the final stage of life in order to relieve \"refractory symptoms\" that cause unbearable suffering if conventional modes of treatment are ineffective or do not act quickly enough.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["Palliative sedation", "TREATMENT", 0, 19], ["refractory symptoms", "PROBLEM", 132, 151], ["treatment", "TREATMENT", 210, 219]]], ["Although there are no research data yet, it is expected that refractory dyspnea with concomitant anxiety and delirium in patients with dementia may require palliative sedation.", [["dyspnea", "DISEASE", 72, 79], ["anxiety", "DISEASE", 97, 104], ["delirium", "DISEASE", 109, 117], ["dementia", "DISEASE", 135, 143], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["research data", "TEST", 22, 35], ["refractory dyspnea", "PROBLEM", 61, 79], ["concomitant anxiety", "PROBLEM", 85, 104], ["delirium", "PROBLEM", 109, 117], ["dementia", "PROBLEM", 135, 143], ["palliative sedation", "TREATMENT", 156, 175], ["no", "UNCERTAINTY", 19, 21], ["refractory", "OBSERVATION_MODIFIER", 61, 71], ["dyspnea", "OBSERVATION", 72, 79]]], ["There is also a risk of shortages of medication, especially midazolam, which is the first-choice benzodiazepine for palliative sedation.", [["midazolam", "CHEMICAL", 60, 69], ["benzodiazepine", "CHEMICAL", 97, 111], ["midazolam", "CHEMICAL", 60, 69], ["benzodiazepine", "CHEMICAL", 97, 111], ["midazolam", "SIMPLE_CHEMICAL", 60, 69], ["benzodiazepine", "SIMPLE_CHEMICAL", 97, 111], ["medication", "TREATMENT", 37, 47], ["midazolam", "TREATMENT", 60, 69], ["benzodiazepine", "TREATMENT", 97, 111], ["palliative sedation", "TREATMENT", 116, 135]]], ["Guidelines advise diazepam or lorazepam as alternatives in such cases.Symptom management including palliative sedationReal and potential shortages of medication, oxygen supplies, and opioid driver pumps are relevant to all countries.", [["diazepam", "CHEMICAL", 18, 26], ["lorazepam", "CHEMICAL", 30, 39], ["oxygen", "CHEMICAL", 162, 168], ["diazepam", "CHEMICAL", 18, 26], ["lorazepam", "CHEMICAL", 30, 39], ["oxygen", "CHEMICAL", 162, 168], ["diazepam", "SIMPLE_CHEMICAL", 18, 26], ["lorazepam", "SIMPLE_CHEMICAL", 30, 39], ["oxygen", "SIMPLE_CHEMICAL", 162, 168], ["diazepam", "TREATMENT", 18, 26], ["lorazepam", "TREATMENT", 30, 39], ["Symptom management", "TREATMENT", 70, 88], ["palliative sedationReal", "TREATMENT", 99, 122], ["medication", "TREATMENT", 150, 160], ["oxygen supplies", "TREATMENT", 162, 177], ["opioid driver pumps", "TREATMENT", 183, 202]]], ["As such, equal to the importance of ensuring adequate personal protective equipment (PPE) and ventilators, is the need to ensure an ongoing supply of equipment required to provide quality palliative care.Voluntary-assisted dying and euthanasiaIf ever there was time for careful scrutiny of decision-making with regard to voluntary-assisted dying (VAD), now is the time.", [["ventilators", "TREATMENT", 94, 105], ["quality palliative care", "TREATMENT", 180, 203]]], ["Older people's perceptions of being a burden will be ever more salient, compounding depression, hopelessness, and loneliness, all of which may fuel VAD requests Wand et al., 2018) .Voluntary-assisted dying and euthanasiaSo far, in the Netherlands, Belgium, and Australia, there are no signs of changing either VAD or euthanasia practice.", [["depression", "DISEASE", 84, 94], ["hopelessness", "DISEASE", 96, 108], ["loneliness", "DISEASE", 114, 124], ["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12], ["depression", "PROBLEM", 84, 94], ["hopelessness", "PROBLEM", 96, 108], ["euthanasia practice", "TREATMENT", 317, 336], ["no signs of", "UNCERTAINTY", 282, 293]]], ["However, since the Corona crisis, the Netherlands' center of expertise on euthanasia has closed.", [["the Corona crisis", "PROBLEM", 15, 32], ["Corona", "OBSERVATION_MODIFIER", 19, 25], ["crisis", "OBSERVATION", 26, 32], ["euthanasia", "OBSERVATION", 74, 84]]], ["It is not clear what the impact of this will be, but there may be a risk to those desperately seeking euthanasia who may resort to other alternatives.", [["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]], ["There are some anecdotes that some people purposively want to be infected by COVID in order to hasten death.Voluntary-assisted dying and euthanasiaIn Belgium, there are currently no specific debates on euthanasia.", [["COVID", "DISEASE", 77, 82], ["death", "DISEASE", 102, 107], ["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41]]], ["While current guidelines are clear that this is not the case, there is a lot of confusion in the media and public opinion, misinterpreting the intent that proportionate and dignified care is the aim for all.", [["confusion", "DISEASE", 80, 89], ["confusion", "PROBLEM", 80, 89]]], ["This is compounded by increasing outbreaks in long-term care facilities precipitating panic among the sector regarding insufficient resources and personnel to deal with the pandemic.", [["panic", "DISEASE", 86, 91], ["panic", "PROBLEM", 86, 91], ["the pandemic", "PROBLEM", 169, 181], ["increasing", "OBSERVATION_MODIFIER", 22, 32], ["outbreaks", "OBSERVATION", 33, 42], ["long-term", "OBSERVATION_MODIFIER", 46, 55]]], ["These are urgent issues to address in Belgium.Long-term care facilities (nursing or care homes)Much of the care of older persons, particularly those with dementia, lies with long-term care facilities.", [["dementia", "DISEASE", 154, 162], ["persons", "ORGANISM", 121, 128], ["persons", "SPECIES", 121, 128], ["dementia", "PROBLEM", 154, 162]]], ["Older patients approaching the end of life can be managed entirely in long-term care facilities without compromising either quality of care or survival (Hui et al., 2014) .", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["The Dutch long-term care sector is fast transitioning former residential homes or other wards to either specific CORONA wards, with quarantine or hospice wards, to provide care for people admitted from their homes or discharged from hospitals.", [["people", "ORGANISM", 181, 187], ["people", "SPECIES", 181, 187], ["The Dutch long-term care sector", "TREATMENT", 0, 31]]], ["This is a major organizational operation.Long-term care facilities (nursing or care homes)On March 12, 2020, the Flemish government in Belgium, and on March 19, 2020, the Dutch government in the Netherlands excluded entry of family members from nursing homes as has been the case in Australia, the USA, and the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 311, 313], ["a major organizational operation", "TREATMENT", 8, 40], ["major", "OBSERVATION_MODIFIER", 10, 15], ["organizational operation", "OBSERVATION", 16, 40]]], ["In the UK, the notion of more stringent \"shielding\" has been implemented for those considered extremely vulnerable, that is people undergoing chemotherapy for cancer or severe chronic obstructive pulmonary disease.Long-term care facilities (nursing or care homes)Exceptions to family visits are sometimes made for residents in a terminal stage; however, even then numbers of family members are highly restricted and touching infected residents precluded.", [["cancer", "ANATOMY", 159, 165], ["pulmonary", "ANATOMY", 196, 205], ["cancer", "DISEASE", 159, 165], ["chronic obstructive pulmonary disease", "DISEASE", 176, 213], ["people", "ORGANISM", 124, 130], ["cancer", "CANCER", 159, 165], ["pulmonary", "ORGAN", 196, 205], ["people", "SPECIES", 124, 130], ["more stringent \"shielding\"", "PROBLEM", 25, 51], ["chemotherapy", "TREATMENT", 142, 154], ["cancer", "PROBLEM", 159, 165], ["severe chronic obstructive pulmonary disease", "PROBLEM", 169, 213], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["chronic", "OBSERVATION_MODIFIER", 176, 183], ["obstructive", "OBSERVATION_MODIFIER", 184, 195], ["pulmonary", "ANATOMY", 196, 205], ["disease", "OBSERVATION", 206, 213]]], ["There are now many stories of people dying alone or saying goodbye via iPads, the impact on residents, and on bereaved families clearly evident.", [["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36]]], ["When patients die, the inability to go to a place of worship or gather for funerals makes it harder for families and communities to mourn and grieve.Long-term care facilities (nursing or care homes)These restrictions are placing an enormous toll on people with dementia who are isolated, socially disconnected, and do not understand COVID-imposed restrictions, culminating in challenging behaviors.", [["dementia", "DISEASE", 261, 269], ["patients", "ORGANISM", 5, 13], ["people", "ORGANISM", 249, 255], ["patients", "SPECIES", 5, 13], ["people", "SPECIES", 249, 255], ["dementia", "PROBLEM", 261, 269]]], ["Apart from unmet need from loneliness and need for intimacy, the sight of staff in PPE can be misinterpreted and frightening.", [["loneliness", "DISEASE", 27, 37], ["frightening", "PROBLEM", 113, 124]]], ["Additionally, imposing social distancing including restriction to rooms is almost impossible to enforce among those with dementia.", [["dementia", "DISEASE", 121, 129], ["dementia", "PROBLEM", 121, 129]]], ["Notably, in the UK, the government released new guidance on Deprivation of Liberty safeguards that may be implemented to protect persons with dementia whose behavior (i.e. wandering) is putting themselves at risk of contracting COVID-19.Long-term care facilities (nursing or care homes)Around the world, solutions to these isolating measures have been to find alternative modes of communication.", [["dementia", "DISEASE", 142, 150], ["COVID-19", "CHEMICAL", 228, 236], ["persons", "ORGANISM", 129, 136], ["persons", "SPECIES", 129, 136], ["Deprivation of Liberty safeguards", "TREATMENT", 60, 93], ["dementia", "PROBLEM", 142, 150], ["contracting COVID", "TEST", 216, 233], ["these isolating measures", "TREATMENT", 317, 341]]], ["There has been an enormous increase in using technology for video conferencing in long-term care.", [["long-term care", "TREATMENT", 82, 96], ["enormous", "OBSERVATION_MODIFIER", 18, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["Open air concerts, at the front doors and windows of facilities, have been provided by spontaneous actions of volunteers.", [["volunteers", "ORGANISM", 110, 120], ["air concerts", "OBSERVATION", 5, 17]]], ["There are now also numerous technologies and multimedia options to allow remote attendance of funerals and memorials.Long-term care facilities (nursing or care homes)Professional caregivers equally require support.", [["multimedia options", "TREATMENT", 45, 63]]], ["Working in the COVID crisis is extremely burdensome and causes stress and anxiety, as does the moral distress associated with watching residents die who may not have otherwise died.", [["anxiety", "DISEASE", 74, 81], ["stress", "PROBLEM", 63, 69], ["anxiety", "PROBLEM", 74, 81], ["the moral distress", "PROBLEM", 91, 109]]], ["Where available, facility psychologists offer support if needed and human resource departments have provided support tools such as online yoga courses.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73]]], ["An additional focus of concern has been adequate provision of PPE for and testing of staff of long-term facilities, often neglected in the rush to mobilize and support hospital-based services.", [["PPE", "TREATMENT", 62, 65], ["adequate", "OBSERVATION_MODIFIER", 40, 48]]], ["In times of pandemics such as this, the weakest part of the health care system will be affected most.", [["pandemics", "PROBLEM", 12, 21], ["pandemics", "OBSERVATION", 12, 21]]], ["Notably in Belgium, a new Taskforce has been set up by the Flemish government (April 9, 2020), the innovative goals of which are to, among others, implement strategies to exchange personnel between different settings including hospitals and nursing homes.Hospice and in-home dyingHospice programs continue in the pandemic, but the provision of hospice care has drastically changed.", [["Hospice", "TREATMENT", 255, 262], ["Hospice programs", "TREATMENT", 280, 296], ["hospice care", "TREATMENT", 344, 356]]], ["In some countries such as the UK where hospice care is predominantly provided by the charity sector, there are great concerns about how the loss of fundraising revenue may lead to closure of clinical services at a time of greatest need.Hospice and in-home dyingIn the USA, the bulk of hospice care is provided in the home setting.", [["hospice care", "TREATMENT", 39, 51], ["fundraising revenue", "TREATMENT", 148, 167], ["hospice care", "TREATMENT", 285, 297]]], ["Community palliative care in the home is also available in Australia.", [["Community palliative care", "TREATMENT", 0, 25]]], ["We have previously advocated for the choice for those with dementia to remain at home, and die at home, or not (Sorinmade et al., 2018) .", [["dementia", "DISEASE", 59, 67], ["dementia", "PROBLEM", 59, 67]]], ["Notably, shifting hospice and palliative care resources to the community was a key finding in a recent review to inform practice in the pandemic (Etkind et al., 2020) .", [["shifting hospice", "TREATMENT", 9, 25], ["palliative care", "TREATMENT", 30, 45]]], ["In the USA, multidisciplinary hospice team members (physicians, nurses, nurses' aides, pharmacists, social workers, chaplains, integrative therapists and volunteers) visit the patient and family in the patient's place of residence.", [["volunteers", "ORGANISM", 154, 164], ["patient", "ORGANISM", 176, 183], ["patient", "ORGANISM", 202, 209], ["patient", "SPECIES", 176, 183], ["patient", "SPECIES", 202, 209]]], ["Recognizing increased risk for both patient/family and hospice staff, internal protocols for hospice agencies now follow guidelines issued by the US Centers for Health and Human Services (Centers for Medicare and Medicaid Services) to protect health care workers who operate in the home and community from COVID-19, including identifying at-risk individuals, screening procedures, and PPE.", [["patient", "ORGANISM", 36, 43], ["Human", "ORGANISM", 172, 177], ["patient", "SPECIES", 36, 43], ["Human", "SPECIES", 172, 177], ["screening procedures", "TEST", 359, 379]]], ["In the USA, statutory requirement for face-to-face encounters between patient and physicians to qualify for Medicare home health care has been waived and can now be conducted using telehealth (Centers for Medicare & Medicaid Services, 2020).Commentary 5Dutch high-care hospices, most of which are part of larger nursing home care organizations, keep on running.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77]]], ["These hospices or palliative care units within long-term care facilities are predominantly run by elder care physicians with 2-year additional training in palliative care.", [["palliative care units", "TREATMENT", 18, 39], ["palliative care", "TREATMENT", 155, 170]]], ["In Belgium, specialist palliative home care teams, largely funded by the government, are now providing most care via teleconsultations and are visiting patients less often at home or in the nursing homes.Commentary 5The impact of necessary social exclusion applies equally, if not more, to hospice care.", [["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160]]], ["While telehealth can allow patients and providers to remain connected, access to technology may not be feasible for patients and caregivers, and this may add to stress and anxiety, particularly for those who need guidance with medications and other care strategies to manage end-of-life symptoms at home.Commentary 5With regard to funding of such services, in the US Medicare pays for evaluation, management, and service provision by a physician or nurse practitioner, including payment for a number of nonface-to-face services such as care management services, remote patient monitoring services, and communication technology-based services.", [["anxiety", "DISEASE", 172, 179], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 116, 124], ["patient", "ORGANISM", 569, 576], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 116, 124], ["patient", "SPECIES", 569, 576], ["anxiety", "PROBLEM", 172, 179], ["medications", "TREATMENT", 227, 238], ["other care strategies", "TREATMENT", 243, 264], ["life symptoms", "PROBLEM", 282, 295], ["evaluation", "TEST", 385, 395], ["management", "TREATMENT", 397, 407]]], ["In Australia, new Medicare Benefits Schedule items have been created to facilitate telehealth provision.", [["new", "OBSERVATION_MODIFIER", 14, 17]]], ["Made available to general practitioners, psychiatrists and other medical practitioners, nurse practitioners, and allied health providers, they are particularly suited to provision of home-based, nursing home, and hospice care.", [["hospice care", "TREATMENT", 213, 225]]], ["Dutch health insurance companies and the Dutch Government have guaranteed that all additional services and staffing will be reimbursed, stating that none of the long-term care facilities nor hospitals have to face bankruptcy.Commentary 5Suggestions: How clinicians can provide quality care to our older patients in the COVID-19 pandemic 1.", [["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 303, 311]]], ["Follow guidelines to flatten the curve of the disease including handwashing, social distancing, appropriate use of PPE, and maintaining screening and testing protocols (World Health Organization, 2020).", [["the disease", "PROBLEM", 42, 53], ["PPE", "TREATMENT", 115, 118], ["testing protocols", "TEST", 150, 167], ["disease", "OBSERVATION", 46, 53]]], ["Embrace innovation such as telemedicine as an alternative to face-to-face visits to minimize disruption of care and services provided to patients, families, and caregivers.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["disruption of care", "TREATMENT", 93, 111]]], ["Back to the drawing board: use biopsychosocial approaches to manage psychiatric conditions such as anxiety, depression, cognitive decline, and alcohol misuse.", [["psychiatric", "DISEASE", 68, 79], ["anxiety", "DISEASE", 99, 106], ["depression", "DISEASE", 108, 118], ["cognitive decline", "DISEASE", 120, 137], ["alcohol misuse", "DISEASE", 143, 157], ["alcohol", "CHEMICAL", 143, 150], ["alcohol", "SIMPLE_CHEMICAL", 143, 150], ["biopsychosocial approaches", "TREATMENT", 31, 57], ["psychiatric conditions", "PROBLEM", 68, 90], ["anxiety", "PROBLEM", 99, 106], ["depression", "PROBLEM", 108, 118], ["cognitive decline", "PROBLEM", 120, 137]]], ["Change work practices to manage workforce demand and supply such as dividing work between physicians that provide care to patients with COVID, and alternate, providing respite and support to each other.", [["COVID", "DISEASE", 136, 141], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["Change work practices", "TREATMENT", 0, 21]]], ["Permanently adapt and refine procedures and treatment protocols based on new evidence and recommendations of professional organization; ensure organizational planning for maintenance of PPE and palliative care resources such as oxygen supplies, medication, and opioid driver pumps.", [["oxygen", "CHEMICAL", 228, 234], ["oxygen", "CHEMICAL", 228, 234], ["oxygen", "SIMPLE_CHEMICAL", 228, 234], ["procedures", "TREATMENT", 29, 39], ["treatment protocols", "TREATMENT", 44, 63], ["professional organization", "TREATMENT", 109, 134], ["organizational planning", "TREATMENT", 143, 166], ["maintenance of PPE", "TREATMENT", 171, 189], ["palliative care resources", "TREATMENT", 194, 219], ["oxygen supplies", "TREATMENT", 228, 243], ["medication", "TREATMENT", 245, 255], ["opioid driver pumps", "TREATMENT", 261, 280]]], ["Strengthen cooperation and transmural collaboration between primary/community, hospital, and long-term care settings.", [["long-term care settings", "TREATMENT", 93, 116]]], ["Be acutely conscious of the acute severing of social connectedness caused by COVID-19 at the most crucial time of end of life.", [["acutely conscious", "PROBLEM", 3, 20], ["acute", "OBSERVATION_MODIFIER", 28, 33]]], ["Facilitate continuing social support of patients at the end of life using remote technologies.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["remote technologies", "TREATMENT", 74, 93]]], ["Prepare psychosocial and spiritual support for after the current crisis, for health care staff and family members of people who died during this COVID-19 period.Conflicts of interestNone.", [["people", "ORGANISM", 117, 123], ["people", "SPECIES", 117, 123], ["spiritual support", "TREATMENT", 25, 42]]]], "PMC7419491": [["IntroductionNonspore-forming bacteria, when subjected to stress, lose their culturability leading to a transient dormancy state [described as viable but nonculturable (VBNC), nonculturable (NC), or active but nonculturable (ABNC)].", [["forming bacteria", "PROBLEM", 21, 37], ["stress", "PROBLEM", 57, 63], ["a transient dormancy state", "PROBLEM", 101, 127], ["bacteria", "OBSERVATION", 29, 37], ["active", "OBSERVATION_MODIFIER", 198, 204]]], ["Despite evidence on the revival of growth in these dormant cells, a number of basic and logical questions have been raised as to whether this nonculturability is a dormancy state of cell adaptation to stress or a stage preceding cell death, partly owing to the unpersuasive revitalization potential.", [["cells", "ANATOMY", 59, 64], ["cell", "ANATOMY", 182, 186], ["cell", "ANATOMY", 229, 233], ["death", "DISEASE", 234, 239], ["cells", "CELL", 59, 64], ["cell", "CELL", 182, 186], ["cell", "CELL", 229, 233], ["dormant cells", "CELL_TYPE", 51, 64], ["a stage preceding cell death", "PROBLEM", 211, 239], ["growth", "OBSERVATION_MODIFIER", 35, 41], ["dormant cells", "OBSERVATION", 51, 64]]], ["Studies also showed the molecular and functional dissimilarity of stressed (Chan et al. 1998), VBNC cells (Heim et al. 2002) from the NC state induced by \u201cstarvation\u201d, which was demonstrated using isolated NC cells (Desnues et al. 2003), leading to the suggestion that NC cells might have been formed as a result of stochastic deterioration.", [["VBNC cells", "ANATOMY", 95, 105], ["NC cells", "ANATOMY", 206, 214], ["NC cells", "ANATOMY", 269, 277], ["VBNC cells", "CELL", 95, 105], ["Heim et al. 2002", "CELL", 107, 123], ["NC cells", "CELL", 206, 214], ["NC cells", "CELL", 269, 277], ["VBNC cells", "CELL_LINE", 95, 105], ["NC cells", "CELL_LINE", 206, 214], ["NC cells", "CELL_LINE", 269, 277], ["Studies", "TEST", 0, 7], ["VBNC cells", "PROBLEM", 95, 105], ["isolated NC cells", "PROBLEM", 197, 214], ["NC cells", "PROBLEM", 269, 277], ["stochastic deterioration", "PROBLEM", 316, 340], ["NC cells", "OBSERVATION", 206, 214], ["stochastic", "OBSERVATION_MODIFIER", 316, 326], ["deterioration", "OBSERVATION", 327, 340]]], ["Nonetheless, while co-crystallization of DNA with the stress induced proteins was proposed as a generic defense strategy to environmental stress in Escherichia coli (Wolf et al. 1999), a resuscitation-promoting factor(s) (Rpf) was also identified in long-term stationary phase cultures of Micrococcus luteus (Mukamolova et al. 1998).IntroductionIt is well known that most of the nonspore-forming bacteria form dormant cells under stress.", [["cells", "ANATOMY", 418, 423], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["Escherichia coli", "ORGANISM", 148, 164], ["Rpf", "GENE_OR_GENE_PRODUCT", 222, 225], ["Micrococcus luteus", "CELL", 289, 307], ["bacteria", "CELL", 396, 404], ["cells", "CELL", 418, 423], ["stress induced proteins", "PROTEIN", 54, 77], ["resuscitation-promoting factor", "PROTEIN", 187, 217], ["Rpf", "PROTEIN", 222, 225], ["long-term stationary phase cultures", "CELL_LINE", 250, 285], ["dormant cells", "CELL_TYPE", 410, 423], ["Escherichia coli", "SPECIES", 148, 164], ["Micrococcus luteus", "SPECIES", 289, 307], ["Escherichia coli", "SPECIES", 148, 164], ["Micrococcus luteus", "SPECIES", 289, 307], ["DNA", "PROBLEM", 41, 44], ["the stress induced proteins", "PROBLEM", 50, 77], ["environmental stress in Escherichia coli", "PROBLEM", 124, 164], ["a resuscitation", "TREATMENT", 185, 200], ["Micrococcus luteus", "PROBLEM", 289, 307], ["Escherichia coli", "OBSERVATION", 148, 164], ["Micrococcus luteus", "OBSERVATION", 289, 307], ["dormant cells", "OBSERVATION", 410, 423]]], ["Combined with a proposition that a cell\u2019s adaptive response is nonspecific for stress factors (see review by K\u00fcltz 2005 and references cited therein), they could even be considered as a basic prototype to understand the bacterial remodeling potential to environmental stress.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["stress factors", "PROTEIN", 79, 93], ["stress factors", "PROBLEM", 79, 93]]], ["However, this necessitates prior demonstration of these dormant cells as a distinct state of adaptation.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["dormant cells", "CELL_TYPE", 56, 69], ["these dormant cells", "PROBLEM", 50, 69]]], ["In addition, interfering signals from other coexisting physiological types may impede further experimentation and interpretation.", [["interfering signals", "PROBLEM", 13, 32], ["interfering", "OBSERVATION", 13, 24]]], ["To date, there is no evidence on the revival of growth demonstrated on isolated dormant cells, although a number of empirical methods involving, for example, reduced levels of gene expression, morphological changes, and/or other related phenotypes were considered to demonstrate and/or detect these dormant cells in a wide variety of bacterial species (see review by Nystrom 2003 and references cited therein), thus leading to a significant progress in the field.", [["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 307, 312], ["cells", "CELL", 88, 93], ["cells", "CELL", 307, 312], ["isolated dormant cells", "CELL_TYPE", 71, 93], ["dormant cells", "CELL_TYPE", 299, 312], ["isolated dormant cells", "PROBLEM", 71, 93], ["empirical methods", "TEST", 116, 133], ["reduced levels of gene expression", "PROBLEM", 158, 191], ["morphological changes", "PROBLEM", 193, 214], ["other related phenotypes", "PROBLEM", 223, 247], ["these dormant cells", "PROBLEM", 293, 312], ["bacterial species", "PROBLEM", 334, 351], ["no evidence on", "UNCERTAINTY", 18, 32], ["dormant cells", "OBSERVATION", 80, 93], ["bacterial species", "OBSERVATION", 334, 351]]], ["Despite evidence on revival, other co-existing cell populations, detritus, and dissolved nutrients were shown to have potential implications on the revival process of these dormant cells.", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 181, 186], ["cell populations", "CELL", 47, 63], ["cells", "CELL", 181, 186], ["dormant cells", "CELL_TYPE", 173, 186], ["other co-existing cell populations", "PROBLEM", 29, 63], ["detritus", "PROBLEM", 65, 73], ["cell populations", "OBSERVATION", 47, 63], ["detritus", "OBSERVATION_MODIFIER", 65, 73], ["dormant cells", "OBSERVATION", 173, 186]]], ["Hence, in the past, studies proved challenging due to the lack of appropriate tools to differentially study these cells.IntroductionThe focus of the present study was to understand (1) whether the dormant cells formed in response to osmotic stress in Enterobacter sp. strain mcp11b, Klebsiella pneumonia strain mcp11d, and E. coli can be separated; (2) if separated, can they be revitalized (resuscitated and re-grown); (3) if revitalized, does the phenomenon occur in all three species; and (4) whether the process of revitalization is abrupt, arbitrary, or follows a definite pattern, which would comprehensively reveal whether this unique physiological state in these nonspore-forming bacteria formed in response to osmotic stress is a dormant state of adaptation to circumvent stress.Bacterial strains ::: Materials and methodsBacterial strains include Enterobacter sp. strain mcp11b and K. pneumonia strain mcp11d, which were isolated by screening polluted waters using media for Fecal Coliforms (m-FC) agar (BD, Maryland, USA) void of rosolic acid.", [["cells", "ANATOMY", 114, 119], ["cells", "ANATOMY", 205, 210], ["mcp11b", "CHEMICAL", 275, 281], ["Klebsiella pneumonia", "DISEASE", 283, 303], ["rosolic acid", "CHEMICAL", 1041, 1053], ["rosolic acid", "CHEMICAL", 1041, 1053], ["cells", "CELL", 114, 119], ["cells", "CELL", 205, 210], ["Enterobacter sp", "ORGANISM", 251, 266], ["mcp11b", "GENE_OR_GENE_PRODUCT", 275, 281], ["Klebsiella pneumonia", "ORGANISM", 283, 303], ["strain", "ORGANISM", 304, 310], ["mcp11d", "ORGANISM", 311, 317], ["E. coli", "ORGANISM", 323, 330], ["Enterobacter sp", "ORGANISM", 857, 872], ["mcp11b", "GENE_OR_GENE_PRODUCT", 881, 887], ["K. pneumonia", "ORGANISM", 892, 904], ["strain", "ORGANISM", 905, 911], ["mcp11d", "ORGANISM", 912, 918], ["rosolic acid", "SIMPLE_CHEMICAL", 1041, 1053], ["dormant cells", "CELL_TYPE", 197, 210], ["Klebsiella pneumonia", "SPECIES", 283, 303], ["E. coli", "SPECIES", 323, 330], ["K. pneumonia", "SPECIES", 892, 904], ["Klebsiella pneumonia strain mcp11d", "SPECIES", 283, 317], ["E. coli", "SPECIES", 323, 330], ["K. pneumonia", "SPECIES", 892, 904], ["studies", "TEST", 20, 27], ["the present study", "TEST", 145, 162], ["the dormant cells", "PROBLEM", 193, 210], ["osmotic stress in Enterobacter sp", "PROBLEM", 233, 266], ["strain mcp", "TEST", 268, 278], ["Klebsiella pneumonia strain mcp11d", "PROBLEM", 283, 317], ["E. coli", "PROBLEM", 323, 330], ["the phenomenon", "PROBLEM", 445, 459], ["bacteria", "PROBLEM", 688, 696], ["osmotic stress", "PROBLEM", 719, 733], ["Materials", "TREATMENT", 810, 819], ["Bacterial strains", "PROBLEM", 831, 848], ["Enterobacter sp", "PROBLEM", 857, 872], ["strain mcp11b", "TEST", 874, 887], ["pneumonia strain mcp11d", "PROBLEM", 895, 918], ["Fecal Coliforms", "TEST", 985, 1000], ["rosolic acid", "TREATMENT", 1041, 1053], ["osmotic stress", "OBSERVATION", 233, 247], ["Enterobacter", "OBSERVATION", 251, 263], ["Klebsiella", "OBSERVATION_MODIFIER", 283, 293], ["pneumonia", "OBSERVATION", 294, 303], ["E. coli", "OBSERVATION_MODIFIER", 323, 330], ["abrupt", "OBSERVATION_MODIFIER", 537, 543], ["osmotic stress", "OBSERVATION", 719, 733], ["strains", "OBSERVATION", 798, 805], ["pneumonia", "OBSERVATION", 895, 904], ["Fecal", "ANATOMY", 985, 990]]], ["Polymerase chain reaction-amplified products of chromosomal DNA of isolates mcp11b and mcp11d were sequenced using the ABI Prism 3100 DNA sequencer and ABI Prism BigDye Terminator cycle sequencing ready-reaction kit.", [["chromosomal", "ANATOMY", 48, 59], ["chromosomal", "CELLULAR_COMPONENT", 48, 59], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["mcp11b", "GENE_OR_GENE_PRODUCT", 76, 82], ["mcp11d", "GENE_OR_GENE_PRODUCT", 87, 93], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["chromosomal DNA", "DNA", 48, 63], ["isolates mcp11b", "DNA", 67, 82], ["mcp11d", "DNA", 87, 93], ["Polymerase chain reaction", "PROBLEM", 0, 25], ["chromosomal DNA of isolates", "TREATMENT", 48, 75], ["mcp11d", "TREATMENT", 87, 93], ["the ABI Prism", "TEST", 115, 128], ["DNA sequencer", "TEST", 134, 147], ["ABI Prism BigDye Terminator cycle sequencing", "TREATMENT", 152, 196]]], ["Primers used to amplify 16s rRNA gene include 27F, 530F, 926F, 519R, 907R, and 1492R (Lane 1991).", [["16s rRNA gene", "DNA", 24, 37]]], ["Sequence similarity search was performed using basic local alignment search tool (BLAST; http://www.ncbi.nlm.nih.gov/BLAST/).", [["Sequence similarity search", "TEST", 0, 26], ["basic local alignment search tool", "TEST", 47, 80]]], ["The 16s rRNA gene sequences of mcp11b and mcp11d were submitted to the GenBank (http://www.ncbi.nlm.nih.gov/), and they were assigned accession numbers of EF419181 and EF419182 and identified as Enterobacter sp. and K. pneumonia.", [["pneumonia", "DISEASE", 219, 228], ["mcp11b", "GENE_OR_GENE_PRODUCT", 31, 37], ["mcp11d", "GENE_OR_GENE_PRODUCT", 42, 48], ["Enterobacter sp", "ORGANISM", 195, 210], ["16s rRNA gene sequences", "DNA", 4, 27], ["mcp11b", "DNA", 31, 37], ["mcp11d", "DNA", 42, 48], ["K. pneumonia", "SPECIES", 216, 228], ["The 16s rRNA gene sequences", "TEST", 0, 27], ["mcp11b", "TEST", 31, 37], ["EF419181", "TEST", 155, 163], ["EF419182", "TEST", 168, 176], ["Enterobacter sp", "PROBLEM", 195, 210], ["K. pneumonia", "PROBLEM", 216, 228], ["Enterobacter", "OBSERVATION", 195, 207], ["pneumonia", "OBSERVATION", 219, 228]]], ["These isolates were also deposited in publicly accessible culture collections namely NCIMB (Aberdeen, Scotland) and NCCB (The Netherlands Culture Collection of Bacteria, Utrecht, Netherlands).", [["NCCB", "TREATMENT", 116, 120], ["The Netherlands Culture", "TEST", 122, 145], ["Bacteria", "PROBLEM", 160, 168]]], ["They were assigned accession numbers, NCIMB 14479 and NCCB 100231 and NCIMB 14480 and NCCB 100232 for Enterobacter sp. mcp11b and K. pneumonia strain mcp11d, respectively.", [["NCIMB 14479", "CHEMICAL", 38, 49], ["NCCB 100231", "CHEMICAL", 54, 65], ["NCIMB 14480", "CHEMICAL", 70, 81], ["NCCB 100232", "CHEMICAL", 86, 97], ["NCIMB 14479", "CELL", 38, 49], ["NCCB 100231", "CELL", 54, 65], ["NCIMB 14480", "CELL", 70, 81], ["NCCB 100232", "CELL", 86, 97], ["Enterobacter sp", "ORGANISM", 102, 117], ["mcp11b", "GENE_OR_GENE_PRODUCT", 119, 125], ["K. pneumonia", "ORGANISM", 130, 142], ["mcp11d", "GENE_OR_GENE_PRODUCT", 150, 156], ["mcp11b", "PROTEIN", 119, 125], ["K. pneumonia", "SPECIES", 130, 142], ["K. pneumonia strain mcp11d", "SPECIES", 130, 156], ["NCIMB", "TEST", 38, 43], ["NCCB", "TEST", 54, 58], ["NCIMB", "TEST", 70, 75], ["NCCB", "TEST", 86, 90], ["Enterobacter sp", "PROBLEM", 102, 117], ["mcp11b", "TEST", 119, 125], ["K. pneumonia strain mcp11d", "PROBLEM", 130, 156], ["pneumonia", "OBSERVATION", 133, 142]]], ["The strain of E. coli was obtained from American Type Culture Collection (ATCC 700891).Microcosms and osmotic stress ::: Materials and methodsWaters used in the microcosm experiments were obtained from the Marina Bay in Singapore.", [["E. coli", "ORGANISM", 14, 21], ["ATCC 700891", "CELL", 74, 85], ["E. coli", "SPECIES", 14, 21], ["E. coli", "SPECIES", 14, 21], ["American Type Culture Collection (ATCC 700891)", "SPECIES", 40, 86], ["E. coli", "PROBLEM", 14, 21], ["methodsWaters", "TREATMENT", 135, 148], ["E. coli", "OBSERVATION", 14, 21], ["osmotic stress", "OBSERVATION", 102, 116]]], ["Waters were collected in pre-sterilized containers and filtered through membrane filters with pore size of 0.45 \u03bcm (Gelman Sciences, Ann Arbor, MI, USA) and sterilized by autoclaving.", [["membrane", "ANATOMY", 72, 80], ["pore", "ANATOMY", 94, 98], ["pre-sterilized containers", "TREATMENT", 25, 50], ["membrane filters", "TREATMENT", 72, 88], ["membrane filters", "OBSERVATION", 72, 88], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["Pre-washed cells grown in Luria\u2013Bertani (LB) of Enterobacter sp. strain mcp11b, K. pneumonia strain mcp11d, and E. coli were inoculated individually to 0.5-L pre-sterilized bottles containing sterile microcosm waters to a final cell density of around 108 cells mL\u22121 to induce saline stress in static conditions at 30\u00b0C. The salinity of the waters used in the microcosms was 30 ppt.", [["cells", "ANATOMY", 11, 16], ["cell", "ANATOMY", 228, 232], ["cells", "ANATOMY", 255, 260], ["K. pneumonia", "DISEASE", 80, 92], ["cells", "CELL", 11, 16], ["Luria\u2013Bertani", "ORGANISM", 26, 39], ["Enterobacter sp", "ORGANISM", 48, 63], ["mcp11b", "GENE_OR_GENE_PRODUCT", 72, 78], ["K. pneumonia strain", "ORGANISM", 80, 99], ["mcp11d", "ORGANISM", 100, 106], ["E. coli", "ORGANISM", 112, 119], ["cell", "CELL", 228, 232], ["saline", "SIMPLE_CHEMICAL", 276, 282], ["Pre-washed cells", "CELL_LINE", 0, 16], ["K. pneumonia", "SPECIES", 80, 92], ["E. coli", "SPECIES", 112, 119], ["K. pneumonia strain mcp11d", "SPECIES", 80, 106], ["E. coli", "SPECIES", 112, 119], ["Enterobacter sp", "PROBLEM", 48, 63], ["strain mcp11b", "TEST", 65, 78], ["K. pneumonia strain mcp11d", "PROBLEM", 80, 106], ["E. coli", "PROBLEM", 112, 119], ["sterile microcosm waters", "TREATMENT", 192, 216], ["saline stress in static conditions", "PROBLEM", 276, 310], ["Enterobacter", "OBSERVATION", 48, 60], ["pneumonia", "OBSERVATION", 83, 92], ["final cell density", "OBSERVATION", 222, 240]]], ["The optimal salinity that is isotonic to nonhalophilic bacteria is around 8 ppt (salinity of a standard physiological saline).", [["saline", "SIMPLE_CHEMICAL", 118, 124], ["isotonic to nonhalophilic bacteria", "PROBLEM", 29, 63], ["a standard physiological saline", "TREATMENT", 93, 124]]], ["Therefore, nonhalophilic bacterium, namely, Enterobacter sp., K. pneumonia, and E. coli, upon introduction in to natural saline waters at 30 ppt, will experience 3.75 times higher salinity resulting in osmotic stress.", [["K. pneumonia", "DISEASE", 62, 74], ["Enterobacter sp.", "ORGANISM", 44, 60], ["K. pneumonia", "ORGANISM", 62, 74], ["E. coli", "ORGANISM", 80, 87], ["Enterobacter sp.", "SPECIES", 44, 60], ["K. pneumonia", "SPECIES", 62, 74], ["E. coli", "SPECIES", 80, 87], ["Enterobacter sp.", "SPECIES", 44, 60], ["K. pneumonia", "SPECIES", 62, 74], ["E. coli", "SPECIES", 80, 87], ["nonhalophilic bacterium", "PROBLEM", 11, 34], ["Enterobacter sp.", "PROBLEM", 44, 60], ["K. pneumonia", "PROBLEM", 62, 74], ["E. coli", "PROBLEM", 80, 87], ["natural saline waters", "TREATMENT", 113, 134], ["osmotic stress", "PROBLEM", 202, 216], ["pneumonia", "OBSERVATION", 65, 74], ["E. coli", "OBSERVATION", 80, 87], ["osmotic stress", "OBSERVATION", 202, 216]]], ["We then used the flow cytometric procedure (Sachidanandham et al. 2005) to measure rigid viable cells (RVC) as an indicator of the presence of dormant cells.Flow cytometric analysis and fluorescence-activated cell sorting ::: Materials and methodsTo determine the viability of the culture, cells were stained using the LIVE/DEAD BacLight kit (Molecular Probes, Eugene/Portland, OR, USA) using the procedure described previously (Sachidanandham et al. 2005).", [["cells", "ANATOMY", 96, 101], ["RVC", "ANATOMY", 103, 106], ["cells", "ANATOMY", 151, 156], ["cell", "ANATOMY", 209, 213], ["cells", "ANATOMY", 290, 295], ["cells", "CELL", 96, 101], ["RVC", "CELL", 103, 106], ["cells", "CELL", 151, 156], ["cell", "CELL", 209, 213], ["cells", "CELL", 290, 295], ["RVC", "CELL_TYPE", 103, 106], ["dormant cells", "CELL_TYPE", 143, 156], ["DEAD", "PROTEIN", 324, 328], ["the flow cytometric procedure", "TREATMENT", 13, 42], ["rigid viable cells", "PROBLEM", 83, 101], ["dormant cells", "PROBLEM", 143, 156], ["Flow cytometric analysis", "TEST", 157, 181], ["fluorescence", "TEST", 186, 198], ["the culture", "TEST", 277, 288], ["the procedure", "TREATMENT", 393, 406], ["RVC", "ANATOMY", 103, 106], ["dormant cells", "OBSERVATION", 143, 156]]], ["In this previous study, using E. coli and an environmental isolate (H03N1), we had shown that LIVE/DEAD BacLight kit can differentiate and precisely enumerate live cells in the liquid nitrogen treatment processes in hyper-saline microcosms.", [["cells", "ANATOMY", 164, 169], ["nitrogen", "CHEMICAL", 184, 192], ["nitrogen", "CHEMICAL", 184, 192], ["E. coli", "ORGANISM", 30, 37], ["cells", "CELL", 164, 169], ["DEAD", "PROTEIN", 99, 103], ["live cells", "CELL_TYPE", 159, 169], ["E. coli", "SPECIES", 30, 37], ["E. coli", "SPECIES", 30, 37], ["H03N1", "SPECIES", 68, 73], ["this previous study", "TEST", 3, 22], ["E. coli", "PROBLEM", 30, 37], ["the liquid nitrogen treatment processes", "TREATMENT", 173, 212], ["hyper-saline microcosms", "TREATMENT", 216, 239]]], ["Several studies have successfully used LIVE/DEAD BacLight kit for the measurement of bacterial viability in environmental isolates (e.g., Haznedaroglua et al. 2008; Portaels et al. 2008).", [["DEAD", "PROTEIN", 44, 48], ["Several studies", "TEST", 0, 15], ["DEAD BacLight kit", "TREATMENT", 44, 61], ["bacterial viability in environmental isolates", "PROBLEM", 85, 130], ["bacterial viability", "OBSERVATION", 85, 104]]], ["These observations, together with our earlier work conducted on osmotically stressed cultures of E. coli and coliform environmental isolate (H03N1) (Sachidanandham et al. 2005), forecasted that no abnormalities in the staining of LIVE/DEAD BacLight kit in the viability measurements were observed (also see Fig. 5, live and dead cell count of Enterobacter sp. strain mcp11b assayed by BacLight).", [["cell", "ANATOMY", 329, 333], ["E. coli", "ORGANISM", 97, 104], ["LIVE", "GENE_OR_GENE_PRODUCT", 230, 234], ["cell", "CELL", 329, 333], ["Enterobacter sp", "ORGANISM", 343, 358], ["LIVE", "PROTEIN", 230, 234], ["DEAD BacLight", "PROTEIN", 235, 248], ["mcp11b", "PROTEIN", 367, 373], ["BacLight", "PROTEIN", 385, 393], ["E. coli", "SPECIES", 97, 104], ["E. coli", "SPECIES", 97, 104], ["osmotically stressed cultures", "TEST", 64, 93], ["E. coli", "PROBLEM", 97, 104], ["coliform environmental isolate", "PROBLEM", 109, 139], ["abnormalities", "PROBLEM", 197, 210], ["the viability measurements", "TEST", 256, 282], ["dead cell count", "TEST", 324, 339], ["Enterobacter sp", "PROBLEM", 343, 358], ["E. coli", "OBSERVATION_MODIFIER", 97, 104], ["Enterobacter sp", "OBSERVATION", 343, 358]]], ["This kit was also used to estimate viable cell count of bacteria directly on various types of environmental samples successfully (see review by Trevors 2003 and references therein).", [["cell", "ANATOMY", 42, 46], ["samples", "ANATOMY", 108, 115], ["cell", "CELL", 42, 46], ["This kit", "TEST", 0, 8], ["bacteria", "PROBLEM", 56, 64], ["viable cell count", "OBSERVATION", 35, 52]]], ["It should be noted that freshly reconstituted reagents need to be used.", [["freshly reconstituted reagents", "TREATMENT", 24, 54]]], ["Storing of reconstituted reagents and reusing them will provide inaccurate enumeration and distribution patterns.Flow cytometric analysis and fluorescence-activated cell sorting ::: Materials and methodsLIVE/DEAD BacLight reagents were reconstituted in physiological saline solution \u201cas and when needed\u201d.", [["cell", "ANATOMY", 165, 169], ["cell", "CELL", 165, 169], ["reconstituted reagents", "TREATMENT", 11, 33], ["Flow cytometric analysis", "TEST", 113, 137], ["fluorescence", "TEST", 142, 154], ["Materials", "TREATMENT", 182, 191], ["methodsLIVE/DEAD BacLight reagents", "TREATMENT", 196, 230], ["physiological saline solution", "TREATMENT", 253, 282]]], ["Flow cytometric analysis and fluorescence-activated cell sorting were carried out using a FACSCalibur (Becton Dickinson, San Jose, CA, USA), which is equipped with four-color multi-parameter analytical and data acquisition capabilities.", [["cell", "ANATOMY", 52, 56], ["cell", "CELL", 52, 56], ["Flow cytometric analysis", "TEST", 0, 24], ["fluorescence", "TEST", 29, 41], ["activated cell sorting", "TEST", 42, 64], ["data acquisition capabilities", "TEST", 206, 235]]], ["It is equipped with a 15-mW argon ion laser, which produces blue light of 488 nm.", [["a 15-mW argon ion laser", "TREATMENT", 20, 43], ["488 nm", "OBSERVATION_MODIFIER", 74, 80]]], ["The following optical settings were used: side scatter (SS), 488 nm/10 band pass (bp); forward scatter (FS), 488 nm/10 bp; FL1, 530 nm/30 bp (green fluorescence); and FL3, 650 nm long pass (red fluorescence).", [["FL1", "DNA", 123, 126], ["FL3", "PROTEIN", 167, 170], ["band pass", "TEST", 71, 80], ["bp", "TEST", 82, 84], ["FS", "TEST", 104, 106], ["nm", "TEST", 113, 115], ["bp", "TEST", 119, 121], ["FL1", "TEST", 123, 126], ["nm", "TEST", 132, 134], ["bp", "TEST", 138, 140], ["green fluorescence", "TEST", 142, 160], ["FL3", "TEST", 167, 170], ["red fluorescence", "TEST", 190, 206]]], ["The argon ion laser can excite propidium iodide (PI) and SYTO 9 in the analysis of BacLight-stained cells.", [["cells", "ANATOMY", 100, 105], ["propidium iodide", "CHEMICAL", 31, 47], ["SYTO 9", "CHEMICAL", 57, 63], ["argon", "CHEMICAL", 4, 9], ["propidium iodide", "CHEMICAL", 31, 47], ["SYTO 9", "CHEMICAL", 57, 63], ["propidium iodide", "SIMPLE_CHEMICAL", 31, 47], ["PI", "SIMPLE_CHEMICAL", 49, 51], ["BacLight", "SIMPLE_CHEMICAL", 83, 91], ["cells", "CELL", 100, 105], ["BacLight-stained cells", "CELL_LINE", 83, 105], ["The argon ion laser", "TREATMENT", 0, 19], ["SYTO", "TEST", 57, 61], ["BacLight-stained cells", "TREATMENT", 83, 105], ["stained cells", "OBSERVATION", 92, 105]]], ["Cells are hydrodynamically focused in the flow cytometer (FCM) to a single file flow through, followed by laser excitation at 488 nm.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the flow cytometer", "TEST", 38, 56], ["hydrodynamically", "OBSERVATION_MODIFIER", 10, 26], ["flow cytometer", "OBSERVATION", 42, 56]]], ["Within the flow cell of the FCM, a relatively slow-moving sample stream is injected into a rapidly moving sheath (microcosm water) stream.", [["flow cell", "ANATOMY", 11, 20], ["cell", "CELL", 16, 20], ["sheath", "TISSUE", 106, 112], ["a relatively slow-moving sample stream", "PROBLEM", 33, 71], ["a rapidly moving sheath (microcosm water) stream", "TREATMENT", 89, 137], ["flow cell", "OBSERVATION", 11, 20], ["relatively", "OBSERVATION_MODIFIER", 35, 45], ["slow", "OBSERVATION_MODIFIER", 46, 50]]], ["Sheath is a term used to describe a liquid that is used to align the cells of interest in a single-file flow through so that they can be interrogated with appropriate laser to study the cell properties (Shapiro 2003).", [["cells", "ANATOMY", 69, 74], ["cell", "ANATOMY", 186, 190], ["cells", "CELL", 69, 74], ["cell", "CELL", 186, 190], ["Sheath", "TREATMENT", 0, 6], ["a liquid", "TREATMENT", 34, 42]]], ["The sample stream is drawn rapidly from the injection point into a narrow fast-moving stream within the sheath stream.", [["sheath stream", "ANATOMY", 104, 117], ["sheath stream", "MULTI-TISSUE_STRUCTURE", 104, 117], ["The sample stream", "TEST", 0, 17], ["narrow", "OBSERVATION_MODIFIER", 67, 73], ["sheath", "ANATOMY_MODIFIER", 104, 110]]], ["Controlling the velocity of these streams, the cells within the center stream can be aligned to single file and interrogated by the laser.", [["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["velocity", "OBSERVATION_MODIFIER", 16, 24], ["streams", "OBSERVATION_MODIFIER", 34, 41]]], ["The emitted fluorescence is captured by photomultiplier tubes (PMT).Flow cytometric analysis and fluorescence-activated cell sorting ::: Materials and methodsLIVE/DEAD BacLight kit differentiates cells with intact cell membranes stained by SYTO 9 (i.e., scored as live) from those with damaged membranes stained by both SYTO 9 and PI (i.e., scored as dead).", [["cell", "ANATOMY", 120, 124], ["cells", "ANATOMY", 196, 201], ["cell membranes", "ANATOMY", 214, 228], ["membranes", "ANATOMY", 294, 303], ["SYTO 9", "CHEMICAL", 240, 246], ["cell", "CELL", 120, 124], ["cells", "CELL", 196, 201], ["cell membranes", "CELLULAR_COMPONENT", 214, 228], ["membranes", "CELLULAR_COMPONENT", 294, 303], ["DEAD", "PROTEIN", 163, 167], ["SYTO 9", "PROTEIN", 240, 246], ["SYTO 9", "PROTEIN", 320, 326], ["photomultiplier tubes (PMT", "TREATMENT", 40, 66], ["Flow cytometric analysis", "TEST", 68, 92], ["fluorescence", "TEST", 97, 109], ["intact cell membranes", "PROBLEM", 207, 228], ["SYTO", "TEST", 240, 244], ["damaged membranes", "PROBLEM", 286, 303], ["photomultiplier tubes", "OBSERVATION", 40, 61], ["intact cell membranes", "OBSERVATION", 207, 228]]], ["PI quenches the SYTO 9 fluorescence in dead cells.", [["cells", "ANATOMY", 44, 49], ["SYTO 9", "CHEMICAL", 16, 22], ["SYTO 9", "CHEMICAL", 16, 22], ["PI", "SIMPLE_CHEMICAL", 0, 2], ["cells", "CELL", 44, 49], ["SYTO 9", "PROTEIN", 16, 22], ["dead cells", "CELL_TYPE", 39, 49], ["the SYTO", "TEST", 12, 20], ["dead cells", "OBSERVATION", 39, 49]]], ["Apart from parameters such as SS and FS, the green emission with respect to SYTO 9 binding and red emission with respect to PI binding were captured in FL1 and FL3 PMTs, respectively.", [["SYTO 9", "CHEMICAL", 76, 82], ["SYTO 9", "CHEMICAL", 76, 82], ["PI", "SIMPLE_CHEMICAL", 124, 126], ["FL1", "SIMPLE_CHEMICAL", 152, 155], ["SYTO 9", "PROTEIN", 76, 82], ["FL1", "CELL_LINE", 152, 155], ["FS", "TEST", 37, 39], ["SYTO", "TEST", 76, 80], ["red emission", "TEST", 95, 107], ["PI binding", "PROBLEM", 124, 134], ["PI binding", "OBSERVATION", 124, 134]]], ["The instrument design of FACSCalibur ensures that sorting occurs in a completely enclosed, aerosol-free environment for enhanced bio-safety, which has been extensively used for fluorescence-activated cell sorting (FACS) in the past.", [["cell", "ANATOMY", 200, 204], ["cell", "CELL", 200, 204]]], ["To achieve optimal data rates (150 to 500 cells/s) for cell sorting, samples were diluted using microcosm waters.", [["cells", "ANATOMY", 42, 47], ["cell", "ANATOMY", 55, 59], ["samples", "ANATOMY", 69, 76], ["cells", "CELL", 42, 47], ["cell", "CELL", 55, 59], ["optimal data rates", "TEST", 11, 29], ["cell sorting", "TEST", 55, 67]]], ["Sorting was always performed in \u201csingle-cell\u201d sort mode using the same water as sheath used in the preparation of microcosm cultures.", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["microcosm cultures", "CELL_LINE", 114, 132], ["the same water as sheath", "TREATMENT", 62, 86], ["microcosm cultures", "TEST", 114, 132]]], ["\u201cGating\u201d is a procedure in which specific cell populations can be enumerated in the flow cytometric analysis and/or separated in the FACS procedures.", [["cell", "ANATOMY", 42, 46], ["cell populations", "CELL", 42, 58], ["a procedure", "TREATMENT", 12, 23], ["specific cell populations", "TREATMENT", 33, 58], ["the flow cytometric analysis", "TEST", 80, 108]]], ["Target live-cell populations were gated in the software for sorting.", [["cell", "ANATOMY", 12, 16], ["live-cell populations", "CELL", 7, 28], ["Target live-cell populations", "CELL_LINE", 0, 28]]], ["Fluorescence microspheres of 2 \u03bcm in size (Polyscience, USA) were used both as size and volumetric calibration standards.", [["Fluorescence microspheres", "TEST", 0, 25], ["size", "OBSERVATION_MODIFIER", 37, 41], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["Data acquisition was carried out using the software CELLQuest (Becton Dickinson), and the data analysis was performed in WinMDI-2.8 (http://facs.scripps.edu/software.html).", [["Data acquisition", "TEST", 0, 16], ["the data analysis", "TEST", 86, 103], ["WinMDI", "TEST", 121, 127]]], ["Total viable cell count (TVC) was assayed by directly staining the microcosm cultures using LIVE/DEAD kit and RVC (cells that retain viability after liquid nitrogen treatment) were assayed after selective inactivation of culturable cells (CC; Sachidanandham et al. 2005).", [["cell", "ANATOMY", 13, 17], ["TVC", "ANATOMY", 25, 28], ["RVC", "ANATOMY", 110, 113], ["cells", "ANATOMY", 115, 120], ["cells", "ANATOMY", 232, 237], ["nitrogen", "CHEMICAL", 156, 164], ["CC", "CHEMICAL", 239, 241], ["nitrogen", "CHEMICAL", 156, 164], ["cell", "CELL", 13, 17], ["RVC", "CELL", 110, 113], ["cells", "CELL", 115, 120], ["cells", "CELL", 232, 237], ["DEAD kit", "PROTEIN", 97, 105], ["RVC", "CELL_TYPE", 110, 113], ["culturable cells", "CELL_TYPE", 221, 237], ["Total viable cell count", "TEST", 0, 23], ["TVC", "TEST", 25, 28], ["the microcosm cultures", "TEST", 63, 85], ["DEAD kit", "TEST", 97, 105], ["RVC (cells", "PROBLEM", 110, 120], ["liquid nitrogen treatment", "TREATMENT", 149, 174], ["culturable cells", "PROBLEM", 221, 237], ["cell count", "OBSERVATION", 13, 23], ["RVC", "ANATOMY", 110, 113]]], ["Bacterial cells stained with BacLight were spotted onto a slide and examined using an epifluorescence microscope with thousand times magnification (BX40, Olympus, Japan).", [["Bacterial cells", "ANATOMY", 0, 15], ["Bacterial cells", "CELL", 0, 15], ["BacLight", "SIMPLE_CHEMICAL", 29, 37], ["BacLight", "PROTEIN", 29, 37], ["Bacterial cells", "PROBLEM", 0, 15], ["an epifluorescence microscope", "TEST", 83, 112], ["Olympus", "TREATMENT", 154, 161], ["cells stained", "OBSERVATION", 10, 23]]], ["Cells were viewed under blue light excitation (488 nm) using the U-25ND6 and U-25ND25 filters (Olympus, Japan).Revitalization of dormant cells ::: Materials and methodsSix hundred to 650 ml of sorted cells in the sheath was aliquoted to equal volumes in sterile tubes and centrifuged at 3,250 \u00d7 g (4,000 rpm) for 15 min.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 200, 205], ["sheath", "ANATOMY", 213, 219], ["Cells", "CELL", 0, 5], ["cells", "CELL", 137, 142], ["cells", "CELL", 200, 205], ["sheath", "TISSUE", 213, 219], ["dormant cells", "CELL_TYPE", 129, 142], ["sorted cells", "CELL_TYPE", 193, 205], ["the U", "TEST", 61, 66], ["U-25ND25 filters", "TREATMENT", 77, 93], ["Olympus", "TREATMENT", 95, 102], ["methods", "TREATMENT", 161, 168], ["the sheath", "TREATMENT", 209, 219], ["sterile tubes", "TREATMENT", 254, 267], ["dormant cells", "OBSERVATION", 129, 142], ["sheath", "ANATOMY", 213, 219], ["tubes", "OBSERVATION", 262, 267]]], ["Baseline revitalization and/or sort \u201ccontaminants of culturable cells\u201d (contaminant in the sort process refers to culturable cells of the same strain), if any, were studied by instantaneously plating an equal volumetric fraction of sorted cells on LB agar using the sterile sheath water as diluent.", [["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 239, 244], ["cells", "CELL", 64, 69], ["cells", "CELL", 125, 130], ["cells", "CELL", 239, 244], ["culturable cells", "CELL_TYPE", 53, 69], ["culturable cells", "CELL_TYPE", 114, 130], ["sorted cells", "CELL_LINE", 232, 244], ["Baseline revitalization", "PROBLEM", 0, 23], ["culturable cells", "PROBLEM", 53, 69], ["LB agar", "TREATMENT", 248, 255], ["the sterile sheath water", "TREATMENT", 262, 286], ["sorted cells", "OBSERVATION", 232, 244]]], ["Incubation up to 24 h at 37\u00b0C did not show any visible colonies in all three strains; hence, the incubation time was prolonged up to 48 h, and the colonies were counted.", [["colonies", "ANATOMY", 55, 63], ["colonies", "ANATOMY", 147, 155], ["any visible colonies", "PROBLEM", 43, 63]]], ["Further incubation until the completion of the entire revitalization assay for a given sorting did not show any variation in the count.", [["Further incubation", "TREATMENT", 0, 18], ["the entire revitalization assay", "TEST", 43, 74], ["the count", "TEST", 125, 134]]], ["Colonies in these plates, if any, could be a result of contaminating culturable cells (CCSC) in the sorting or weak resuscitation in the sheath, as the sorting process usually takes 3 to 4 h.", [["Colonies", "ANATOMY", 0, 8], ["cells", "ANATOMY", 80, 85], ["CCSC", "ANATOMY", 87, 91], ["sheath", "ANATOMY", 137, 143], ["cells", "CELL", 80, 85], ["CCSC", "CELL", 87, 91], ["sheath", "TISSUE", 137, 143], ["culturable cells", "CELL_TYPE", 69, 85], ["CCSC", "CELL_TYPE", 87, 91], ["Colonies in these plates", "TEST", 0, 24], ["contaminating culturable cells", "PROBLEM", 55, 85], ["weak resuscitation", "TREATMENT", 111, 129], ["the sheath", "TREATMENT", 133, 143], ["plates", "OBSERVATION_MODIFIER", 18, 24], ["weak", "OBSERVATION_MODIFIER", 111, 115], ["resuscitation", "OBSERVATION", 116, 129], ["sheath", "ANATOMY", 137, 143]]], ["Thus, these were taken as CCSC.", [["CCSC", "CANCER", 26, 30]]], ["In parallel, a portion of the samples collected from the microcosm cultures for sorting was also plated (before liquid nitrogen treatment) using the identical procedure as that of the assay of sort contaminants, and this resulted in profuse colonies of CC.", [["samples", "ANATOMY", 30, 37], ["colonies", "ANATOMY", 241, 249], ["CC", "CHEMICAL", 253, 255], ["nitrogen", "CHEMICAL", 119, 127], ["the samples", "TEST", 26, 37], ["the microcosm cultures", "TEST", 53, 75], ["liquid nitrogen treatment", "TREATMENT", 112, 137], ["the identical procedure", "TREATMENT", 145, 168], ["the assay", "TEST", 180, 189], ["sort contaminants", "PROBLEM", 193, 210], ["profuse colonies of CC", "PROBLEM", 233, 255], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["profuse colonies", "OBSERVATION", 233, 249]]], ["Single-cell sort mode sorts exclusively target cells within the sort loop.", [["cell", "ANATOMY", 7, 11], ["cells", "ANATOMY", 47, 52], ["cells", "CELL", 47, 52], ["target cells", "CELL_TYPE", 40, 52], ["target cells", "OBSERVATION", 40, 52], ["sort loop", "OBSERVATION", 64, 73]]], ["If a target cell appears together with a nontarget cell within the sort loop, it will be rejected, thus leading to high sort purity.", [["cell", "ANATOMY", 12, 16], ["cell", "ANATOMY", 51, 55], ["cell", "CELL", 12, 16], ["cell", "CELL", 51, 55], ["a target cell", "PROBLEM", 3, 16], ["high sort purity", "PROBLEM", 115, 131], ["sort loop", "OBSERVATION", 67, 76]]], ["An aliquot of sorted cells was re-stained using BacLight and examined under microscope for the live cells.", [["cells", "ANATOMY", 21, 26], ["cells", "ANATOMY", 100, 105], ["cells", "CELL", 21, 26], ["cells", "CELL", 100, 105], ["sorted cells", "CELL_TYPE", 14, 26], ["BacLight", "PROTEIN", 48, 56], ["An aliquot of sorted cells", "TREATMENT", 0, 26], ["BacLight", "TREATMENT", 48, 56], ["sorted cells", "OBSERVATION", 14, 26]]], ["Cells were sorted from arbitrarily chosen time periods of 8, 9, or 12 days of Enterobacter sp. strain mcp11b, K. pneumonia strain mcp11d, and E. coli microcosm cultures respectively or specified therein.", [["Cells", "ANATOMY", 0, 5], ["cultures", "ANATOMY", 160, 168], ["Cells", "CELL", 0, 5], ["Enterobacter sp", "ORGANISM", 78, 93], ["K. pneumonia", "ORGANISM", 110, 122], ["strain", "ORGANISM", 123, 129], ["mcp11d", "ORGANISM", 130, 136], ["E. coli", "ORGANISM", 142, 149], ["K. pneumonia", "SPECIES", 110, 122], ["E. coli", "SPECIES", 142, 149], ["K. pneumonia strain mcp11d", "SPECIES", 110, 136], ["E. coli", "SPECIES", 142, 149], ["Cells", "TEST", 0, 5], ["Enterobacter sp", "PROBLEM", 78, 93], ["pneumonia strain mcp11d", "PROBLEM", 113, 136], ["E. coli microcosm cultures", "TEST", 142, 168], ["pneumonia", "OBSERVATION", 113, 122]]], ["Sorted cells resuspended in phosphate-buffered saline (PBS; salinity, 8 ppt) were incubated in a shaking bath at 100 rpm at 37\u00b0C. Aliquots were drawn periodically, serially diluted using sterile PBS, and plated on LB agar.", [["cells", "ANATOMY", 7, 12], ["Aliquots", "ANATOMY", 130, 138], ["phosphate", "CHEMICAL", 28, 37], ["phosphate", "CHEMICAL", 28, 37], ["Sorted cells", "CELL", 0, 12], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 28, 53], ["Aliquots", "ORGANISM_SUBSTANCE", 130, 138], ["Sorted cells", "CELL_TYPE", 0, 12], ["phosphate", "TREATMENT", 28, 37], ["buffered saline (PBS", "TREATMENT", 38, 58], ["salinity", "TREATMENT", 60, 68], ["a shaking bath", "TREATMENT", 95, 109], ["sterile PBS", "TREATMENT", 187, 198]]], ["Counting was performed after 48 h incubation at 37\u00b0C in all the analyses, and the value of CCSC, if any, was subtracted from these values resulting in revitalized cell counts (RVC).", [["cell", "ANATOMY", 163, 167], ["RVC", "ANATOMY", 176, 179], ["C", "GENE_OR_GENE_PRODUCT", 51, 52], ["cell", "CELL", 163, 167], ["all the analyses", "TEST", 56, 72], ["revitalized cell counts", "TEST", 151, 174], ["cell counts", "OBSERVATION", 163, 174]]], ["The relative ratio of culturable cells to that of resuscitated cells were estimated using the formula:", [["cells", "ANATOMY", 33, 38], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 33, 38], ["cells", "CELL", 63, 68], ["culturable cells", "CELL_TYPE", 22, 38], ["resuscitated cells", "CELL_TYPE", 50, 68], ["culturable cells", "PROBLEM", 22, 38], ["resuscitated cells", "PROBLEM", 50, 68], ["culturable cells", "OBSERVATION", 22, 38]]]], "c113bc83ae3c68cc6ccadbc376372341941868b7": [["To the Editor-In the year 2000, South Africa President Thado Mbeki was the spokesman of an organized movement of AIDS denialism, which still echoes in many countries, such as Russia.", [["AIDS", "DISEASE", 113, 117], ["AIDS denialism", "PROBLEM", 113, 127]]], ["The \"common cold\" argument against the potential severity of COVID-19 spread through social media.", [["COVID-19", "CHEMICAL", 61, 69], ["COVID", "TEST", 61, 66]]], ["The balance of socioeconomic versus sanitary achievements of lockdown may be contaminated by global ideological discussions and/or local political interests.", [["balance", "OBSERVATION_MODIFIER", 4, 11]]], ["2 Public health challenges become more intense when decisions depend on mathematical modeling and scarce, suboptimal empirical evidence.", [["mathematical modeling", "TEST", 72, 93]]], ["Such occurrences obviously have implications for infection control and patient safety.", [["infection", "DISEASE", 49, 58], ["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["infection control", "TREATMENT", 49, 66], ["infection", "OBSERVATION", 49, 58]]]], "PMC7260485": [["IntroductionCoronaviruses (CoVs) are enveloped, single-stranded RNA viruses belonging to the family Coronaviridae within the order Nidovirales.", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 131, 142], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32]]], ["Coronaviruses (CoV) are of four different genera, \u03b1, \u03b2, \u03b3, and \u03b4 CoVs.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoV", "ORGANISM", 15, 18], ["\u03b1", "GENE_OR_GENE_PRODUCT", 50, 51], ["\u03b2", "GENE_OR_GENE_PRODUCT", 53, 54], ["\u03b3", "GENE_OR_GENE_PRODUCT", 56, 57], ["\u03b4 CoVs", "GENE_OR_GENE_PRODUCT", 63, 69], ["\u03b1", "PROTEIN", 50, 51], ["\u03b2", "PROTEIN", 53, 54], ["\u03b3", "PROTEIN", 56, 57], ["CoVs", "PROTEIN", 65, 69], ["Coronaviruses", "PROBLEM", 0, 13], ["different genera", "TEST", 32, 48], ["\u03b1", "TEST", 50, 51], ["\u03b2", "TEST", 53, 54], ["\u03b3", "TEST", 56, 57]]], ["Among these \u03b2 CoVs like SARS-CoV, Middle East respiratory syndrome (MERS-CoV), and novel coronavirus (SARS-CoV-2) is responsible for severe and potentially fatal respiratory infections.[1], [2], [3]Table 1.IntroductionIt was reported that CoVs enter host cells Angiotensin-Converting Enzyme-2 (ACE-2) receptor-mediated endocytosis, which is a pH-dependent process.", [["respiratory", "ANATOMY", 162, 173], ["cells", "ANATOMY", 255, 260], ["SARS-CoV", "DISEASE", 24, 32], ["Middle East respiratory syndrome", "DISEASE", 34, 66], ["respiratory infections", "DISEASE", 162, 184], ["Angiotensin", "CHEMICAL", 261, 272], ["\u03b2 CoVs", "GENE_OR_GENE_PRODUCT", 12, 18], ["SARS-CoV", "ORGANISM", 24, 32], ["Middle East respiratory", "ORGANISM", 34, 57], ["MERS-CoV", "ORGANISM", 68, 76], ["novel coronavirus", "ORGANISM", 83, 100], ["SARS-CoV-2", "ORGANISM", 102, 112], ["CoVs", "SIMPLE_CHEMICAL", 239, 243], ["host cells", "CELL", 250, 260], ["Angiotensin-Converting Enzyme-2", "GENE_OR_GENE_PRODUCT", 261, 292], ["ACE-2", "GENE_OR_GENE_PRODUCT", 294, 299], ["CoVs", "PROTEIN", 239, 243], ["Angiotensin-Converting Enzyme-2 (ACE-2) receptor", "PROTEIN", 261, 309], ["CoV-2", "SPECIES", 107, 112], ["SARS-CoV", "SPECIES", 24, 32], ["Middle East respiratory syndrome (MERS-CoV", "SPECIES", 34, 76], ["SARS-CoV-2", "SPECIES", 102, 112], ["SARS", "PROBLEM", 24, 28], ["CoV", "PROBLEM", 29, 32], ["Middle East respiratory syndrome", "PROBLEM", 34, 66], ["novel coronavirus", "PROBLEM", 83, 100], ["potentially fatal respiratory infections", "PROBLEM", 144, 184], ["Angiotensin", "TEST", 261, 272], ["Converting Enzyme", "TEST", 273, 290], ["ACE", "TEST", 294, 297], ["receptor-mediated endocytosis", "PROBLEM", 301, 330], ["a pH-dependent process", "PROBLEM", 341, 363], ["Middle", "ANATOMY_MODIFIER", 34, 40], ["respiratory syndrome", "OBSERVATION", 46, 66], ["coronavirus", "OBSERVATION", 89, 100], ["responsible for", "UNCERTAINTY", 117, 132], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["fatal", "OBSERVATION_MODIFIER", 156, 161], ["respiratory infections", "OBSERVATION", 162, 184], ["endocytosis", "OBSERVATION", 319, 330], ["dependent", "OBSERVATION_MODIFIER", 346, 355], ["process", "OBSERVATION", 356, 363]]], ["In this process, Spike (S) protein plays a major role in receptor binding and membrane fusion of SARS-CoV-2 for entry into host cells.", [["membrane", "ANATOMY", 78, 86], ["cells", "ANATOMY", 128, 133], ["Spike (S)", "GENE_OR_GENE_PRODUCT", 17, 26], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["host cells", "CELL", 123, 133], ["Spike (S) protein", "PROTEIN", 17, 34], ["host cells", "CELL_TYPE", 123, 133], ["Spike (S) protein", "PROBLEM", 17, 34], ["receptor binding", "TREATMENT", 57, 73], ["membrane fusion", "TREATMENT", 78, 93], ["SARS", "PROBLEM", 97, 101], ["CoV", "TEST", 102, 105], ["host cells", "OBSERVATION", 123, 133]]], ["It contains a large ectodomain, transmembrane anchor, and a short intracellular tail.", [["transmembrane", "ANATOMY", 32, 45], ["intracellular tail", "ANATOMY", 66, 84], ["transmembrane", "CELLULAR_COMPONENT", 32, 45], ["intracellular tail", "CELLULAR_COMPONENT", 66, 84], ["ectodomain", "PROTEIN", 20, 30], ["transmembrane anchor", "PROTEIN", 32, 52], ["short intracellular tail", "PROTEIN", 60, 84], ["a large ectodomain, transmembrane anchor", "PROBLEM", 12, 52], ["a short intracellular tail", "PROBLEM", 58, 84], ["large", "OBSERVATION_MODIFIER", 14, 19], ["ectodomain", "OBSERVATION_MODIFIER", 20, 30], ["transmembrane anchor", "OBSERVATION", 32, 52], ["short", "OBSERVATION_MODIFIER", 60, 65], ["tail", "OBSERVATION_MODIFIER", 80, 84]]], ["The ectodomain of SARS-CoV-2 consists of two subunits.", [["SARS", "DISEASE", 18, 22], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 28], ["ectodomain", "PROTEIN", 4, 14], ["SARS-CoV", "SPECIES", 18, 26], ["The ectodomain of SARS", "TEST", 0, 22], ["CoV", "TEST", 23, 26]]], ["S1 subunit of SARS-CoV-2 is responsible for binding with the ACE-2 receptor for viral entry to host cells.", [["cells", "ANATOMY", 100, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["ACE-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["host cells", "CELL", 95, 105], ["S1 subunit", "PROTEIN", 0, 10], ["ACE-2 receptor", "PROTEIN", 61, 75], ["host cells", "CELL_TYPE", 95, 105], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["the ACE-2 receptor", "TREATMENT", 57, 75], ["SARS", "OBSERVATION", 14, 18], ["host cells", "OBSERVATION", 95, 105]]], ["Following receptor binding, the SARS-CoV-2 enter the cytosol of the host cell, by pH-dependent proteolytic cleavage of spike protein by TMPRSS2.", [["cytosol", "ANATOMY", 53, 60], ["cell", "ANATOMY", 73, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["cytosol", "CELLULAR_COMPONENT", 53, 60], ["host cell", "CELL", 68, 77], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 136, 143], ["spike protein", "PROTEIN", 119, 132], ["TMPRSS2", "PROTEIN", 136, 143], ["receptor binding", "TEST", 10, 26], ["the SARS", "TEST", 28, 36], ["CoV", "TEST", 37, 40], ["pH", "TEST", 82, 84], ["spike protein", "PROBLEM", 119, 132], ["TMPRSS2", "TEST", 136, 143], ["host cell", "OBSERVATION", 68, 77]]], ["Then the fusion of viral and host cell membranes occurs in acidified endosomes, allowing viral genomes to affect host cells with the aid of the S2 subunit [1], [4], [5].IntroductionCoronavirus disease 19 (COVID-19) caused by SARS-CoV-2 was the pandemic, affected nearly 1400000 people worldwide as on 7 April 2020, according to WHO.", [["cell membranes", "ANATOMY", 34, 48], ["endosomes", "ANATOMY", 69, 78], ["cells", "ANATOMY", 118, 123], ["IntroductionCoronavirus disease", "DISEASE", 169, 200], ["SARS", "DISEASE", 225, 229], ["cell membranes", "CELLULAR_COMPONENT", 34, 48], ["acidified endosomes", "CELLULAR_COMPONENT", 59, 78], ["host cells", "CELL", 113, 123], ["[4]", "SIMPLE_CHEMICAL", 160, 163], ["SARS-CoV-2", "ORGANISM", 225, 235], ["people", "ORGANISM", 278, 284], ["host cells", "CELL_TYPE", 113, 123], ["S2 subunit", "PROTEIN", 144, 154], ["people", "SPECIES", 278, 284], ["SARS-CoV", "SPECIES", 225, 233], ["the fusion", "TREATMENT", 5, 15], ["viral and host cell membranes", "TREATMENT", 19, 48], ["acidified endosomes", "PROBLEM", 59, 78], ["IntroductionCoronavirus disease", "PROBLEM", 169, 200], ["COVID", "TEST", 205, 210], ["SARS", "PROBLEM", 225, 229], ["fusion", "OBSERVATION", 9, 15], ["viral", "OBSERVATION", 19, 24], ["host cell membranes", "OBSERVATION", 29, 48], ["acidified endosomes", "OBSERVATION", 59, 78]]], ["However, rapid spread, potential mortality, and lack of clinically approved drugs and vaccines against COVID-19 are the major challenges.", [["COVID-19", "CHEMICAL", 103, 111], ["rapid spread", "PROBLEM", 9, 21], ["drugs", "TREATMENT", 76, 81], ["vaccines", "TREATMENT", 86, 94], ["COVID", "TEST", 103, 108], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["spread", "OBSERVATION_MODIFIER", 15, 21]]], ["There is a need, therefore, for quick discovery of drugs against this emerging infectious disease.", [["infectious disease", "DISEASE", 79, 97], ["drugs", "TREATMENT", 51, 56], ["this emerging infectious disease", "PROBLEM", 65, 97], ["infectious", "OBSERVATION", 79, 89]]], ["However, the slow phase of discovery and associated costs are the major challenges in discovering drugs against SARS-CoV-2.IntroductionDrug repurposing using existing drugs is an attractive strategy to accelerate drug discovery against COVID-19.", [["SARS", "DISEASE", 112, 116], ["COVID-19", "CHEMICAL", 236, 244], ["SARS-CoV-2", "ORGANISM", 112, 122], ["SARS-CoV", "SPECIES", 112, 120], ["discovering drugs", "TREATMENT", 86, 103], ["SARS", "PROBLEM", 112, 116], ["existing drugs", "TREATMENT", 158, 172], ["an attractive strategy", "TREATMENT", 176, 198], ["COVID", "TEST", 236, 241], ["slow", "OBSERVATION_MODIFIER", 13, 17], ["phase", "OBSERVATION_MODIFIER", 18, 23]]], ["Recently researchers focused on screening of FDA approved drugs against SARS-CoV-2 [6], [7], [8].", [["SARS", "DISEASE", 72, 76], ["[7]", "SIMPLE_CHEMICAL", 88, 91], ["[8]", "SIMPLE_CHEMICAL", 93, 96], ["SARS-CoV", "SPECIES", 72, 80], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80]]], ["Salinomycin (SAL) is a carboxylic polyether ionophore isolated from Streptomyces albus.", [["Salinomycin", "CHEMICAL", 0, 11], ["SAL", "CHEMICAL", 13, 16], ["carboxylic polyether ionophore", "CHEMICAL", 23, 53], ["Salinomycin", "CHEMICAL", 0, 11], ["SAL", "CHEMICAL", 13, 16], ["carboxylic polyether ionophore", "CHEMICAL", 23, 53], ["Salinomycin", "SIMPLE_CHEMICAL", 0, 11], ["SAL", "SIMPLE_CHEMICAL", 13, 16], ["carboxylic polyether ionophore", "SIMPLE_CHEMICAL", 23, 53], ["Streptomyces albus", "ORGANISM", 68, 86], ["Streptomyces albus", "SPECIES", 68, 86], ["Streptomyces albus", "SPECIES", 68, 86], ["Salinomycin (SAL)", "TREATMENT", 0, 17], ["a carboxylic polyether ionophore", "TREATMENT", 21, 53], ["Streptomyces albus", "TREATMENT", 68, 86]]], ["Ionophores show a broad spectrum of bioactivity, like antibacterial, antifungal, antiparasitic, antiviral, and recently, they are also used as anti-tumor agents [9].", [["anti-tumor", "ANATOMY", 143, 153], ["Ionophores", "TREATMENT", 0, 10], ["a broad spectrum of bioactivity", "PROBLEM", 16, 47], ["antibacterial", "TREATMENT", 54, 67], ["antifungal", "TREATMENT", 69, 79], ["antiparasitic", "TREATMENT", 81, 94], ["antiviral", "TREATMENT", 96, 105], ["anti-tumor agents", "TREATMENT", 143, 160], ["broad", "OBSERVATION_MODIFIER", 18, 23], ["bioactivity", "OBSERVATION", 36, 47], ["antibacterial", "OBSERVATION_MODIFIER", 54, 67]]], ["However, poor absorption, low bioavailability, and off-target effects are the potential limitations for effective repurposing of SAL as an antiviral agent against SARS-CoV-2.", [["SAL", "CHEMICAL", 129, 132], ["SARS", "DISEASE", 163, 167], ["SAL", "CHEMICAL", 129, 132], ["SAL", "SIMPLE_CHEMICAL", 129, 132], ["SARS-CoV-2", "ORGANISM", 163, 173], ["SARS-CoV", "SPECIES", 163, 171], ["poor absorption", "PROBLEM", 9, 24], ["effective repurposing of SAL", "TREATMENT", 104, 132], ["an antiviral agent", "TREATMENT", 136, 154], ["SARS", "PROBLEM", 163, 167]]], ["In the present study, we, therefore, propose the pulmonary delivery of SAL using nanostructured lipid carriers (NLCs).HypothesisIn the present study, we proposed to prepare NLCs for intra-pulmonary delivery of SAL to prevent SARS-CoV-2 infection (Fig. 1).", [["pulmonary", "ANATOMY", 49, 58], ["NLCs", "ANATOMY", 173, 177], ["intra-pulmonary", "ANATOMY", 182, 197], ["SAL", "CHEMICAL", 71, 74], ["SAL", "CHEMICAL", 210, 213], ["SARS-CoV-2 infection", "DISEASE", 225, 245], ["pulmonary", "ORGAN", 49, 58], ["SAL", "SIMPLE_CHEMICAL", 71, 74], ["nanostructured lipid carriers", "SIMPLE_CHEMICAL", 81, 110], ["NLCs", "SIMPLE_CHEMICAL", 173, 177], ["SAL", "SIMPLE_CHEMICAL", 210, 213], ["CoV-2", "ORGANISM", 230, 235], ["SARS-CoV-2", "SPECIES", 225, 235], ["the pulmonary delivery of SAL using nanostructured lipid carriers (NLCs", "TREATMENT", 45, 116], ["the present study", "TEST", 131, 148], ["NLCs", "TREATMENT", 173, 177], ["intra-pulmonary delivery of SAL", "TREATMENT", 182, 213], ["SARS", "PROBLEM", 225, 229], ["CoV", "PROBLEM", 230, 233], ["2 infection", "PROBLEM", 234, 245], ["pulmonary", "ANATOMY", 49, 58], ["infection", "OBSERVATION", 236, 245]]], ["The proposed drug delivery system with the following advantages:\u2022Noninvasive means of administration\u2022Localized delivery to lung epithelium directly\u2022Avoid first-pass metabolism\u2022Reduced off-target effects\u2022Rapid and effective drug absorption", [["lung epithelium", "ANATOMY", 123, 138], ["lung epithelium", "TISSUE", 123, 138], ["The proposed drug delivery system", "TREATMENT", 0, 33], ["lung epithelium", "PROBLEM", 123, 138], ["Rapid and effective drug absorption", "PROBLEM", 203, 238], ["lung", "ANATOMY", 123, 127], ["epithelium", "ANATOMY_MODIFIER", 128, 138]]]], "PMC7110669": [["IntroductionChikungunya is an arboviral disease caused by chikungunya viral (CHIKV) infection that is transmitted to humans by infected mosquitoes of the Aedes genus (Pialoux et al., 2007, Robinson, 1955).", [["Chikungunya", "DISEASE", 12, 23], ["arboviral disease", "DISEASE", 30, 47], ["chikungunya viral (CHIKV) infection", "DISEASE", 58, 93], ["Chikungunya", "ORGANISM", 12, 23], ["chikungunya viral", "ORGANISM", 58, 75], ["CHIKV", "ORGANISM", 77, 82], ["humans", "ORGANISM", 117, 123], ["Aedes genus", "ORGANISM", 154, 165], ["chikungunya viral", "SPECIES", 58, 75], ["humans", "SPECIES", 117, 123], ["CHIKV", "SPECIES", 77, 82], ["humans", "SPECIES", 117, 123], ["an arboviral disease", "PROBLEM", 27, 47], ["chikungunya viral (CHIKV) infection", "PROBLEM", 58, 93], ["arboviral disease", "OBSERVATION", 30, 47], ["chikungunya", "OBSERVATION_MODIFIER", 58, 69]]], ["CHIKV was first identified in Tanzania in 1953 (Lumsden, 1955).", [["CHIKV", "ORGANISM", 0, 5], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5]]], ["In the Western Hemisphere, however, the first locally-transmitted infection occurred in December 2013 (Leparc-Goffart et al., 2014a, Lanciotti and Valadere, 2014, Teixeira et al., 2015) in the Caribbean (Halstead, 2015, Weaver and Lecuit, 2015).", [["infection", "DISEASE", 66, 75], ["transmitted infection", "PROBLEM", 54, 75], ["infection", "OBSERVATION", 66, 75]]], ["In 2016 alone, there were over 500,000 cumulative CHIKV cases (Pan American Health Organization, 2017).", [["CHIKV", "SPECIES", 50, 55]]], ["In Canada, 479 confirmed and probable cases were diagnosed in 2014 (Drebot et al., 2015), of which, 128 cases were imported (Pan American Health Organization, 2017).IntroductionThe disease is characterized by acute-onset of high grade fever, severe arthralgia, followed by maculopapular rash (Weaver et al., 2012).", [["maculopapular", "ANATOMY", 273, 286], ["fever", "DISEASE", 235, 240], ["arthralgia", "DISEASE", 249, 259], ["maculopapular rash", "DISEASE", 273, 291], ["The disease", "PROBLEM", 177, 188], ["high grade fever", "PROBLEM", 224, 240], ["severe arthralgia", "PROBLEM", 242, 259], ["maculopapular rash", "PROBLEM", 273, 291], ["disease", "OBSERVATION", 181, 188], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["high grade", "OBSERVATION_MODIFIER", 224, 234], ["fever", "OBSERVATION", 235, 240], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["arthralgia", "OBSERVATION", 249, 259], ["maculopapular", "OBSERVATION_MODIFIER", 273, 286]]], ["CHIKV is usually self-limited, with the majority of symptoms typically resolving in 7-10 days (Pialoux et al., 2007).", [["CHIKV", "DISEASE", 0, 5], ["CHIKV", "ORGANISM", 0, 5], ["CHIKV", "SPECIES", 0, 5], ["CHIKV", "PROBLEM", 0, 5], ["symptoms", "PROBLEM", 52, 60]]], ["Generally, overall mortality is low but there exists a risk for severe disease and death associated with CHIKV infection (Renault et al., 2007).", [["death", "DISEASE", 83, 88], ["CHIKV infection", "DISEASE", 105, 120], ["CHIKV", "ORGANISM", 105, 110], ["CHIKV", "SPECIES", 105, 110], ["severe disease", "PROBLEM", 64, 78], ["death", "PROBLEM", 83, 88], ["CHIKV infection", "PROBLEM", 105, 120], ["risk for", "UNCERTAINTY", 55, 63], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["disease", "OBSERVATION", 71, 78]]], ["Rheumatologic symptoms and neurologic, carditis, respiratory, renal, and ocular manifestations are among the severe sequelae of CHIKV (Robinson, 1955, Lumsden, 1955, Sissoko et al., 2009, Brighton et al., 1983, Rajapakse et al., 2010).", [["neurologic", "ANATOMY", 27, 37], ["respiratory", "ANATOMY", 49, 60], ["renal", "ANATOMY", 62, 67], ["ocular", "ANATOMY", 73, 79], ["neurologic, carditis, respiratory, renal, and ocular manifestations", "DISEASE", 27, 94], ["CHIKV", "DISEASE", 128, 133], ["renal", "CANCER", 62, 67], ["CHIKV", "ORGANISM", 128, 133], ["CHIKV", "SPECIES", 128, 133], ["Rheumatologic symptoms", "PROBLEM", 0, 22], ["neurologic, carditis", "PROBLEM", 27, 47], ["respiratory, renal, and ocular manifestations", "PROBLEM", 49, 94], ["carditis", "OBSERVATION", 39, 47], ["respiratory", "ANATOMY", 49, 60], ["renal", "ANATOMY", 62, 67], ["ocular", "ANATOMY", 73, 79], ["CHIKV", "OBSERVATION", 128, 133]]], ["When developed, these conditions can persist for several months or years after acute infection (Sissoko et al., 2009, Brighton et al., 1983, Soumahoro et al., 2009, Borgherini et al., 2008, Larrieu et al., 2010).", [["infection", "DISEASE", 85, 94], ["acute infection", "PROBLEM", 79, 94], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["infection", "OBSERVATION", 85, 94]]], ["Furthermore, CHIKV is a common cause of virus-induced arthritis in the Eastern Hemisphere, with documented epidemics in Africa, Southeast Asia, and the Indian Ocean islands (Staples et al., 2009, Arroyo-Avila et al., 2017, Economopoulou et al., 2009, Leparc-Goffart et al., 2014b).IntroductionEpidemiologic evidence suggests that CHIKV patients at risk of severe disease outcomes are elderly subjects (Godaert et al., 2017) and those with certain comorbidities, e.g., obesity (Padmakumar et al., 2010), diabetes (Jean-Baptiste et al., 2016), cardiac diseases (Alvarez et al., 2017), and asthma (Paganin et al., 2010).", [["cardiac", "ANATOMY", 542, 549], ["CHIKV", "DISEASE", 13, 18], ["arthritis", "DISEASE", 54, 63], ["CHIKV", "DISEASE", 330, 335], ["obesity", "DISEASE", 468, 475], ["diabetes", "DISEASE", 503, 511], ["cardiac diseases", "DISEASE", 542, 558], ["asthma", "DISEASE", 587, 593], ["CHIKV", "ORGANISM", 13, 18], ["CHIKV", "ORGANISM", 330, 335], ["patients", "ORGANISM", 336, 344], ["cardiac", "ORGAN", 542, 549], ["patients", "SPECIES", 336, 344], ["CHIKV", "SPECIES", 13, 18], ["CHIKV", "SPECIES", 330, 335], ["CHIKV", "PROBLEM", 13, 18], ["virus", "PROBLEM", 40, 45], ["arthritis in the Eastern Hemisphere", "PROBLEM", 54, 89], ["CHIKV", "PROBLEM", 330, 335], ["severe disease outcomes", "PROBLEM", 356, 379], ["obesity", "PROBLEM", 468, 475], ["diabetes", "PROBLEM", 503, 511], ["cardiac diseases", "PROBLEM", 542, 558], ["asthma", "PROBLEM", 587, 593], ["CHIKV", "OBSERVATION", 13, 18], ["virus", "OBSERVATION", 40, 45], ["arthritis", "OBSERVATION", 54, 63], ["Eastern Hemisphere", "ANATOMY", 71, 89], ["epidemics", "OBSERVATION", 107, 116], ["CHIKV", "OBSERVATION", 330, 335], ["severe", "OBSERVATION_MODIFIER", 356, 362], ["disease", "OBSERVATION", 363, 370], ["obesity", "OBSERVATION", 468, 475], ["cardiac", "ANATOMY", 542, 549], ["diseases", "OBSERVATION", 550, 558], ["asthma", "OBSERVATION", 587, 593]]], ["The presence of these comorbidities was proposed to predispose CHIKV patients to severe complications of the viral infection (Padmakumar et al., 2010, Jean-Baptiste et al., 2016, Alvarez et al., 2017, Paganin et al., 2010).", [["CHIKV", "DISEASE", 63, 68], ["viral infection", "DISEASE", 109, 124], ["CHIKV", "ORGANISM", 63, 68], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["CHIKV", "SPECIES", 63, 68], ["these comorbidities", "PROBLEM", 16, 35], ["CHIKV", "PROBLEM", 63, 68], ["severe complications", "PROBLEM", 81, 101], ["the viral infection", "PROBLEM", 105, 124], ["comorbidities", "OBSERVATION", 22, 35], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["complications", "OBSERVATION", 88, 101], ["viral", "OBSERVATION_MODIFIER", 109, 114], ["infection", "OBSERVATION", 115, 124]]], ["However, the prevalence of co-existing medical conditions in severe CHIKV cases has not been described.", [["CHIKV", "DISEASE", 68, 73], ["CHIKV", "ORGANISM", 68, 73], ["CHIKV", "SPECIES", 68, 73], ["co-existing medical conditions", "PROBLEM", 27, 57], ["severe CHIKV cases", "PROBLEM", 61, 79], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["CHIKV", "OBSERVATION", 68, 73]]], ["A systematic evaluation and detailed estimate for the prevalence of comorbidities in CHIKV severe cases may aid the public health sector in developing policies for surveillance, preparedness and response to the infection and its severe outcomes.", [["CHIKV", "DISEASE", 85, 90], ["infection", "DISEASE", 211, 220], ["CHIKV", "ORGANISM", 85, 90], ["CHIKV", "SPECIES", 85, 90], ["A systematic evaluation", "TEST", 0, 23], ["comorbidities", "PROBLEM", 68, 81], ["CHIKV severe cases", "PROBLEM", 85, 103], ["surveillance", "TEST", 164, 176], ["the infection", "PROBLEM", 207, 220], ["its severe outcomes", "PROBLEM", 225, 244], ["infection", "OBSERVATION", 211, 220], ["severe", "OBSERVATION_MODIFIER", 229, 235]]], ["The present study was undertaken to evaluate the prevalence of co-existing chronic conditions in CHIKV patients and in severe cases.", [["CHIKV", "DISEASE", 97, 102], ["CHIKV", "ORGANISM", 97, 102], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["CHIKV", "SPECIES", 97, 102], ["The present study", "TEST", 0, 17], ["co-existing chronic conditions", "PROBLEM", 63, 93], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["conditions", "OBSERVATION", 83, 93], ["CHIKV", "OBSERVATION", 97, 102], ["severe", "OBSERVATION_MODIFIER", 119, 125]]], ["We conducted a systematic review and meta-analysis of published literature to describe the frequency of chronic comorbidities in CHIKV and to explore their possible contributions to the severity and complication of this viral condition.Search strategy and selection criteria ::: MethodsA search was conducted in PubMed, Ovid MEDLINE, Embase and Embase Classic databases to the last week of July 2017 using the search terms (MeSH) \u201cChikungunya\u201d AND \u201cDiabetes, Hypertension, Stroke, Cardiovascular Diseases, Coronary Artery Diseases, Obesity, OR Asthma\u201d.", [["Cardiovascular", "ANATOMY", 481, 495], ["Coronary", "ANATOMY", 506, 514], ["CHIKV", "DISEASE", 129, 134], ["Chikungunya", "DISEASE", 431, 442], ["Diabetes", "DISEASE", 449, 457], ["Hypertension", "DISEASE", 459, 471], ["Stroke", "DISEASE", 473, 479], ["Cardiovascular Diseases", "DISEASE", 481, 504], ["Coronary Artery Diseases", "DISEASE", 506, 530], ["Obesity", "DISEASE", 532, 539], ["Asthma", "DISEASE", 544, 550], ["CHIKV", "ORGANISM", 129, 134], ["Coronary Artery", "MULTI-TISSUE_STRUCTURE", 506, 521], ["CHIKV", "SPECIES", 129, 134], ["a systematic review", "TEST", 13, 32], ["chronic comorbidities", "PROBLEM", 104, 125], ["CHIKV", "PROBLEM", 129, 134], ["the severity", "PROBLEM", 182, 194], ["this viral condition", "PROBLEM", 215, 235], ["Chikungunya", "PROBLEM", 431, 442], ["Diabetes", "PROBLEM", 449, 457], ["Hypertension", "PROBLEM", 459, 471], ["Stroke", "PROBLEM", 473, 479], ["Cardiovascular Diseases", "PROBLEM", 481, 504], ["Coronary Artery Diseases", "PROBLEM", 506, 530], ["Obesity", "PROBLEM", 532, 539], ["Asthma", "PROBLEM", 544, 550], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["comorbidities", "OBSERVATION", 112, 125], ["CHIKV", "OBSERVATION", 129, 134], ["Diabetes", "OBSERVATION", 449, 457], ["Hypertension", "OBSERVATION", 459, 471], ["Stroke", "OBSERVATION", 473, 479], ["Cardiovascular", "ANATOMY", 481, 495], ["Diseases", "OBSERVATION", 496, 504], ["Coronary Artery", "ANATOMY", 506, 521], ["Diseases", "OBSERVATION", 522, 530], ["Obesity", "OBSERVATION", 532, 539], ["Asthma", "OBSERVATION", 544, 550]]], ["When these articles were restricted to studies in human and deduplicated, 82 abstracts were searched for title and abstract review as they satisfied our selection criteria (see below).", [["human", "ORGANISM", 50, 55], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55]]], ["We excluded reports published as review articles, letters, editorials, conference abstracts, case reports (with less than 3 cases) or vaccination trials.", [["vaccination trials", "TREATMENT", 134, 152]]], ["Ten articles were excluded at the full text review stage as they were either not related to the study objectives (4 studies), not reporting prevalence of chronic disease in CHIKV (3 studies), case reports with small numbers of cases (i.e., <3 cases; 2 reports), or a review article (see Figure 1 and Supplementary Table S1).", [["chronic disease", "DISEASE", 154, 169], ["CHIKV", "DISEASE", 173, 178], ["CHIKV", "SPECIES", 173, 178], ["the study objectives", "TEST", 92, 112], ["chronic disease in CHIKV", "PROBLEM", 154, 178], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["disease", "OBSERVATION", 162, 169], ["CHIKV", "OBSERVATION", 173, 178]]], ["After identifying one study through bibliography searching, 11 reports were included for systematic review and meta-analysis (Arroyo-Avila et al., 2017, Economopoulou et al., 2009, Padmakumar et al., 2010, Jean-Baptiste et al., 2016, S\u00e1 deOliveira et al., 2017, Perti et al., 2016, Crosby et al., 2016, Chusri et al., 2014, Couturier et al., 2012, Tandale et al., 2009, Borgherini et al., 2007).Inter-reviewer agreement ::: MethodsThe abstracts of the identified studies were independently reviewed by two readers (SGR and SY).", [["one study", "TEST", 18, 27], ["systematic review", "TEST", 89, 106], ["meta-analysis", "TEST", 111, 124], ["Methods", "TREATMENT", 424, 431]]], ["Percentage agreement and Cohen\u2019s Kappa (\u03ba) statistic (Cohen, 1989) were calculated and interpreted in accordance with Landis and Koch\u2019s benchmarks (Landis and Koch, 1977) for assessing the agreement between reviewers as poor (<0), slight (0.0-0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80), and excellent (0.81-1.0).", [["moderate", "OBSERVATION_MODIFIER", 268, 276]]], ["The agreement on the inclusion between the two reviewers was 93%, with \u03ba = 0.68 (95% CI: 0.38-0.97).Data extraction and analysis ::: MethodsData extracted from the selected studies included the first author\u2019s name, publication date, country, dates of recruitment, total sample size (divided to males and females), age estimates (from reported mean, median or the mid-point for age range of the highest subject frequency), prevalence of symptoms (including pyrexia, arthralgia, cephalgia, myalgia, joint edema, dermatitis, and malaise) and percentage of comorbidities including diabetes (both type I and type II, if separately mentioned), hypertension, heart diseases (combined from cardiovascular disease, coronary artery disease, coronary vascular disease, atrial fibrillation, chronic ischemic heart disease, acute coronary syndrome for duration less than 6 months, cardiac disorder, cardiac heart failure, and congestive cardiac failure), asthma (not including chronic obstructive pulmonary disease), stroke, and obesity.", [["joint", "ANATOMY", 497, 502], ["heart", "ANATOMY", 652, 657], ["cardiovascular", "ANATOMY", 682, 696], ["coronary artery", "ANATOMY", 706, 721], ["coronary", "ANATOMY", 731, 739], ["vascular", "ANATOMY", 740, 748], ["atrial", "ANATOMY", 758, 764], ["heart", "ANATOMY", 796, 801], ["coronary", "ANATOMY", 817, 825], ["cardiac", "ANATOMY", 868, 875], ["cardiac", "ANATOMY", 886, 893], ["heart", "ANATOMY", 894, 899], ["cardiac", "ANATOMY", 924, 931], ["pulmonary", "ANATOMY", 984, 993], ["pyrexia", "DISEASE", 456, 463], ["arthralgia", "DISEASE", 465, 475], ["cephalgia", "DISEASE", 477, 486], ["myalgia", "DISEASE", 488, 495], ["joint edema", "DISEASE", 497, 508], ["dermatitis", "DISEASE", 510, 520], ["diabetes", "DISEASE", 577, 585], ["hypertension", "DISEASE", 638, 650], ["heart diseases", "DISEASE", 652, 666], ["cardiovascular disease", "DISEASE", 682, 704], ["coronary artery disease", "DISEASE", 706, 729], ["coronary vascular disease", "DISEASE", 731, 756], ["atrial fibrillation", "DISEASE", 758, 777], ["ischemic heart disease", "DISEASE", 787, 809], ["acute coronary syndrome", "DISEASE", 811, 834], ["cardiac disorder", "DISEASE", 868, 884], ["cardiac heart failure", "DISEASE", 886, 907], ["congestive cardiac failure", "DISEASE", 913, 939], ["asthma", "DISEASE", 942, 948], ["chronic obstructive pulmonary disease", "DISEASE", 964, 1001], ["stroke", "DISEASE", 1004, 1010], ["obesity", "DISEASE", 1016, 1023], ["joint", "ORGANISM_SUBDIVISION", 497, 502], ["heart", "ORGAN", 652, 657], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 706, 721], ["coronary vascular", "MULTI-TISSUE_STRUCTURE", 731, 748], ["atrial", "MULTI-TISSUE_STRUCTURE", 758, 764], ["heart", "ORGAN", 796, 801], ["cardiac", "ORGAN", 868, 875], ["heart", "ORGAN", 894, 899], ["cardiac", "ORGAN", 924, 931], ["pulmonary", "ORGAN", 984, 993], ["CI", "TEST", 85, 87], ["Data extraction", "TEST", 100, 115], ["symptoms", "PROBLEM", 436, 444], ["pyrexia", "PROBLEM", 456, 463], ["arthralgia", "PROBLEM", 465, 475], ["cephalgia", "PROBLEM", 477, 486], ["myalgia", "PROBLEM", 488, 495], ["joint edema", "PROBLEM", 497, 508], ["dermatitis", "PROBLEM", 510, 520], ["malaise", "PROBLEM", 526, 533], ["percentage of comorbidities", "PROBLEM", 539, 566], ["diabetes", "PROBLEM", 577, 585], ["type II", "PROBLEM", 603, 610], ["hypertension", "PROBLEM", 638, 650], ["heart diseases", "PROBLEM", 652, 666], ["cardiovascular disease", "PROBLEM", 682, 704], ["coronary artery disease", "PROBLEM", 706, 729], ["coronary vascular disease", "PROBLEM", 731, 756], ["atrial fibrillation", "PROBLEM", 758, 777], ["chronic ischemic heart disease", "PROBLEM", 779, 809], ["acute coronary syndrome", "PROBLEM", 811, 834], ["cardiac disorder", "PROBLEM", 868, 884], ["cardiac heart failure", "PROBLEM", 886, 907], ["congestive cardiac failure", "PROBLEM", 913, 939], ["asthma", "PROBLEM", 942, 948], ["chronic obstructive pulmonary disease)", "PROBLEM", 964, 1002], ["stroke", "PROBLEM", 1004, 1010], ["obesity", "PROBLEM", 1016, 1023], ["size", "OBSERVATION_MODIFIER", 277, 281], ["myalgia", "ANATOMY", 488, 495], ["joint", "ANATOMY", 497, 502], ["edema", "OBSERVATION", 503, 508], ["dermatitis", "OBSERVATION", 510, 520], ["hypertension", "OBSERVATION", 638, 650], ["heart", "ANATOMY", 652, 657], ["diseases", "OBSERVATION", 658, 666], ["coronary artery", "ANATOMY", 706, 721], ["coronary vascular", "ANATOMY", 731, 748], ["atrial", "ANATOMY", 758, 764], ["fibrillation", "OBSERVATION", 765, 777], ["chronic", "OBSERVATION_MODIFIER", 779, 786], ["ischemic", "OBSERVATION_MODIFIER", 787, 795], ["heart", "ANATOMY", 796, 801], ["disease", "OBSERVATION", 802, 809], ["acute", "OBSERVATION_MODIFIER", 811, 816], ["coronary", "ANATOMY", 817, 825], ["syndrome", "OBSERVATION", 826, 834], ["cardiac", "ANATOMY", 868, 875], ["disorder", "OBSERVATION", 876, 884], ["heart", "ANATOMY", 894, 899], ["failure", "OBSERVATION", 900, 907], ["congestive", "OBSERVATION_MODIFIER", 913, 923], ["cardiac", "ANATOMY", 924, 931], ["failure", "OBSERVATION", 932, 939], ["asthma", "OBSERVATION", 942, 948], ["chronic", "OBSERVATION_MODIFIER", 964, 971], ["obstructive", "OBSERVATION_MODIFIER", 972, 983], ["pulmonary", "ANATOMY", 984, 993], ["disease", "OBSERVATION", 994, 1001], ["stroke", "OBSERVATION", 1004, 1010], ["obesity", "OBSERVATION", 1016, 1023]]], ["The prevalence of comorbidities was measured by extracting the proportion of co-existing medical conditions from CHIKV cases and from severe disease outcome.", [["CHIKV", "ORGANISM", 113, 118], ["CHIKV", "SPECIES", 113, 118], ["comorbidities", "PROBLEM", 18, 31], ["co-existing medical conditions", "PROBLEM", 77, 107], ["CHIKV cases", "PROBLEM", 113, 124], ["severe disease outcome", "PROBLEM", 134, 156], ["comorbidities", "OBSERVATION", 18, 31], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["disease", "OBSERVATION", 141, 148]]], ["Severe CHIKV was identified as cases that underwent ICU, those with acute diseases (e.g., acute encephalitis) and subjects with atypical CHIKV (atypical clinical manifestations of CHIKV include vesiculobullous lesions, febrile seizures, and meningoencephalitis), joints involvement (e.g., inflammatory joint destruction), hospitalization, and/or death.", [["vesiculobullous lesions", "ANATOMY", 194, 217], ["joints", "ANATOMY", 263, 269], ["joint", "ANATOMY", 302, 307], ["CHIKV", "DISEASE", 7, 12], ["encephalitis", "DISEASE", 96, 108], ["CHIKV", "DISEASE", 137, 142], ["CHIKV", "DISEASE", 180, 185], ["vesiculobullous lesions", "DISEASE", 194, 217], ["febrile seizures", "DISEASE", 219, 235], ["meningoencephalitis", "DISEASE", 241, 260], ["joints", "DISEASE", 263, 269], ["inflammatory joint destruction", "DISEASE", 289, 319], ["death", "DISEASE", 346, 351], ["CHIKV", "ORGANISM", 7, 12], ["CHIKV", "ORGANISM", 180, 185], ["vesiculobullous lesions", "PATHOLOGICAL_FORMATION", 194, 217], ["joints", "MULTI-TISSUE_STRUCTURE", 263, 269], ["joint", "MULTI-TISSUE_STRUCTURE", 302, 307], ["CHIKV", "SPECIES", 7, 12], ["CHIKV", "SPECIES", 137, 142], ["CHIKV", "SPECIES", 180, 185], ["Severe CHIKV", "PROBLEM", 0, 12], ["acute diseases", "PROBLEM", 68, 82], ["acute encephalitis)", "PROBLEM", 90, 109], ["atypical CHIKV", "PROBLEM", 128, 142], ["CHIKV", "PROBLEM", 180, 185], ["vesiculobullous lesions", "PROBLEM", 194, 217], ["febrile seizures", "PROBLEM", 219, 235], ["meningoencephalitis", "PROBLEM", 241, 260], ["joints involvement", "PROBLEM", 263, 281], ["inflammatory joint destruction", "PROBLEM", 289, 319], ["death", "PROBLEM", 346, 351], ["CHIKV", "OBSERVATION", 7, 12], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["diseases", "OBSERVATION", 74, 82], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["encephalitis", "OBSERVATION", 96, 108], ["atypical", "OBSERVATION_MODIFIER", 128, 136], ["CHIKV", "OBSERVATION", 137, 142], ["vesiculobullous", "OBSERVATION_MODIFIER", 194, 209], ["lesions", "OBSERVATION", 210, 217], ["meningoencephalitis", "OBSERVATION", 241, 260], ["joints", "ANATOMY", 263, 269], ["inflammatory", "OBSERVATION_MODIFIER", 289, 301], ["joint", "ANATOMY", 302, 307], ["destruction", "OBSERVATION", 308, 319]]], ["The primary outcome measure was to evaluate the overall prevalence of comorbidities in the CHIKV infection and stratify the estimates by severity.", [["CHIKV infection", "DISEASE", 91, 106], ["CHIKV", "ORGANISM", 91, 96], ["CHIKV", "SPECIES", 91, 96], ["comorbidities", "PROBLEM", 70, 83], ["the CHIKV infection", "PROBLEM", 87, 106], ["CHIKV", "OBSERVATION_MODIFIER", 91, 96], ["infection", "OBSERVATION", 97, 106]]], ["Weighted average was used to calculate the average age and the overall prevalence of clinical symptoms and comorbidities.", [["clinical symptoms", "PROBLEM", 85, 102], ["comorbidities", "PROBLEM", 107, 120]]], ["Median age of the studies populations (\u223c50 years old) was used to categorize the CHIKV patients into two groups, below and above the median age.", [["CHIKV", "ORGANISM", 81, 86], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["CHIKV", "SPECIES", 81, 86], ["CHIKV", "OBSERVATION", 81, 86]]], ["The weighted average prevalence of each comorbidity was calculated (\u00b1SD) within each group.", [["each comorbidity", "PROBLEM", 35, 51]]], ["Publication bias was assessed both by the visual inspection of funnel plot (Supplementary Figure S1) and by Egger\u2019s test.", [["Publication bias", "TEST", 0, 16], ["the visual inspection", "TEST", 38, 59], ["funnel plot", "TEST", 63, 74]]], ["Egger\u2019s test is widely used to assess the tendency for the effects estimated in small sample size studies to differ from those estimated in larger studies.", [["Egger\u2019s test", "TEST", 0, 12], ["small sample size studies", "TEST", 80, 105], ["small", "OBSERVATION_MODIFIER", 80, 85]]], ["The results of Egger\u2019s test are presented in terms of bias coefficient.", [["Egger\u2019s test", "TEST", 15, 27]]], ["Publication bias was only observed in studies identified to estimate the proportion of cardiac diseases.", [["cardiac", "ANATOMY", 87, 94], ["cardiac diseases", "DISEASE", 87, 103], ["cardiac", "ORGAN", 87, 94], ["Publication bias", "TEST", 0, 16], ["cardiac diseases", "PROBLEM", 87, 103], ["cardiac", "ANATOMY", 87, 94], ["diseases", "OBSERVATION", 95, 103]]], ["Meta-analyses were carried out to assess the pooled prevalence (and 95% CI) of clinical symptoms and the proportions of each comorbidity in the overall and severe cases.", [["Meta-analyses", "TEST", 0, 13], ["clinical symptoms", "PROBLEM", 79, 96], ["each comorbidity in the overall and severe cases", "PROBLEM", 120, 168], ["severe", "OBSERVATION_MODIFIER", 156, 162]]], ["Meta-analysis tests were conducted using Comprehensive Meta-Analysis software, CMA version 3.9 (Englewood, NJ, USA) (Borenstein, 2005).", [["Meta-analysis tests", "TEST", 0, 19], ["Comprehensive Meta-Analysis software", "TEST", 41, 77], ["CMA version", "TEST", 79, 90]]], ["Variances of raw proportions or percentages were pooled based on a binary random-effects model (\u00c7o\u011faltay and Karada\u011f, 2015), given the population heterogeneity and assuming the relationships between comorbidities and CHIKV infections vary across populations.", [["CHIKV infections", "DISEASE", 217, 233], ["CHIKV", "ORGANISM", 217, 222], ["CHIKV", "SPECIES", 217, 222], ["the population heterogeneity", "PROBLEM", 131, 159], ["comorbidities", "PROBLEM", 199, 212], ["CHIKV infections", "PROBLEM", 217, 233], ["raw", "OBSERVATION_MODIFIER", 13, 16], ["proportions", "OBSERVATION_MODIFIER", 17, 28], ["CHIKV infections", "OBSERVATION", 217, 233]]], ["Forest plots were used to illustrate the prevalence of comorbidities in CHIKV from the selected studies in the entire patients and in severe cases.Data extraction and analysis ::: MethodsAssessing the heterogeneity among the selected studies was carried out using the Q test (Cochran, 1954) that informs about the presence versus the absence of heterogeneity.", [["CHIKV", "ORGANISM", 72, 77], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["CHIKV", "SPECIES", 72, 77], ["Forest plots", "TREATMENT", 0, 12], ["comorbidities", "PROBLEM", 55, 68], ["CHIKV", "PROBLEM", 72, 77], ["the selected studies", "TEST", 83, 103], ["Data extraction", "TEST", 147, 162], ["the selected studies", "TEST", 221, 241], ["the Q test", "TEST", 264, 274], ["heterogeneity", "OBSERVATION", 345, 358]]], ["The Q test, however, does not report the extent of heterogeneity and has inadequate power to detect heterogeneity among the small number of studies identified for some comorbidities.", [["The Q test", "TEST", 0, 10], ["some comorbidities", "PROBLEM", 163, 181], ["heterogeneity", "OBSERVATION", 51, 64], ["small", "OBSERVATION_MODIFIER", 124, 129]]], ["Therefore, we calculated the I2 index to complement the Q test and describe the degree of between-study heterogeneity (Higgins and Thompson, 2002).", [["the I2 index", "TEST", 25, 37], ["the Q test", "TEST", 52, 62]]], ["I2 index values were categorized as low (0\u201330%), moderate (30\u201360%), substantial (60\u201390%), and considerable (>90%) as recommended (Liberati et al., 2009).", [["I2 index values", "TEST", 0, 15], ["low", "OBSERVATION_MODIFIER", 36, 39], ["moderate", "OBSERVATION_MODIFIER", 49, 57], ["substantial", "OBSERVATION_MODIFIER", 68, 79]]], ["We also quantified the true heterogeneity by estimating the between-study variance in the random-effects model (\u03c42), as previously described (DerSimonian and Laird, 1986).ResultsSystematic analysis of studies that described the epidemiological, demographic and clinical features of CHIKV cases and reported the prevalence of a number of chronic diseases in the infectious disease, has identified 11 reports (Arroyo-Avila et al., 2017, Economopoulou et al., 2009, Padmakumar et al., 2010, Jean-Baptiste et al., 2016, S\u00e1 deOliveira et al., 2017, Perti et al., 2016, Crosby et al., 2016, Chusri et al., 2014, Couturier et al., 2012, Tandale et al., 2009, Borgherini et al., 2007) with 2,773 patients (Table 1).", [["CHIKV", "DISEASE", 282, 287], ["chronic diseases", "DISEASE", 337, 353], ["infectious disease", "DISEASE", 361, 379], ["CHIKV", "ORGANISM", 282, 287], ["patients", "ORGANISM", 688, 696], ["patients", "SPECIES", 688, 696], ["CHIKV", "SPECIES", 282, 287], ["the true heterogeneity", "PROBLEM", 19, 41], ["ResultsSystematic analysis", "TEST", 171, 197], ["studies", "TEST", 201, 208], ["CHIKV cases", "PROBLEM", 282, 293], ["chronic diseases", "PROBLEM", 337, 353], ["the infectious disease", "PROBLEM", 357, 379], ["true", "OBSERVATION_MODIFIER", 23, 27], ["heterogeneity", "OBSERVATION", 28, 41], ["chronic", "OBSERVATION_MODIFIER", 337, 344], ["diseases", "OBSERVATION", 345, 353], ["infectious", "OBSERVATION", 361, 371]]], ["This limited number of reports is the result of our strict search strategy and selection criteria and our focus only on the studies recording the prevalence of comorbidities in CHIKV.", [["CHIKV", "DISEASE", 177, 182], ["CHIKV", "ORGANISM", 177, 182], ["CHIKV", "SPECIES", 177, 182], ["the studies", "TEST", 120, 131], ["comorbidities", "PROBLEM", 160, 173], ["CHIKV", "PROBLEM", 177, 182], ["CHIKV", "OBSERVATION", 177, 182]]], ["The majority of the cases were from South Asia, particularly India, followed by a significant number from South America.", [["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["With the exception of a report from Brazil (S\u00e1 deOliveira et al., 2017), the number of cases in the selected studies varied by \u223c25-fold and ranged from 45 (Chusri et al., 2014) to 1,111 (Padmakumar et al., 2010) cases.", [["the selected studies", "TEST", 96, 116]]], ["The 1,111 cases from India (Padmakumar et al., 2010) were not included in any meta-analysis since it was the only study referring to the prevalence of obesity in CHIKV.", [["obesity", "DISEASE", 151, 158], ["CHIKV", "DISEASE", 162, 167], ["CHIKV", "ORGANISM", 162, 167], ["CHIKV", "SPECIES", 162, 167], ["obesity", "PROBLEM", 151, 158], ["CHIKV", "PROBLEM", 162, 167], ["obesity", "OBSERVATION", 151, 158], ["CHIKV", "OBSERVATION", 162, 167]]], ["The sex ratio (male:female) was 0.83 with a weighted overall average age (\u00b1SD) of 42.9 \u00b1 13.9 years (range: 21-70 years).ResultsMeta-analysis for the identified studies showed that the most prevalent clinical symptoms were pyrexia (90.7%; 95% CI: 86.6-93.6%) and arthralgia (85.2%; 95% CI: 70.2-93.4%) with cephalgia, myalgia, joint edema, dermatitis and malaise in \u223c30-50% of the cases.", [["joint", "ANATOMY", 327, 332], ["pyrexia", "DISEASE", 223, 230], ["arthralgia", "DISEASE", 263, 273], ["cephalgia", "DISEASE", 307, 316], ["myalgia", "DISEASE", 318, 325], ["joint edema", "DISEASE", 327, 338], ["dermatitis", "DISEASE", 340, 350], ["joint edema", "PATHOLOGICAL_FORMATION", 327, 338], ["the identified studies", "TEST", 146, 168], ["the most prevalent clinical symptoms", "PROBLEM", 181, 217], ["pyrexia", "PROBLEM", 223, 230], ["CI", "TEST", 243, 245], ["arthralgia", "PROBLEM", 263, 273], ["CI", "TEST", 286, 288], ["cephalgia", "PROBLEM", 307, 316], ["myalgia", "PROBLEM", 318, 325], ["joint edema", "PROBLEM", 327, 338], ["dermatitis", "PROBLEM", 340, 350], ["malaise", "PROBLEM", 355, 362], ["myalgia", "OBSERVATION", 318, 325], ["joint", "ANATOMY", 327, 332], ["edema", "OBSERVATION", 333, 338], ["dermatitis", "OBSERVATION", 340, 350]]], ["There was a small heterogeneity (Cochran\u2019s Q) in the estimates of clinical symptoms among the identified studies with an I2 index varied up to 56.8% (Table 1).", [["a small heterogeneity (Cochran\u2019s Q", "PROBLEM", 10, 44], ["clinical symptoms", "PROBLEM", 66, 83], ["an I2 index", "TEST", 118, 129], ["small", "OBSERVATION_MODIFIER", 12, 17], ["heterogeneity", "OBSERVATION_MODIFIER", 18, 31]]], ["As shown in Figure 2(panel A), hypertension was the most prevalent comorbidity in CHIKV infection (31.3% of the cases; 95% CI: 17.9-48.8%) followed by diabetes (20.5%; 95% CI: 12.7-31.3%), cardiac diseases (14.8%; 95% CI: 8.1-25.5%) and asthma (only in 7.9% of the cases; 95% CI: 3.3-17.7).", [["cardiac", "ANATOMY", 189, 196], ["hypertension", "DISEASE", 31, 43], ["CHIKV infection", "DISEASE", 82, 97], ["diabetes", "DISEASE", 151, 159], ["cardiac diseases", "DISEASE", 189, 205], ["asthma", "DISEASE", 237, 243], ["CHIKV", "ORGANISM", 82, 87], ["cardiac", "ORGAN", 189, 196], ["CHIKV", "SPECIES", 82, 87], ["hypertension", "PROBLEM", 31, 43], ["CHIKV infection", "PROBLEM", 82, 97], ["CI", "TEST", 123, 125], ["diabetes", "TEST", 151, 159], ["CI", "TEST", 172, 174], ["cardiac diseases", "PROBLEM", 189, 205], ["CI", "TEST", 218, 220], ["asthma", "PROBLEM", 237, 243], ["CI", "TEST", 276, 278], ["hypertension", "OBSERVATION", 31, 43], ["most prevalent", "OBSERVATION_MODIFIER", 52, 66], ["CHIKV", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97], ["cardiac", "ANATOMY", 189, 196], ["diseases", "OBSERVATION", 197, 205], ["asthma", "OBSERVATION", 237, 243]]], ["Prevalence of obesity was reported only in one of the identified studies (Padmakumar et al., 2010).", [["obesity", "DISEASE", 14, 21], ["obesity", "PROBLEM", 14, 21], ["obesity", "OBSERVATION", 14, 21]]], ["Characteristics of this study were mentioned in Table 1 but were excluded from any further meta-analysis given this limited data set.", [["this study", "TEST", 19, 29], ["any further meta-analysis", "TEST", 79, 104]]], ["The prevalence of diabetes, hypertension, cardiac diseases and asthma varied by 25-, 5-, 28- and 50-fold among the identified studies, respectively.", [["cardiac", "ANATOMY", 42, 49], ["diabetes", "DISEASE", 18, 26], ["hypertension", "DISEASE", 28, 40], ["cardiac diseases", "DISEASE", 42, 58], ["asthma", "DISEASE", 63, 69], ["cardiac", "ORGAN", 42, 49], ["diabetes", "PROBLEM", 18, 26], ["hypertension", "PROBLEM", 28, 40], ["cardiac diseases", "PROBLEM", 42, 58], ["asthma", "PROBLEM", 63, 69], ["diabetes", "OBSERVATION", 18, 26], ["hypertension", "OBSERVATION", 28, 40], ["cardiac", "ANATOMY", 42, 49], ["diseases", "OBSERVATION", 50, 58], ["asthma", "OBSERVATION", 63, 69]]], ["This wide among-studies variation in the proportion of comorbidities may have resulted in the heterogeneity (I2 index) observed for the estimates of comorbidities that varied from 25.1% to 96.4% (Figure 2).", [["comorbidities", "PROBLEM", 55, 68], ["the heterogeneity (I2 index", "PROBLEM", 90, 117], ["comorbidities", "PROBLEM", 149, 162], ["wide", "OBSERVATION_MODIFIER", 5, 9], ["comorbidities", "OBSERVATION", 55, 68]]], ["However, the true heterogeneity estimated by between-study variance in the random-effect model (\u03c42) was varied between 0.029 to 0.074 for the examined comorbidities.", [["the true heterogeneity", "PROBLEM", 9, 31], ["study variance", "TEST", 53, 67], ["true", "OBSERVATION_MODIFIER", 13, 17], ["heterogeneity", "OBSERVATION", 18, 31]]], ["As shown in Table 2, the proportion of diabetes, hypertension and cardiac diseases was 4- to 5-fold higher (p <0.05) in elder patients than their younger counterparts.", [["cardiac", "ANATOMY", 66, 73], ["diabetes", "DISEASE", 39, 47], ["hypertension", "DISEASE", 49, 61], ["cardiac diseases", "DISEASE", 66, 82], ["cardiac", "ORGAN", 66, 73], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["diabetes", "PROBLEM", 39, 47], ["hypertension", "PROBLEM", 49, 61], ["cardiac diseases", "PROBLEM", 66, 82], ["diabetes", "OBSERVATION", 39, 47], ["hypertension", "OBSERVATION", 49, 61], ["cardiac", "ANATOMY", 66, 73], ["diseases", "OBSERVATION", 74, 82]]], ["We found a significant direct correlation between patients\u2019 age and the prevalence of diabetes (r= 0.65, p= 0.03), hypertension (r= 0.68, p= 0.033) and cardiac diseases (r= 0.65, p= 0.029) but inverse relationship (r= \u22120.88, p= 0.023) with asthma (data not shown).ResultsSevere CHIKV cases were defined as cases that underwent ICU, those with acute diseases (e.g., acute encephalitis) and subjects with atypical CHIKV (atypical clinical manifestations of CHIKV include vesiculobullous lesions, febrile seizures, and meningoencephalitis), joints involvement (e.g., inflammatory joint destruction), hospitalization, and/or death (see above).", [["cardiac", "ANATOMY", 152, 159], ["vesiculobullous lesions", "ANATOMY", 469, 492], ["joints", "ANATOMY", 538, 544], ["joint", "ANATOMY", 577, 582], ["diabetes", "DISEASE", 86, 94], ["hypertension", "DISEASE", 115, 127], ["cardiac diseases", "DISEASE", 152, 168], ["asthma", "DISEASE", 240, 246], ["encephalitis", "DISEASE", 371, 383], ["CHIKV", "DISEASE", 412, 417], ["CHIKV", "DISEASE", 455, 460], ["vesiculobullous lesions", "DISEASE", 469, 492], ["febrile seizures", "DISEASE", 494, 510], ["meningoencephalitis", "DISEASE", 516, 535], ["joints", "DISEASE", 538, 544], ["inflammatory joint destruction", "DISEASE", 564, 594], ["death", "DISEASE", 621, 626], ["patients", "ORGANISM", 50, 58], ["cardiac", "ORGAN", 152, 159], ["CHIKV", "ORGANISM", 278, 283], ["CHIKV", "ORGANISM", 455, 460], ["vesiculobullous lesions", "PATHOLOGICAL_FORMATION", 469, 492], ["joints", "MULTI-TISSUE_STRUCTURE", 538, 544], ["joint", "MULTI-TISSUE_STRUCTURE", 577, 582], ["patients", "SPECIES", 50, 58], ["CHIKV", "SPECIES", 278, 283], ["CHIKV", "SPECIES", 412, 417], ["CHIKV", "SPECIES", 455, 460], ["diabetes", "PROBLEM", 86, 94], ["p", "TEST", 105, 106], ["hypertension", "PROBLEM", 115, 127], ["p", "TEST", 138, 139], ["cardiac diseases", "PROBLEM", 152, 168], ["p", "TEST", 179, 180], ["inverse relationship", "PROBLEM", 193, 213], ["p", "TEST", 225, 226], ["asthma", "PROBLEM", 240, 246], ["acute diseases", "PROBLEM", 343, 357], ["acute encephalitis)", "PROBLEM", 365, 384], ["atypical CHIKV", "PROBLEM", 403, 417], ["CHIKV", "PROBLEM", 455, 460], ["vesiculobullous lesions", "PROBLEM", 469, 492], ["febrile seizures", "PROBLEM", 494, 510], ["meningoencephalitis", "PROBLEM", 516, 535], ["joints involvement", "PROBLEM", 538, 556], ["inflammatory joint destruction", "PROBLEM", 564, 594], ["death", "PROBLEM", 621, 626], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["hypertension", "OBSERVATION", 115, 127], ["cardiac", "ANATOMY", 152, 159], ["diseases", "OBSERVATION", 160, 168], ["asthma", "OBSERVATION", 240, 246], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["diseases", "OBSERVATION", 349, 357], ["acute", "OBSERVATION_MODIFIER", 365, 370], ["encephalitis", "OBSERVATION", 371, 383], ["atypical", "OBSERVATION_MODIFIER", 403, 411], ["CHIKV", "OBSERVATION", 412, 417], ["vesiculobullous", "OBSERVATION_MODIFIER", 469, 484], ["lesions", "OBSERVATION", 485, 492], ["meningoencephalitis", "OBSERVATION", 516, 535], ["joints", "ANATOMY", 538, 544], ["inflammatory", "OBSERVATION_MODIFIER", 564, 576], ["joint", "ANATOMY", 577, 582], ["destruction", "OBSERVATION", 583, 594]]], ["Cases with severe CHIKV had a significantly higher proportion of diabetes (22.9% vs. 20.5%, p <0.05) (Figure 2; panel B).", [["CHIKV", "DISEASE", 18, 23], ["diabetes", "DISEASE", 65, 73], ["CHIKV", "SPECIES", 18, 23], ["severe CHIKV", "PROBLEM", 11, 23], ["diabetes", "PROBLEM", 65, 73], ["p", "TEST", 92, 93], ["Figure", "TEST", 102, 108], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["CHIKV", "OBSERVATION", 18, 23], ["diabetes", "OBSERVATION", 65, 73]]], ["Infected patients with diabetes (both types I and II, combined) \u2013 but not those with hypertension or cardiac diseases \u2013 had OR of 1.2 (95% CI: 1.05-1.48; p= 0.0135) for developing severe CHIKV outcome compared to those with no diabetes.DiscussionThe present study was undertaken to systematically evaluate the prevalence of chronic comorbidities in CHIKV non-severe and severe cases of infection.", [["cardiac", "ANATOMY", 101, 108], ["diabetes", "DISEASE", 23, 31], ["hypertension", "DISEASE", 85, 97], ["cardiac diseases", "DISEASE", 101, 117], ["CHIKV", "DISEASE", 187, 192], ["diabetes", "DISEASE", 227, 235], ["infection", "DISEASE", 386, 395], ["patients", "ORGANISM", 9, 17], ["cardiac", "ORGAN", 101, 108], ["patients", "SPECIES", 9, 17], ["CHIKV", "SPECIES", 187, 192], ["CHIKV", "SPECIES", 349, 354], ["diabetes", "PROBLEM", 23, 31], ["hypertension", "PROBLEM", 85, 97], ["cardiac diseases", "PROBLEM", 101, 117], ["CI", "TEST", 139, 141], ["p", "TEST", 154, 155], ["developing severe CHIKV outcome", "PROBLEM", 169, 200], ["diabetes", "PROBLEM", 227, 235], ["The present study", "TEST", 246, 263], ["chronic comorbidities", "PROBLEM", 324, 345], ["CHIKV non-severe", "PROBLEM", 349, 365], ["infection", "PROBLEM", 386, 395], ["diabetes", "OBSERVATION", 23, 31], ["cardiac", "ANATOMY", 101, 108], ["diseases", "OBSERVATION", 109, 117], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["CHIKV", "OBSERVATION", 187, 192], ["diabetes", "OBSERVATION", 227, 235], ["chronic", "OBSERVATION_MODIFIER", 324, 331], ["comorbidities", "OBSERVATION", 332, 345], ["CHIKV", "OBSERVATION", 349, 354], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["infection", "OBSERVATION", 386, 395]]], ["Meta-analysis of the data extracted from the identified studies (Figure 2) suggests that hypertension and diabetes are the most frequent comorbidities in patients with CHIKV infection with prevalence rates that varied from 20-30%.", [["hypertension", "DISEASE", 89, 101], ["diabetes", "DISEASE", 106, 114], ["CHIKV infection", "DISEASE", 168, 183], ["patients", "ORGANISM", 154, 162], ["CHIKV", "ORGANISM", 168, 173], ["patients", "SPECIES", 154, 162], ["CHIKV", "SPECIES", 168, 173], ["the data", "TEST", 17, 25], ["the identified studies", "TEST", 41, 63], ["hypertension", "PROBLEM", 89, 101], ["diabetes", "PROBLEM", 106, 114], ["the most frequent comorbidities", "PROBLEM", 119, 150], ["CHIKV infection", "PROBLEM", 168, 183], ["prevalence rates", "TEST", 189, 205], ["hypertension", "OBSERVATION", 89, 101], ["diabetes", "OBSERVATION", 106, 114], ["CHIKV", "OBSERVATION", 168, 173]]], ["As expected, the prevalence of the examined chronic comorbidities was increased with age except for asthma.", [["asthma", "DISEASE", 100, 106], ["chronic comorbidities", "PROBLEM", 44, 65], ["asthma", "PROBLEM", 100, 106], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["comorbidities", "OBSERVATION", 52, 65], ["asthma", "OBSERVATION", 100, 106]]], ["Although the reports identified here did not distinguish between the prevalence of type 1 and/or type 2 diabetes in CHIKV, results of the present study suggest an increased risk of developing severe CHIKV complications in people with diabetes (OR = 1.2; 95% CI: 1.05-1.48) than in those with other or no underlying chronic diseases.", [["diabetes", "DISEASE", 104, 112], ["CHIKV complications", "DISEASE", 199, 218], ["diabetes", "DISEASE", 234, 242], ["chronic diseases", "DISEASE", 315, 331], ["CHIKV", "ORGANISM", 116, 121], ["CHIKV", "ORGANISM", 199, 204], ["people", "ORGANISM", 222, 228], ["people", "SPECIES", 222, 228], ["CHIKV", "SPECIES", 116, 121], ["CHIKV", "SPECIES", 199, 204], ["type 1", "PROBLEM", 83, 89], ["type 2 diabetes", "PROBLEM", 97, 112], ["CHIKV", "PROBLEM", 116, 121], ["the present study", "TEST", 134, 151], ["developing severe CHIKV complications", "PROBLEM", 181, 218], ["diabetes", "PROBLEM", 234, 242], ["CI", "TEST", 258, 260], ["underlying chronic diseases", "PROBLEM", 304, 331], ["diabetes", "OBSERVATION", 104, 112], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["CHIKV", "OBSERVATION", 199, 204], ["no underlying", "UNCERTAINTY", 301, 314], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["diseases", "OBSERVATION", 323, 331]]], ["Similar observations were also reported in H1N1 (Badawi and Ryoo, 2016a), MERS-CoV (Badawi and Ryoo, 2016b) and influenza (Mertz et al., 2013).", [["influenza", "DISEASE", 112, 121], ["MERS-CoV", "ORGANISM", 74, 82], ["MERS-CoV", "SPECIES", 74, 82], ["influenza", "PROBLEM", 112, 121]]], ["For example, a recent study noted that, compared to subjects with no comorbidities, severe pandemic influenza cases are significantly elevated with obesity (OR for mortality 2.74; 95% CI: 1.56-4.80), cardiovascular diseases (2.92; 95% CI: 1.76-4.86), hypertension (1.49; 95% CI: 1.10-2.01) and neuromuscular disease (2.68; 95% CI: 1.91-3.75) (Mertz et al., 2013).", [["cardiovascular", "ANATOMY", 200, 214], ["neuromuscular", "ANATOMY", 294, 307], ["influenza", "DISEASE", 100, 109], ["obesity", "DISEASE", 148, 155], ["cardiovascular diseases", "DISEASE", 200, 223], ["hypertension", "DISEASE", 251, 263], ["neuromuscular disease", "DISEASE", 294, 315], ["neuromuscular", "ORGAN", 294, 307], ["a recent study", "TEST", 13, 27], ["comorbidities", "PROBLEM", 69, 82], ["severe pandemic influenza cases", "PROBLEM", 84, 115], ["significantly elevated", "PROBLEM", 120, 142], ["obesity", "PROBLEM", 148, 155], ["mortality", "TEST", 164, 173], ["CI", "TEST", 184, 186], ["cardiovascular diseases", "PROBLEM", 200, 223], ["CI", "TEST", 235, 237], ["hypertension", "PROBLEM", 251, 263], ["CI", "TEST", 275, 277], ["neuromuscular disease", "PROBLEM", 294, 315], ["CI", "TEST", 327, 329], ["no", "UNCERTAINTY", 66, 68], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["pandemic", "OBSERVATION_MODIFIER", 91, 99], ["influenza", "OBSERVATION", 100, 109], ["obesity", "OBSERVATION", 148, 155], ["cardiovascular", "ANATOMY", 200, 214], ["hypertension", "OBSERVATION", 251, 263], ["neuromuscular", "ANATOMY", 294, 307]]], ["It may be worth noting that in CHIKV we identified only one study (Padmakumar et al., 2010) evaluating the effect of overweight on disease severity and this was not included in any of our meta-analyses.", [["overweight", "DISEASE", 117, 127], ["CHIKV", "SPECIES", 31, 36], ["one study", "TEST", 56, 65], ["overweight on disease severity", "PROBLEM", 117, 147]]], ["This study reported a significant association between overweight and CHIKV sequelae (OR = 1.3; 95% CI: 1.2-1.4) (Padmakumar et al., 2010).", [["overweight", "DISEASE", 54, 64], ["CHIKV sequelae", "DISEASE", 69, 83], ["CHIKV", "SPECIES", 69, 74], ["This study", "TEST", 0, 10], ["CHIKV sequelae", "PROBLEM", 69, 83], ["CI", "TEST", 99, 101]]], ["Chronic conditions influencing the severity of CHIKV such as diabetes were also noted to have similar effects in other respiratory illnesses (Badawi and Ryoo, 2016a, Badawi and Ryoo, 2016b, Mertz et al., 2013, Kusznierz et al., 2013).", [["respiratory", "ANATOMY", 119, 130], ["CHIKV", "DISEASE", 47, 52], ["diabetes", "DISEASE", 61, 69], ["respiratory illnesses", "DISEASE", 119, 140], ["CHIKV", "ORGANISM", 47, 52], ["CHIKV", "SPECIES", 47, 52], ["Chronic conditions", "PROBLEM", 0, 18], ["CHIKV", "PROBLEM", 47, 52], ["diabetes", "PROBLEM", 61, 69], ["other respiratory illnesses", "PROBLEM", 113, 140], ["CHIKV", "OBSERVATION", 47, 52], ["respiratory illnesses", "OBSERVATION", 119, 140]]], ["Furthermore, a number of case-control studies demonstrated the incidence of metabolic syndrome and related diseases, e.g., diabetes and hypertension, to be 2-fold higher in severe cases of dengue fever than in non-severe conditions (Fujimoto and Koifman, 2014, Pang et al., 2012).DiscussionAlthough the prevalence of metabolic syndrome-related conditions such as diabetes, hypertension and cardiac diseases varied widely among the selected studies, the vast majority of the reports showed values clustering around the pooled estimated averages for each comorbidity, as evidenced by the low I2 index values (Figure 2).", [["cardiac", "ANATOMY", 390, 397], ["metabolic syndrome", "DISEASE", 76, 94], ["diabetes", "DISEASE", 123, 131], ["hypertension", "DISEASE", 136, 148], ["dengue fever", "DISEASE", 189, 201], ["metabolic syndrome", "DISEASE", 317, 335], ["diabetes", "DISEASE", 363, 371], ["hypertension", "DISEASE", 373, 385], ["cardiac diseases", "DISEASE", 390, 406], ["cardiac", "ORGAN", 390, 397], ["metabolic syndrome", "PROBLEM", 76, 94], ["related diseases", "PROBLEM", 99, 115], ["diabetes", "PROBLEM", 123, 131], ["hypertension", "PROBLEM", 136, 148], ["dengue fever", "PROBLEM", 189, 201], ["metabolic syndrome", "PROBLEM", 317, 335], ["related conditions", "PROBLEM", 336, 354], ["diabetes", "PROBLEM", 363, 371], ["hypertension", "PROBLEM", 373, 385], ["cardiac diseases", "PROBLEM", 390, 406], ["the selected studies", "TEST", 427, 447], ["values clustering", "PROBLEM", 489, 506], ["each comorbidity", "PROBLEM", 548, 564], ["the low I2 index values", "PROBLEM", 582, 605], ["metabolic syndrome", "OBSERVATION", 76, 94], ["diabetes", "OBSERVATION", 123, 131], ["hypertension", "OBSERVATION", 136, 148], ["severe", "OBSERVATION_MODIFIER", 173, 179], ["metabolic syndrome", "OBSERVATION", 317, 335], ["hypertension", "OBSERVATION", 373, 385], ["cardiac", "ANATOMY", 390, 397], ["diseases", "OBSERVATION", 398, 406], ["low", "OBSERVATION_MODIFIER", 586, 589]]], ["Comorbidities related to metabolic syndrome are thought to be etiologically linked to CHIKV pathogenesis.", [["metabolic syndrome", "DISEASE", 25, 43], ["CHIKV", "DISEASE", 86, 91], ["CHIKV", "ORGANISM", 86, 91], ["CHIKV", "SPECIES", 86, 91], ["Comorbidities", "PROBLEM", 0, 13], ["metabolic syndrome", "PROBLEM", 25, 43], ["CHIKV pathogenesis", "PROBLEM", 86, 104], ["metabolic syndrome", "OBSERVATION", 25, 43], ["thought to be", "UNCERTAINTY", 48, 61], ["CHIKV", "OBSERVATION", 86, 91]]], ["These disorders are known to downregulate key mediators of host innate immune response to pathogenesis.", [["These disorders", "PROBLEM", 0, 15], ["pathogenesis", "PROBLEM", 90, 102]]], ["For example, diabetes, hyperglycemia and insulinopenia attenuate the synthesis of pro-inflammatory cytokines such as IFN-\u03b3 and interleukins to functionally impair the innate and humoral immune systems of the host (Badawi and Ryoo, 2016a).", [["diabetes", "DISEASE", 13, 21], ["hyperglycemia", "DISEASE", 23, 36], ["insulinopenia", "DISEASE", 41, 54], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 117, 122], ["interleukins", "GENE_OR_GENE_PRODUCT", 127, 139], ["pro-inflammatory cytokines", "PROTEIN", 82, 108], ["IFN", "PROTEIN", 117, 120], ["interleukins", "PROTEIN", 127, 139], ["diabetes", "PROBLEM", 13, 21], ["hyperglycemia", "PROBLEM", 23, 36], ["insulinopenia", "PROBLEM", 41, 54], ["the synthesis of pro-inflammatory cytokines", "PROBLEM", 65, 108], ["IFN-\u03b3 and interleukins", "PROBLEM", 117, 139], ["diabetes", "OBSERVATION", 13, 21], ["hyperglycemia", "OBSERVATION", 23, 36], ["pro-inflammatory cytokines", "OBSERVATION", 82, 108]]], ["Furthermore, the cytokine overload related to the Th1 to Th2 shift in severe viral infection, when accompanied by the increased cytokine synthesis from metabolic diseases, can be detrimental in synergistically affecting the endothelium and leads to a range of subsequent complications related to both the infectious and chronic conditions (Toledo et al., 2016).", [["endothelium", "ANATOMY", 224, 235], ["viral infection", "DISEASE", 77, 92], ["metabolic diseases", "DISEASE", 152, 170], ["Th1", "GENE_OR_GENE_PRODUCT", 50, 53], ["endothelium", "TISSUE", 224, 235], ["cytokine", "PROTEIN", 17, 25], ["cytokine", "PROTEIN", 128, 136], ["the cytokine overload", "PROBLEM", 13, 34], ["severe viral infection", "PROBLEM", 70, 92], ["the increased cytokine synthesis", "PROBLEM", 114, 146], ["metabolic diseases", "PROBLEM", 152, 170], ["subsequent complications", "PROBLEM", 260, 284], ["the infectious and chronic conditions", "PROBLEM", 301, 338], ["cytokine overload", "OBSERVATION", 17, 34], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["cytokine synthesis", "OBSERVATION", 128, 146], ["metabolic diseases", "OBSERVATION", 152, 170], ["endothelium", "ANATOMY", 224, 235], ["infectious", "OBSERVATION", 305, 315], ["chronic", "OBSERVATION_MODIFIER", 320, 327]]], ["Furthermore, diabetes is known to impair macrophage and lymphocyte functions, subsequently reducing the host's immune response (Dooley and Chaisson, 2009).", [["macrophage", "ANATOMY", 41, 51], ["lymphocyte", "ANATOMY", 56, 66], ["diabetes", "DISEASE", 13, 21], ["macrophage", "CELL", 41, 51], ["lymphocyte", "CELL", 56, 66], ["diabetes", "PROBLEM", 13, 21], ["lymphocyte functions", "TEST", 56, 76], ["diabetes", "OBSERVATION", 13, 21], ["lymphocyte functions", "OBSERVATION", 56, 76]]], ["This was noted when increased levels of HbA1c (i.e., \u22659%) were linked to the severity of pneumonia (Akbar, 2001).", [["pneumonia", "DISEASE", 89, 98], ["HbA1c", "GENE_OR_GENE_PRODUCT", 40, 45], ["HbA1c", "TEST", 40, 45], ["pneumonia", "PROBLEM", 89, 98], ["pneumonia", "OBSERVATION", 89, 98]]], ["While diabetes may impair the immune system leading to increased level and duration of viremia, heart conditions and hypertension were thought to facilitate the passage of neurotropic viruses, e.g., flavivirus, across the blood-brain barrier to predispose patients to neurologic complications (Jean et al., 2007).DiscussionThe present study has several limitations.", [["immune system", "ANATOMY", 30, 43], ["heart", "ANATOMY", 96, 101], ["blood", "ANATOMY", 222, 227], ["brain", "ANATOMY", 228, 233], ["neurologic", "ANATOMY", 268, 278], ["diabetes", "DISEASE", 6, 14], ["viremia", "DISEASE", 87, 94], ["hypertension", "DISEASE", 117, 129], ["neurologic complications", "DISEASE", 268, 292], ["immune system", "ANATOMICAL_SYSTEM", 30, 43], ["heart", "ORGAN", 96, 101], ["neurotropic viruses", "ORGANISM", 172, 191], ["blood", "MULTI-TISSUE_STRUCTURE", 222, 227], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 228, 241], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 256, 264], ["diabetes", "PROBLEM", 6, 14], ["the immune system", "PROBLEM", 26, 43], ["increased level", "PROBLEM", 55, 70], ["viremia", "PROBLEM", 87, 94], ["heart conditions", "PROBLEM", 96, 112], ["hypertension", "PROBLEM", 117, 129], ["the passage of neurotropic viruses", "PROBLEM", 157, 191], ["flavivirus", "PROBLEM", 199, 209], ["neurologic complications", "PROBLEM", 268, 292], ["The present study", "TEST", 323, 340], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["viremia", "OBSERVATION", 87, 94], ["heart", "ANATOMY", 96, 101], ["hypertension", "OBSERVATION", 117, 129], ["neurotropic viruses", "OBSERVATION", 172, 191], ["brain", "ANATOMY", 228, 233]]], ["The identified reports have shown a wide among-studies variance in the proportion of diabetes, hypertension, cardiac diseases and asthma, which may have contributed to the heterogeneity observed in the meta-analysis.", [["cardiac", "ANATOMY", 109, 116], ["diabetes", "DISEASE", 85, 93], ["hypertension", "DISEASE", 95, 107], ["cardiac diseases", "DISEASE", 109, 125], ["asthma", "DISEASE", 130, 136], ["cardiac", "ORGAN", 109, 116], ["a wide among-studies variance", "PROBLEM", 34, 63], ["diabetes", "PROBLEM", 85, 93], ["hypertension", "PROBLEM", 95, 107], ["cardiac diseases", "PROBLEM", 109, 125], ["asthma", "PROBLEM", 130, 136], ["the heterogeneity", "PROBLEM", 168, 185], ["wide", "OBSERVATION_MODIFIER", 36, 40], ["diabetes", "OBSERVATION", 85, 93], ["hypertension", "OBSERVATION", 95, 107], ["cardiac", "ANATOMY", 109, 116], ["diseases", "OBSERVATION", 117, 125], ["asthma", "OBSERVATION", 130, 136]]], ["Other sources of heterogeneity may be related to the large range of sample size and the different study designs.", [["heterogeneity", "PROBLEM", 17, 30], ["the different study", "TEST", 84, 103], ["heterogeneity", "OBSERVATION", 17, 30], ["may be related to", "UNCERTAINTY", 31, 48], ["large", "OBSERVATION_MODIFIER", 53, 58], ["range", "OBSERVATION_MODIFIER", 59, 64], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["These factors may levy some limitations on the estimated contribution of chronic diseases to severe CHIKV cases and render our results as a guide to generate more accurate estimates for intervention strategies for infection in patients with chronic disorders.", [["chronic diseases", "DISEASE", 73, 89], ["CHIKV", "DISEASE", 100, 105], ["infection", "DISEASE", 214, 223], ["chronic disorders", "DISEASE", 241, 258], ["CHIKV", "ORGANISM", 100, 105], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["CHIKV", "SPECIES", 100, 105], ["chronic diseases", "PROBLEM", 73, 89], ["severe CHIKV cases", "PROBLEM", 93, 111], ["intervention strategies", "TREATMENT", 186, 209], ["infection", "PROBLEM", 214, 223], ["chronic disorders", "PROBLEM", 241, 258], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["diseases", "OBSERVATION", 81, 89], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["CHIKV", "OBSERVATION", 100, 105]]], ["Furthermore, the small number of studies selected here did not allow us to evaluate the prevalence of chronic comorbidities in each outcome of the severe CHIKV cases.", [["CHIKV", "DISEASE", 154, 159], ["CHIKV", "ORGANISM", 154, 159], ["CHIKV", "SPECIES", 154, 159], ["chronic comorbidities", "PROBLEM", 102, 123], ["the severe CHIKV cases", "PROBLEM", 143, 165], ["small", "OBSERVATION_MODIFIER", 17, 22], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["comorbidities", "OBSERVATION", 110, 123], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["CHIKV", "OBSERVATION", 154, 159]]], ["Additionally, little information was provided in the original articles on the chronic comorbidities in terms of how long patients were suffering from the condition(s), the onset of the condition(s) prior to or following CHIKV manifestation or whether or not the patients have received a treatment.DiscussionThe study of comorbidities in CHIKV infection is important for reducing the burden of the disease via guiding approaches for improved patient outcome or differential case management.", [["CHIKV infection", "DISEASE", 337, 352], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 262, 270], ["CHIKV", "ORGANISM", 337, 342], ["patient", "ORGANISM", 441, 448], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 262, 270], ["patient", "SPECIES", 441, 448], ["CHIKV", "SPECIES", 220, 225], ["CHIKV", "SPECIES", 337, 342], ["the chronic comorbidities", "PROBLEM", 74, 99], ["a treatment", "TREATMENT", 285, 296], ["The study", "TEST", 307, 316], ["comorbidities", "PROBLEM", 320, 333], ["CHIKV infection", "PROBLEM", 337, 352], ["the disease", "PROBLEM", 393, 404], ["differential case management", "TREATMENT", 460, 488], ["infection", "OBSERVATION", 343, 352]]], ["The present study provides evidence for a particular higher prevalence of diabetes in severe cases of CHIKV infections than in non-severe cases.", [["diabetes", "DISEASE", 74, 82], ["CHIKV infections", "DISEASE", 102, 118], ["CHIKV", "ORGANISM", 102, 107], ["CHIKV", "SPECIES", 102, 107], ["The present study", "TEST", 0, 17], ["diabetes", "PROBLEM", 74, 82], ["CHIKV infections", "PROBLEM", 102, 118], ["diabetes", "OBSERVATION", 74, 82], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["CHIKV infections", "OBSERVATION", 102, 118]]], ["The causal association, however, between chronic diseases and severe infection cannot be simply substantiated from these observations.", [["chronic diseases", "DISEASE", 41, 57], ["infection", "DISEASE", 69, 78], ["chronic diseases", "PROBLEM", 41, 57], ["severe infection", "PROBLEM", 62, 78], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["diseases", "OBSERVATION", 49, 57], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["infection", "OBSERVATION", 69, 78]]], ["However, even in the absence of causal inference between the non-communicable and infectious diseases, it may be justified that once non-severe episodes of infection are confirmed in subjects with diabetes that they remain under close surveillance to avert complications.", [["infectious diseases", "DISEASE", 82, 101], ["infection", "DISEASE", 156, 165], ["diabetes", "DISEASE", 197, 205], ["the non-communicable and infectious diseases", "PROBLEM", 57, 101], ["infection", "PROBLEM", 156, 165], ["diabetes", "PROBLEM", 197, 205], ["complications", "PROBLEM", 257, 270], ["infectious", "OBSERVATION", 82, 92], ["infection", "OBSERVATION", 156, 165]]], ["This measure may prove important in averting severe disease outcome.", [["averting severe disease outcome", "PROBLEM", 36, 67], ["may prove", "UNCERTAINTY", 13, 22], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["disease", "OBSERVATION", 52, 59]]], ["Indeed, there are no current clear lines of prevention and treatment for CHIKV disease outside avoidance of mosquitoes and use of insect repellents.", [["CHIKV disease", "DISEASE", 73, 86], ["CHIKV", "ORGANISM", 73, 78], ["CHIKV", "SPECIES", 73, 78], ["treatment", "TREATMENT", 59, 68], ["CHIKV disease", "PROBLEM", 73, 86], ["no", "UNCERTAINTY", 18, 20], ["clear", "OBSERVATION_MODIFIER", 29, 34], ["lines", "OBSERVATION", 35, 40]]], ["Coupling these practices with educating the public on the risk of severe infection can be an effective public health approach for the intervention of infection-related complications particularly in the middle- and low-income countries where the prevalence of chronic diseases is rising.Conflict of interestThe authors declare no conflict of interest.", [["infection", "DISEASE", 73, 82], ["infection", "DISEASE", 150, 159], ["chronic diseases", "DISEASE", 259, 275], ["severe infection", "PROBLEM", 66, 82], ["infection", "PROBLEM", 150, 159], ["related complications", "PROBLEM", 160, 181], ["chronic diseases", "PROBLEM", 259, 275], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["infection", "OBSERVATION", 73, 82], ["infection", "OBSERVATION", 150, 159], ["middle", "ANATOMY_MODIFIER", 202, 208], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["diseases", "OBSERVATION", 267, 275], ["rising", "OBSERVATION_MODIFIER", 279, 285]]]]}